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The metabolic syndrome (MS), consequent upon the pandemic of obesity and diabetes, is 
associated with an increased risk for cardiovascular (CV) disease. Development of sub-
clinical cardiac structural and functional changes associated with CV disease risk factors 
may be detected on echocardiography. The extent to which these structural changes and 
CV risk factors are dependent on genetic factors is not clearly established. This project 
was designed to investigate the relationship between CV disease risk factors, cardiac 
structural and functional changes and underlying genetic abnormalities. Specifically, the 
risk factor profile and the presence of the MS were determined. This was then correlated 
with the echocardiographic findings and gene polymorphisms. 
Method: 
 A randomly selected cohort of 1428 subjects from the Phoenix community was studied. 
Demographic data was collected using the WHO STEPS instrument. Blood samples for 
biochemistry and genetic analysis, together with anthropometric measurements, were 
collected. Blood pressure and echocardiography was performed on all subjects. The 
metabolic syndrome was classified according to the National Cholesterol Education Panel 
(NECP) Adult Treatment Panel III (ATP III) and International Diabetes Federation (IDF) 
criteria. The Lipoprotein Lipase and Human Paraoxonase-1 genes were genotyped on a 







There was a high prevalence of CV risk factors in this sample; particularly increased waist 
circumference (79%), obesity (64%) insulin resistance (58%) and hypertension (50%) 
across the age groups. This translated into a high prevalence of MS (38% using NCEP 
ATPIII and 46% using IDF criteria). There were significant echocardiographic differences 
between subjects with and without MS for chamber dimensions (p<0.001), left 
ventricular wall thickness (p<0.001) and mass (p<0.001), diastolic indices (E-wave 
{p<0.001}, trans-mitral ratio {p=0.017}) and sub-epicardial adipose tissue (SEAT) thickness 
(p<0.001). Stepwise multivariate analysis identified age (95% CI 0.975; 0.998), gender 
(95%CI 0.48; 0.9) and hypertension (95% CI 0.53; 0.99) as independent risk factors for 
diastolic abnormalities. Logistic regression identified age as the most significant 
contributor to diastolic abnormalities (OR=1.02; 95%CI 1.009; 1.03; Wald=13.4), followed 
by the waist circumference (OR=1.025; 95%CI 1.014; 1.037) and BMI (OR=1.075; 95% CI 
1.035; 1.117).  Genetic analysis showed significant associations between the 
heterozygous variant of Q192R genotype (PON-1 gene) and elevated HDL levels and also 
between this variant and obese women (p= <0.05). 
Conclusion: 
The high prevalence of CV risk factors and MS in this community has reached epidemic 
proportions. Although the MS was associated with significant remodelling of cardiac 
structure, alteration of diastolic indices and increased sub-epicardial adipose tissue 






physiology. This augurs poorly for this population group unless intervention is introduced 





















1.1 Problem identification and motivation for this study 
The prevalence of cardiovascular disease (CVD) in developing countries is reaching 
epidemic proportions (Yusuf et al., 2001). This has been attributed to the change in 
disease profile, with a transition from poverty-driven, communicable diseases to chronic, 
non-communicable diseases (Beaglehole & Bonita, 2008), owing to the exposure to risk 
factors for CVD in these populations. Traditional risk factor clustering (hyperinsulinaemia 
and hyperglycaemia associated with insulin resistance, together with adipokines 
{adipocyte cytokines}) have been well documented to lead to vascular endothelial 
dysfunction, abnormal lipid profile, hypertension (Lindsay et al., 2004), and vascular 
inflammation. These factors all contribute to the development of CVD (Koh et al., 2005), 
including coronary artery disease (CAD) and stroke, and have been associated with high 
cardiovascular mortality and morbidity (de Las Fuentes, 2007). 
Coronary artery disease is characterised by complex pathophysiological mechanisms, 
ending in atherosclerosis (Lusis et al., 2004). The prevalence of this disease has reached 
alarming proportions in both developed and in developing countries. In addition, marked 
changes in disease profiles have been documented in migrant populations, especially in 
urbanised groups, as a result of exposure to multiple risk factors linked to lifestyle and 
behavioural adaptations (Yusuf et al., 2001).  Since CVD risk factors are heterogeneous 
and complex in nature, individual susceptibility to CVD is determined by the interplay of 
traditional risk factors, together with biochemical and environmental factors (Lusis, 





2004), as well as heritable components (Damani, 2007), operating differentially in 
different populations.   
Each of these risk factors increases the risk of CAD to varying degrees and, in 
combination, significantly increase risk. Risk factor clustering has long been recognised to 
contribute to CVD risk and has been developed into syndromic entities such as the 
metabolic syndrome (MS). To what extent the metabolic syndrome is independently 
associated with increased risk is not clear, nor is it well established whether risk factors 
confer added risk through structural changes in the cardiovascular (CV) system. The 
worldwide pandemic of obesity and other CV risk factors has rekindled interest in the 
identification of high-risk, asymptomatic subjects, with the view to implement intensive, 
medical interventions that would reduce CVD risk.  
 
Although risk factors like hypertension, Type 2 Diabetes mellitus (DM) (Liu et al., 2001) 
and obesity (Peterson et al., 2004) have been shown to alter cardiac structure, few 
studies have examined the effect of individual or clustering of MS components on cardiac 
structure and function, particularly in defining pre-clinical cardiac disease. 
Echocardiography is a non-invasive modality that permits accurate assessment of the 
cardiac phenotype and function in the presence or absence of these risk factors. The 
measurements derived would allow extrapolation regarding the degree of 
pathophysiological transition, and hence timeous intervention. Whether these structural 
changes are mediated through the risk factors alone, or whether the changes occur 





through genetic signalling via pathophysiological pathways contributing to CVD, has 
recently become very topical.  
Insulin resistance and obesity have been reported as the main components of the 
metabolic syndrome (MS), where there appears to be a continuum between the two 
conditions. Insulin resistance, which is related to obesity and DM, is characterised by 
defective signalling at many levels (Ginsberg et al., 2005). With ensuing insulin resistance, 
the expression of lipoprotein lipase (LPL), a lipolytic enzyme that is essential for the 
hydrolysis of chylomicrons, is reduced with subsequent reduction of LPL activity (Mead & 
Ramji, 2002).  
LPL is a key regulator of lipoprotein metabolism, with LPL regulation being subject to 
insulin regulation. Therefore low LPL activity could result in significant metabolic 
consequences. This has been shown by studies which implicate LPL in conditions 
characterised by hypertriglyceridemia (like MS), in addition to tissue lipid accumulation 
which is associated with obesity-related insulin resistance (Lim et al., 2009).  
 
It is known that genetic factors may affect insulin sensitivity profoundly, with those genes 
involved with DM being polygenic, involving single nucleotide polymorphisms (SNPs) in 
multiple genes.   
Since insulin resistance is reported as one of the central components of MS (Grundy, 
2006), and LPL activity reported to be subject to both insulin regulation (Pollare, 1991), 
and to the influence of genetics (Weissglas-Volkov & Pajukanta, 2010), we believed that it 





was important to study genes involved in lipoprotein metabolism to determine whether 
genetic variations could account for individual susceptibility to MS.   
 
There is strong evidence that links oxidative stress with insulin resistance, impaired 
glucose tolerance and DM (Meigs et al., 2003; Ceriello & Motz, 2004), where oxidative 
stress is reported to impair insulin action. In fact, Reaven (2007) reported a correlation 
between MS and endothelial dysfunction in individuals with susceptibility to oxidative 
stress. This hypothesis is based on the evidence that suggest that prolonged exposure to 
high glucose results in the generation of mitochondrial NADH by substrate-induced 
increase in the citric acid cycle activity (Maddux et al., 2001). This process culminates in 
the formation of free radicals, superoxide  in particular, which causes toxic effects to the 
endothelium, in addition to impaired endothelium-dependant vasodilation; all of which is 
mediated by oxidative stress.  
 
A reduced intracellular antioxidant defence system in humans is associated with insulin 
resistance (Ceriello & Motz, 2004), with the deficiency in the reactive oxygen species 
(ROS)-scavenging ability conferring a genetic predisposition to insulin resistance and its 
advancing complications (Ceriello & Motz, 2004) in some individuals. Several genetic 
polymorphisms have been described that are associated with insulin resistance and 
oxidative stress. Serum paraoxonase-1 (PON-1), in particular, which is an antioxidant and 
a high-density lipoprotein (HDL)-associated enzyme encoded by the PON-1 gene, has 
significant anti-atherogenic properties (Shih et al., 1998). PON-1 activity has been 





reported to decrease in the presence of insulin resistance due to oxidative stress, with 
reduced serum PON-1 activity being associated with DM and CVD (Barbieri, et al., 2002). 
It is also well established that PON-1 gene polymorphisms (Q192R, L55M) alter both the 
level and activity of the enzyme (Clendenning et al., 1996; Blatter-Garin et al., 1994; 
Mackness et al., 1993; Aviram et al., 2000).  
Since MS increases risk for CVD and is associated with high levels of lipid peroxides 
(Reaven, 2007), and PON-1 is reported to contribute to the prevention of low-density 
lipoprotein (LDL) oxidation and lipid peroxidation (Mackness et al., 1993), we felt it was 
important to explore the interaction between MS and PON-1 polymorphisms as 
mechanisms of atherogenesis, particularly in ethnic groups with a strong predisposition 
for developing premature CAD. There are limited descriptions in the literature linking the 
risk factor profile and the genetic variations to the development of the metabolic 
syndrome in the South African Asian Indian community (Ranjith et al., 2002), which has a 
high prevalence of CV risk factors, particularly DM and hypertension. In this community, 
we searched for a possible link between common SNPs in the Lipoprotein lipase (LPL) and 
Paraoxonase 1 (PON-1) gene and CV risk factors and the resultant susceptibility to the 






Chapter 1                                                                                                                                          Aims and Objectives 
7 
 
1.2 Aims and objectives 
The main aim of this study was to determine the prevalence of cardiovascular risk factors 
in the Phoenix community and their relationship to cardiac structural changes and 
genetic patterns. The specific objectives were: 
1.2.1 To determine the major risk factors for cardiovascular disease in the Phoenix 
community 
1.2.2 To identify the prevalence of metabolic syndrome in this community 
1.2.3 To define the echocardiographic parameters in normal individuals and establish 
what changes, if any,  occur with identifiable cardiovascular risk factors 
1.2.4 To identify echocardiographic variables that may be associated with metabolic 
syndrome 














1.3 The Literature Review 
Cardiovascular disease (CVD) has reached epidemic proportions worldwide and accounts 
for the main cause of death in low and middle-income countries (WHO, 2009e; Poole-
Wilson, 2005). This was highlighted by the INTERHEART study, which derived data from 
individuals in 52 countries, ranging in socio-economic status (Yusuf et al., 2004). Recent 
studies have identified several major risk factors which contribute to the rising burden of 
CVD (Yusuf et al., 2001) and to the development of myocardial infarction (MI). Yusuf et 
al. (2004) reported nine potentially modifiable risk factors comprising behavioural, 
biological and psychosocial factors for the development of MI worldwide. These were 
smoking, history of hypertension or DM, waist-hip ratio, dietary patterns, physical 
activity, and consumption of alcohol, blood apolipoproteins and psychosocial factors.  
Coronary artery disease and MI are the most common form of CVD (Gazino, 2005) caused 
most commonly by atherosclerotic lesions (McPhee & Hammer, 2010). Atherosclerosis 
has been, until recently, viewed as a lipid-based disease in which the initiation and 
advancement of the disease is related to a low-grade systemic inflammatory state (Libby, 
2002). When atherosclerosis progresses to flow-limiting disease, namely ischaemia, 
clinical and symptomatic CVD ensues (Virmani et al., 2006). The earliest manifestation of 
atherosclerosis is characterised by the appearance of fatty streaks in medium-sized and 
large arteries, which begins in adolescence, and, in the absence of accelerating factors, 
develops slowly through to old age. Urbanisation, industrialisation, automation and 
affluence of a society that arise out of epidemiological and socio-economic transition 





have been associated with acceleration in the development of the disease. This is further 
exacerbated by the effects of unhealthy lifestyle changes which result in a sedentary 
activity profile and nutritional changes with the consumption of a cholesterol-and-salt-
rich diet, which is low in fresh fruit and vegetables.  
This global transition has also resulted in the changing of diseases patterns, which is now 
dominated by chronic diseases like CVD and DM. In addition, progress in modern 
medicine, improvements in childhood nutrition and pharmaceuticals have resulted in a 
decline in death from infectious diseases. The subsequent increase in life-expectancy of 
the population, especially the elderly, exposes them to CV risk factors to an age where 
cardiovascular disease manifests clinically. This phenomenon is now contributing to the 
rising burden of healthcare, with the burden further increased by the disproportionately 
higher prevalence of traditional CV risk factors in migrant ethnic minorities (Wu et al., 
2011) like the South Asian Indians in the United States and the United Kingdom, and 
more worryingly, in the young.  
 
1.3.1 The Epidemiology of Cardiovascular disease 
The epidemiology of CV disease has been linked to the accumulation of risk factors 
related to biological factors, and activity and consumption patterns throughout the 
course of an individual’s life (Fuster & Kelly, 2010), with recent studies pointing to the 
contributory effects of nutrition in early life, on the cardiovascular profile later in life 





(Victora et al., 2008). The recent increase in CVD prevalence has been attributed to the 
rise of the presence of abnormal blood lipid profiles, the rise in unhealthy lifestyle and 
behavioural traits (like smoking, inactivity), and the transition to “westernised” diets. The 
increasing prevalence of smoking and hypertension, which, consequently, have been 
reported as the most common CV risk factors in the world (including in middle- and high-
income countries) (WHO, 2009b), further increase this burden. The manifestation of 
hyperinsulinaemia then results from the unhealthy combination of hypertension, obesity, 
and impaired glucose tolerance (Modan et al., 1985; Ruderman et al., 1998). 
Cardiovascular risk has also been reported in foetal life and infancy, accumulating 
throughout childhood through to adolescence and adulthood (Ong & Loos, 2007).  This 
was particularly evident in populations undergoing a transition from chronic under-
nutrition to adequate nutrition (Hales & Barker, 2001), where foetal under-nutrition was 
suggested to cause insulin resistance. The WHO still positions childhood malnutrition as 
the most common risk factor in low-income countries (WHO, 2009e). The thrifty 
phenotype hypothesis was suggested by Neel in 1962 as the possible underlying 
mechanism for the development of CV risk and disease progression based on poor 
postnatal nutritional resources (Hales & Barker, 2001).  
Neel (1962) proposed that genes which allowed the conservation of glucose and efficient 
storage of energy as fat during periods of food abundance, aided survival during times of 
food shortage. With the development of agriculture and affluence, the pressures of 
caloric deficit gradually waned, to the point where these “thrifty genes” were no longer 





needed in some societies. This is most evident in those societies which are undergoing 
socio-economic changes from poverty, where the effect of these thrifty genes may 
manifest with the subsequent development of DM and the metabolic syndrome (Hales & 
Barker, 2001).  
This hypothesis was further supported by a recent study that followed up babies from 
birth to adulthood in five low and middle-income countries (Victora et al., 2008). The 
authors showed that under-nutrition and lower birth weight in childhood were risk 
factors for elevated blood pressure, high glucose concentrations and abnormal lipid 
profiles once adjusted for adult body mass index and height. They suggested that the 
rapid weight gained in the postnatal period was linked to the development of these CV 
risk factors.  
 
Inasmuch as these mechanisms may explain CV risk in low income and developing 
countries, it appears to be limited to certain population groups or ethnicities, since it 
does not explain the excessively high incidence of risk factor clustering that manifest in, 
for example, Asian Indians who are born at normal weight (Dhawan, 1995).  
 
1.3.2 Cardiovascular risk in South Asian Indians  
The population of South Asian Indians number approximately 20% of the world’s 
population (Gupta et al., 2004). With immigration and subsequent adoption of lifestyle 
and dietary habits (particularly a high-fat diet leading to obesity) from western countries, 





their CV risk profile has greatly increased. It is well reported that Asian Indians are 
ethnically more susceptible to developing CVD than other ethnic groups (Yusuf S et al., 
2001; UKPDS, 1998; Sandeep et al., 2011), including other groups of Asians. This excess of 
CV risk has been partly explained by Mukhopadhya et al. (2005) who reported that  Asian 
Indians had an increased predisposition for development of insulin resistance, and has 
been found to occur more commonly in young Indians than in young Chinese (Pan et al., 
2004). Insulin resistance in turn, has been suggested to confer a greater prothrombotic 
risk (Kain et al., 2003) and has been reported to be significantly associated with the 
presence of CV risk factors, even in subjects with normal glucose tolerance (Sandeep et 
al., 2011). Insulin resistance has also been reported more frequently in new-borns in 
subjects of Asian Indian descent, which persists through to childhood (Krishnaveni et al., 
2005).  Other studies (Anand et al., 2000; Hoogeveen et al., 2001) have shown that 
homocysteine, lipoprotein (a) and plasminogen activator inhibitor-1 levels are higher in 
the Asian Indian than in the Caucasian population, and may account for the 
prothrombotic state documented in Asian Indians. 
 
Asian Indians also have a more adverse metabolic and cardiovascular profile when 
compared to other population groups. This was reported in a study of South Asian, Afro-
Caribbean and European subjects aged 40 – 69 years (McKeige et al., 1991) where, with 
the exception of total cholesterol, South Asian Indian men showed lower HDL levels, 
higher fasting insulin and triglycerides levels, higher waist-to-hip ratios and a higher 





prevalence of DM, as compared to the Afro-Caribbean and European subjects. In 
addition, the SHARE study, involving subjects from South Asian, European and Chinese 
subjects showed that Asian Indians carried 4.5 higher odds of developing CAD as 
compared to European subjects  (Anand et al., 2000), as well as a higher prevalence of 
CVD for similar degrees of atherosclerosis in the three populations.  
Furthermore, Asian Indians are known to have a higher percentage of subcutaneous and 
abdominal fat in spite of lower muscle mass and body mass index (BMI) (Misra, 2003).  
This phenotype, known as the “thin-fat” phenotype has been reported to be an 
important contributor to insulin resistance (Misra et al., 2004).  Insulin resistance related 
to obesity, therefore, occurs frequently at a lower BMI (Misra & Khurana, 2008) in Asian 
Indians, even at traditional ‘normal’ levels of less than 25kg/m2 (Snehalatha et al., 2003). 
Thus, the BMI may underestimate the true CVD risk in Asians, especially when it is used 
alone as an indicator of obesity or for CV risk scoring. This was further evidenced in two 
studies, Conus et al. (2004) and St-Onge et al. (2004), where vascular endothelial 
dysfunction, abnormal lipid profiles and hypertension, which are traditionally associated 
with metabolically obese subjects, was reported in individuals who did not have an excess 
of body fat. This rationale has been instrumental for the World Health Organisation 
(WHO) revising the cut-offs for obesity from 30 kg/m2 to BMI to 25 kg/m2 in 2004 (WHO 
Expert Consultation) for Asian Indians. In addition, since BMI is a measure of general 
adiposity (Lemieux, 2007), some large-scale studies have rather recommended the waist-
to-hip ratio together with waist circumference as better measures of abdominal obesity 





(Grundy, 2005; Yusuf et al., 2004). Relative adiposity present in native South Indian 
children at birth has been found to be due to in-uteri programming of insulin resistance, 
promoted through genetic mechanisms (Yajnik et al., 2002).   
The genetic contribution for CAD was also promulgated by Yusuf et al. (2001), in an 
attempt to elucidate the cause for variations in risk factor prevalence, as well as possibly 
explain the increased risk in some individuals in a population for CAD, and not others. 
Inasmuch as South Asian Indians have been identified as having an increased propensity 
for CVD, the disease prevalence is on a rampant increase in other ethnic groups in 
developing countries as well. The development of premature CAD (Enas et al., 2007) and 
higher mortality rates from CVD in Asian Indians (Harding, 2003) further exacerbates the 
situation as the extent and severity of CAD in Asian Indians has been reported as being 
more aggressive and malignant when compared to other population groups (Murray et 
al., 1994), in spite of traditional CVD risk factors being similar or lower than other 
populations groups (Patel et al., 2006). These risk factors are projected to rise to 
epidemic proportions, in the near future (Gupta et al., 2007), further stimulating the 
increased incidence of premature CAD. However, a major cause for concern is that the 
prevalence of CV risk factors is even higher in Asian Indians in the diaspora, reportedly a 
3-to-5 fold increased risk of a CV cause of death (McKeigue et al., 1991) than other ethnic 
groups in their adopted countries.  
 
 





1.3.3 Cardiovascular risk in South Africans 
Africans are presently living in a period of immense change, consequent on the 
transformation in the socioeconomic status and patterns of living, and a marked increase 
in urbanisation (Mayosi et al., 2009). This socio-economic transition has now exposed 
many individuals to the changes in diet and lifestyle which accompany urbanisation. This 
transition is also believed to be responsible for the increase in DM and other non-
communicable diseases (Motala et al., 2011) which are leading to the rise in the 
prevalence of CV disease, alarmingly in the younger population. This poses a major health 
concern with both epidemiological and economic implications (Morcos et al., 2009), 
especially in the vulnerable low-middle-income countries of the world, such as South 
Africa (Tibazarwa et al., 2009), where the rate of transition has escalated following the 
abolishment of apartheid policies in 1994. 
There is evidence to indicate that, as leading causes of death in sub-Saharan Africa, CV 
disease is a close second to HIV, tuberculosis and malaria (Opie & Mayosi, 2005). In South 
Africa, combined with poverty-related diseases, the HIV/AIDs pandemic and high injury 
rates, the emerging increase in chronic diseases of lifestyle (CDL), now quadruples the 
country’s burden of disease (Leeder et al., 2004; Steyn et al., 2004). The South African 
National Burden of Disease reported in 2000 that CDL were the leading cause of death, 
followed by HIV/AIDS, infectious diseases and injuries (Bradshaw et al., 2007). The 
escalation of CDL to epidemic proportions have also been attributed, in part, to the  focus 
of more human resources and infrastructure on the treatment of communicable diseases, 





and low prioritisation of prevention strategies (Stewart et al., 2011) for CVD. However, it 
appears that the overburdened and underfunded Healthcare system still struggles to 
cope even with HIV/AIDs and poverty-related diseases, and is cause for concern as 
mortality rates amongst South Africans for DM and CVD are also on the rise (Mayosi et 
al., 2009). Since it is well established that CVD is largely preventable (Pearson et al., 2003) 
if population-wide interventions are initiated, it is logical that attempts to investigate the 
prevalence of CVD in these high-risk populations should be renewed, with a view to 
implement strategies that will stem the tide of the CVD epidemic. 
Several studies have been done in South Africa, looking at the CV risk factor profile of 
Blacks and Caucasians, where a general trend of increasing prevalence of obesity has 
been documented (Mbanya et al., 2010; Mayosi et al., 2009; Puoane et al., 2002). A study 
by Kalke & Joffe (2007) showed that the prevalence of CAD in Africans was 4%, attributed 
to the contribution of low total cholesterol and the effects of insulin resistance, as 
compared to 23% prevalence in the White population.  They projected that this 
prevalence was on the increasing trend, as the effects of urbanisation and a sedentary 
lifestyle translated into high-cholesterol diets and insulin resistance. This was also evident 
in an urban community in Mamre, near Cape Town, where subjects were reported to be 
at a high probability of suffering a CVD event in the next 10 years (Steyn et al., 2004).  
Although the Asian Indian population is known to be high-risk for CVD, there is very 
limited data available on community-based evaluations of traditional CVD risk factors.   
 





1.3.3.1 CARDIOVASCULAR RISK IN SOUTH AFRICAN ASIAN INDIANS 
There are approximately 1.2 million Asian Indians currently living in South Africa (Stats SA 
P0302, 2011), who make up approximately 2.5 % of the total population.  It has been 
established that the leading causes of morbidity and mortality in the Asian Indian 
community is related to CAD and other CV complications (Seedat et al., 1990).   This 
community-based survey in the Durban metropolitan area documented the prevalence of 
CV risk factors in 778 subjects between 15 and 69 years of age, and found that the 
prominent risk factors were hypercholesterolemia, hypertriglyceridemia, DM, and 
smoking in men. A later study by Motala et al. (1993) reported that there was a high risk 
for the progression of impaired glucose tolerance to overt DM in Indian subjects in South 
Africa. The high prevalence of risk factors and the severe nature of coronary heart 
disease (CHD) in the South African Indian population lead these researchers to 
recommend an immediate and intensive primary prevention programme of CHD risk 
factors. To date, as far as we are aware, no such programme has been initiated.   
The initial epidemiological study on hypertension in the South African Indian community 
was performed in 1978 by Seedat et al., who reported a prevalence of 19% (higher in 
females than males).  A later study in 1988 by Omar et al. documented the prevalence of 
hypertension as 14.2% and DM as 9%.  In yet a later study, these researchers 
documented an increase in the prevalence of DM in the South African Indian community 
(11%), with glucose intolerance found in 5.8% of the sample in Chatsworth, Durban 
(Omar et al., 1993).  These two risk factors (hypertension and DM), coupled with urban 





lifestyle patterns and sedentary habits, have consequently been suggested as the reasons 
for the excess in coronary heart disease in the South African Indian community (Seedat, 
1994), although Sewdarsen et al. (1987) found that dyslipidaemia and obesity were also 
major contributory factors. This large study by Sewdarsen et al. (1987) compared fasting 
serum lipid and lipoprotein levels in 620 consecutive male survivors of myocardial 
infarction with those of 524 healthy male volunteer controls. Hypercholesterolemia was 
reported as the most common abnormality (25%), with obesity being significantly more 
common in patients with hypertriglyceridemia. Type 2 Diabetes Mellitus and 
hypertension were observed more commonly in patients with combined 
hypercholesterolemia and hypertriglyceridemia, illustrating a pattern of clustered risk 
factors. Later studies of subjects in this population group identified smoking and a 
positive family history for CAD (Ranjith et al., 2002) as common risk factors for CAD. More 
recent evidence from Ranjith et al. (2008) suggests that genetic polymorphisms may have 
an impact on the phenotypic expression of the metabolic syndrome in young Asian Indian 
males presenting with acute myocardial infarction. Since the interplay between genetic 
abnormalities and the response to environmental factors could not be clearly established, 
the study authors strongly recommended further studies of other genes involved in lipid 
metabolism and insulin resistance. Since then, further evaluations have not been 
performed on community subjects in the Asian Indian population in Durban.   
The high prevalence of hypertension and DM, coupled with their comorbid complications 
in all the communities in South Africa places a high burden on the resources of the public 





health sector.  In fact, risk factor clustering has been reported to increase an individual’s 
risk for the development of CVD, and is becoming a frequent clinical finding as the young 
and ageing population becomes exposed to the effects of the socio-economic transition.   
 
1.3.4 The Metabolic Syndrome 
The metabolic syndrome (MS) has been described as a heterogeneous (Zimmet et al., 
2001) clustering of several risk factors (hypertension, dyslipidaemia, glucose intolerance, 
abdominal obesity). The syndrome is believed, through mechanisms that remain unclear, 
to greatly increase the risk of CVD in an individual with an increased number of risk 
factors.  
Unlike DM and obesity, which have clear diagnostic criteria, there have been many 
eponyms of MS before the evolution of the current definitions. The first observations 
were reported in 1923 by Kylin, where he described the combination of hyperglycaemia 
and gout as a syndrome. This was further extended by Himsworth (1936), when he 
proposed the delineation of DM into the insulin-resistant and the insulin-sensitive 
variety, where insulin resistance was associated with obesity.  This idea was 
systematically re-introduced by Reaven in 1988 in his Banting Lecture, when he coined 
the term “Syndrome X” and proposed a pathophysiological link between the CV risk 
factors. He suggested that insulin resistance was the common etiological factor for a 
cluster of metabolic risk factors, hence the term ‘syndrome’ (Reaven, 1988).  At that time, 
there appeared to be some contention as to what the main determinant of Syndrome X 





was: the researchers in the DM field (sharing a similar view to Reaven) maintained that 
insulin resistance was the dominant determinant, while others, between 1998 and 2000, 
replaced Syndrome X with “the Metabolic Syndrome”, which described the clustering of 
metabolic risk factors (Alberti et al., 1998; Groop, 2001). In keeping with the evolution of 
this syndrome, some authors (Groop et al., 2001) coined the concept of the 
‘dysmetabolic syndrome’, in order to better describe the abnormalities that are 
suggested by the definitions. 
In 1998, the WHO (Alberti et al.) proposed unifying criteria for the diagnosis of MS, as 
there were marked differences in the prevalence of MS in different studies, which some 
attributed to unavailability of clearly defined criteria (Isomaa et al., 2001). The WHO 
criteria comprised of clinically evident insulin resistance, that is, impaired glucose 
tolerance, impaired fasting glucose or DM (Huang, 2009). Furthermore, two additional 
risk factors were necessary to fit the criteria, those being elevated blood pressure, 
elevated triglycerides, low HDL, obesity and microalbuminuria (Alberti, 1998). These 
criteria were simplified by the National Cholesterol Adult Panel Adult Treatment Panel III 
(NCEP ATP III) in 2001, by restricting the diagnosis of MS to three out of the five risk 
factors, for simpler recognition of the components, and for easier clinical practice. The 
NCEP ATP III criteria were further recently supported by those of the American Heart 
Association and National Heart, Lung, and Blood Institute (with minor modifications) 
(Grundy et al., 2005). The International Diabetes Federation (IDF) replaced the WHO 





criteria for the diagnosis of MS, with the mandatory inclusion of ethnic-specific waist 
circumference cut-offs (Alberti et al., 2005).  
Most recently, in a joint statement from the International Diabetes Federation Task Force 
on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American 
Heart Association; World Heart Federation; International Atherosclerosis Society; and 
International Association for the Study of Obesity (Alberti et al., 2009) proposed unifying 
criteria for the definition for MS. This definition is identical to the NECP ATP III, but 
included the IDF waist circumference ethnic and gender cut-offs, and was called the 
‘Harmonizing criteria’. 
The specific criteria for each of the 3 definitions are detailed in the Methods section in 
Chapter 2.   
 
1.3.4.1 THE PATHOPHYSIOLOGY OF THE METABOLIC SYNDROME 
The underlying pathophysiology unifying the individual components of MS remains 
unclear, but has been related to many factors: obesity and insulin resistance, in addition 
to chronic stress, increased cellular oxidative stress, micro RNA molecules, intrinsic 
glucocorticoid actions, but to name a few (Kassi et al., 2011).  The current literature 
reports that obesity and insulin resistance are the central components responsible for the 
pathogenesis of MS, as these have been reported to contribute to the development of 
metabolic risk factors (Phillips, 2008). Atherogenic dyslipidaemia, elevated blood pressure 
and elevated plasma glucose are the well-recognised metabolic risk factors, which are 





associated with a prothrombotic and proinflammatory state (Alberti et al., 2009). 
Atherogenic dyslipidaemia comprises lipoprotein abnormalities, which include elevated 
serum triglycerides and apolipoprotein B, reduced HDL levels and increased small LDL 
particles (Grundy, 2007). The metabolic syndrome appears to initiate atherogenesis by 
the promotion of apoB-containing lipoproteins elevation, which in turn, advances the 
development of atherosclerotic lesions. The development of the atherosclerotic plaque is 
accelerated by low levels of HDL, elevated glucose levels and inflammatory cytokines 
(Grundy, 2008).  
An inflammatory milieu has been proposed to explain the link between obesity, insulin 
resistance and DM, constituting the MS, while it has been suggested (Das, 2002) that the 
underlying pathophysiology of MS may also be related to low-grade systemic 
inflammation. These observations were established on the presence of raised plasma 
levels of C-reactive protein (CRP), tumour necrosis factor (TNF-α) and IL (inter-leukin)-6 in 
hypertensive, obese, insulin resistant and diabetic individuals. Consequently, these levels 
were also observed in non-diabetic subjects (IRAS study), and correlated significantly with 
an increasing number CV risk factors (Festa et al., 2000), as well as in patients with CAD, 
before and after the onset of these diseases (Das 2001; Das 2002). Another more recent 
study (Samaras et al., 2010) showed that visceral adipose tissue in diabetics express 
higher levels of adipokines involved in inflammation, which was related to fasting glucose 
and insulin action, further strengthening the link between visceral obesity, inflammation 
and DM. 
 





The sudden and dramatic rise in the prevalence of MS has been reported in many 
population and ethnic groups without marked change in the human genome (Phillips, 
2008), and is suggestive of the important role that is modulated by environmental, 
lifestyle and nutritional, as well as genetic factors in susceptible individuals. Furthermore, 
a high heritability for each of the components of the syndrome (Groop et al., 2001), has 
been reported in twin and familial aggregation studies. Together with the large variation 
in terms of age and susceptibility in subjects with similar CV risk factor profiles, a case for 
the possible interplay between genetics and environmental factors (Onat et al., 2009) 
becomes increasingly more plausible.  
 
1.3.4.1.1 Insulin resistance 
Glucose is the primary signal for secretion of insulin by the pancreatic islets beta cells. 
The main effects of insulin are to decrease plasma glucose and free fatty acid 
concentrations, as well as to stimulate protein synthesis (McPhee & Hammer, 2010). 
Circulating insulin allows for the diffusion and utilisation of glucose into the adipocytes 
and muscle cells. In individuals who are metabolically normal i.e. insulin sensitive, 
changes in insulin sensitivity are accompanied by compensatory alterations in the 
response of the beta (ß)-cell to glucose. In subjects who are insulin resistant, a 
compensatory increase in insulin secretion from the pancreas occurs in order to 
overcome impaired insulin action in the peripheral tissues, resulting in a compensatory 
increase in ß –cell mass to maintain normoglycaemia (McPhee & Hammer, 2010). Insulin 
resistance itself is believed to be mediated by glucose signalling as well as genetic factors 





(Goodarzi et al., 2007).   
 
• The signalling cascade 
At the cellular level, most of the metabolic effects of insulin are mediated by the 
signalling cascade involving the insulin receptor substrate (IRS) proteins, phosphorylation, 
and activation of the enzyme phosphatidylinositol (PI) 3-kinase, through which insulin 
produces most of its metabolic actions (Cheatham et al., 1994). The response in subjects 
with normal sensitivity to insulin, where insulin itself is sufficient to suppress lipolysis, 
results in a reduction of very low-density lipoprotein (VLDL), triglyceride and 
apolipoprotein-B production and secretion, thereby preventing the pathophysiological 
cascade that leads to insulin resistance (Ginsberg et al., 2005). The response in subjects 
who are obese with DM is very different, and is characterised by defects at many levels 
(Cusi et al., 2000). An inadequate strength of insulin signalling from the insulin receptor 
downstream to the final substrates of insulin action via IRS-1 /PI 3-kinase pathway 
(Ginsberg et al., 2005) results in diminished glucose uptake and utilisation in insulin 
target tissues (Jiang et al., 1999; Cusi et al., 2000).  
 
• Adipocytokines  
Certain adipocytokines are also implicated as a cause for impaired signalling by means of 
the insulin receptor, thereby increasing lipolysis, the excess of which is secreted into the 
plasma (Mazurek et al., 2003). This release of non-esterified fatty acids, particularly those 
from visceral adipocytes (as these drain directly into the portal system), bathes the liver 





in fatty acids, resulting in the liver becoming insulin resistant (Bergman et al., 2007).  The 
increase in free-fatty acids (FFA) has also been directly implicated as a cause for 
dyslipidaemia associated with insulin resistance, as triglyceride synthesis and storage is 
increased, with the excess being secreted as VLDL (Sniderman et al., 2007). This then 
results in alterations to lipoprotein lipase.  
 
• Oxidation of free-fatty acids and lipotoxicity 
Another mechanism for insulin resistance in obese individuals arises from the increase in 
the oxidation of fatty acids. When the storage capacity of adipose tissue is saturated, 
unoxidized long-chain fatty acids are driven into non-adipose tissues, such as the liver, 
muscle, heart, and pancreatic-islets. The consequent formation of reactive lipid moieties 
then produces adverse effects by promoting metabolically relevant cellular dysfunction 
(lipotoxicity) and lipoapoptosis (Kusminski et al., 2009). The excess oxidised FFAs are then 
esterified into triglyceride, which, in excess amounts results in an increase in the 
mitochondrial acetyl coenzyme A (COA) and NADH: NAD ratios, inactivating pyruvate 
dehydrogenase. The subsequent rise in the levels of intracellular citrate levels, leads to 
the inhibition of phosphofructokinase, and G6P accumulation. This then results in 
diminished glucose uptake and the inhibition of glycolysis, since G6P inhibits hexokinase 
activity (Haring, 1991; Cheatham et al., 1994). 
 
Insulin resistance in peripheral tissues, like the muscle, arises from disruption of the 
glucose-fatty acid cycle. In the skeletal muscle, however, it occurs because of the 





inhibitory effect of increased plasma FFAs on insulin-mediated glucose transports 
(Cornier et al., 2008). The continuum between insulin resistance and obesity is further 
highlighted by its association with general obesity, central obesity, hypertension, and 
abnormal lipid levels, which are each components of MS. In fact, Grundy et al. (2005) 
reported that obesity, coupled with physical inactivity and a diet high in fat, was 
responsible for insulin resistance. This was further supported by Roche (2005), who 
suggested a progressive phenotype that inter-linked insulin resistance with obesity, DM 
and MS.   
 
1.3.4.1.2 Adiposity 
Eckel and co-researchers (2005) suggested that the dramatic rise in the prevalence of 
obesity was one of the main reasons for the promulgation of the metabolic syndrome 
definitions. Many experts believe that obesity is a dominant driver in insulin resistance 
(Cornier et al., 2007), as it has been established that body fat is a strong predictor of 
insulin resistance and CV risk (Misra et al. 2004,). The literature also documents a 
stronger correlation observed between central or abdominal obesity or  "android or 
male-type obesity," as reported by Vague (1947) and increased CV risk, insulin resistance, 
DM, hypertension and mortality as compared to the "gynoid or female-type of fat 
distribution" in the lower body or gluteo-femoral or peripheral depot (Wajchenberg, 
2000). 
 





Abdominal fat is composed of two different anatomic depots, namely, subcutaneous and 
intra-abdominal fat. Subcutaneous fat can be separated into superficial and deep layers, 
while intra-abdominal fat can be divided into intra-peritoneal and retro-peritoneal sites. 
Intra-peritoneal fat, also termed visceral fat, is composed of mesenteric and omental fat 
masses (Märin et al., 1992).  
 
The expanded mass of adipose tissue, as seen in obesity, results in an increased 
production of FFAs (Ginsberg et al., 2005). Insulin resistance accelerates FFA lipolysis 
from adipose tissue triglyceride stores, and vice versa, with the visceral adipose store 
being known to contribute to insulin insensitivity and increased FFA lipolysis (Bergman et 
al., 2007). Visceral adipose tissue, which was initially thought of as an inert storage organ, 
is currently viewed as a depot for pathogenic fat (Mahabadi et al., 2009), with some 
researchers (Juhan-Vague et al., 2003; Kershaw et al., 2004; Wellen & Hotamisligil, 2003) 
regarding it as an endocrine organ because of the bioactive molecules that are produced. 
Recent literature provides a strong role for the systemic effects of adipose tissue on 
atherosclerosis,  as it correlates significantly with inflammatory markers (Pou et al., 
2007), CV factors (Rosito et al., 2008) and the metabolic syndrome (Fox et al., 2007). This 
may possibly be explained when surplus adipose tissue produces a disproportionately 
high amount of non-esterified acids and proinflammatory adipocytokines which hamper 
systemic responsiveness to insulin (Schinner, 2005; Ghanim, 2004). Furthermore, insulin 
action may be modified locally within the adipose tissue, through the paracrine effect of 
the adipocytokines. Once these adipocytokines reach the portal circulation, they are 





drained into the liver where they are responsible for modulation of the synthesis of 
hepatic proteins and trigger the development of an inflammatory milieu (Tremblay et al., 
2011). This process is also believed to result in impaired glucose action, compensatory 
hyperinsulinaemia and glucose intolerance.  
 
1.3.4.1.3 Cardiac structural alterations related to insulin resistance  
In the normal cardiac myocyte, glucose serves many crucial functions like serving as fuel 
supply, gene expression and sarcomeric changes (Young et al., 2002). Loss of regulation 
of glucose therefore results in disruption of these regulatory functions in the heart. With 
ensuing insulin resistance (Figure 1.1), cardiac remodelling occurs through the 
contributory effects of lipotoxicity, sympathetic up-regulation, inflammation, oxidative 
stress, and fibrosis (Taegtmeyer et al., 2002). Other documented changes related to 
insulin resistance are an increased size of the left atrium (LA), as well as an increase in the 













Figure 1.1: Possible mechanisms which underlie cardiac remodelling in insulin 
resistance 
 
                                                                                                                                                   Rutter et al., 2003 
 
Experimental, pathological, epidemiological and clinical studies have shown that overt 
DM causes changes within the cardiac structure and function in the absence of coronary 
atherosclerosis, hypertension or any other known cardiac disease. The elevation of 
plasma nonesterified fatty acid levels observed in subjects with DM results in the 
activation of PPARα (van de Weijer et al., 2011). With ensuing pressure overload and/or 
prolonged exposure to hyperglycaemia and/or hyperlipidaemia, a decrease in PPARα 
expression results, limiting the fatty acid oxidation capacity of the heart. The excess of 
accumulation of intramyocardial lipids then results in lipotoxicity, which plays a critical 
role in the development of contractile dysfunction and the diabetic cardiomyopathy 
(Cosson & Kevorkian, 2003). Left ventricular diastolic dysfunction is perceived as the 
earliest preclinical manifestation of the diabetic cardiomyopathy, and these changes may 





be detected non-invasively, using echocardiography. Echocardiography may also be used 
to evaluate the accumulation of visceral fat around the heart, which recently, has been 
found to be associated with the presence of MS and CAD.   
 
• Sub-epicardial adipose tissue 
The role of sub-epicardial adipose tissue, which is also called the visceral or pericardial fat 
around the heart, its relationship to normal cardiac structure and its role in 
cardiovascular risk has until only recently, been very limited (Iacobellis, 2003). Epicardial 
fat is more closely related to abdominal visceral fat (which makes up the largest 
deposition of visceral fat [Rosito et al., 2008]), than total fat, which, during 
embryogenesis, originates from brown fat tissue, and later differentiates into white 
adipose tissue (Marchington et al., 1989). Iacobellis et al. (2005) described the local 
interactions between the adipose and muscular components of the heart as they shared 
the same blood supply, with no fascia separating the myocardial and epicardial layers. 
Other functions of sub-epicardial adipose tissue (SEAT) were to act as a buffer against 
toxic levels of free-fatty acids between the myocardium and the vascular bed 
(Marchington et al., 1989), and to provide a steady supply of free fatty acids to meet 
energy demands of the myocardium. However, SEAT may also exert a harmful effect on 
the myocardium, since pericardial fat has also been associated with metabolic risk factors 
and CVD (Rosito et al., 2008), and is believed to alter, via the expression of several 
biomarkers (Baker, 2006), cardiac function and promote atherogenesis.  





There are two mechanisms that have been hypothesised to potentially explain the 
interrelationship between SEAT and CAD. Chaowalit et al. (2006) summarised the first as 
one which was associated with conventional CV risk factors and MS. The second, related 
to the possible paracrine function of SEAT, emanates from the local interaction of adipose 
tissue locally with coronary arteries (Baker et al., 2006). 
The paracrine release of cytokines from the periadventitial epicardial fat diffuses into the 
coronary walls, interacting with cells in each of its layers. This, in turn, leads to the 
amplification of vascular inflammation and plaque instability (Mazurek et al., 2003).  
Furthermore, periadventitial applications of inflammatory cytokines and adipokines have 
been known to induce inflammatory cell influx into the arterial wall, suggesting that these 
molecules from pericoronary tissues may be responsible for the alteration of arteriolar 
homeostasis (Miyata et al., 2000). Current research also proposes a link between visceral 
adiposity, inflammation and the risk of DM, based on the increased release of 
inflammatory markers from visceral fat in diabetics (Samaras et al., 2010; Van de Weijer 
et al., 2011).  SEAT thickness, in particular, has also recently been associated with the 
clinical parameters of the MS (Chaowalit et al., 2006): with the epidemic rise of MS, 
evaluation of SEAT may well be a useful composite marker for the detection of the 
syndrome. 
 
1.3.4.2 THE PREVALENCE OF THE METABOLIC SYNDROME 
The prevalence of the MS is increasing worldwide (Grundy, 2008), with prevalence 
estimates dependent upon the definition which is used. The age-adjusted prevalence of 





MS in the United States has been reported as 23.7% (Ford et al., 2002), with 
approximately 13% of adolescents having the syndrome (Ford et al., 2003). This 
prevalence has been reported in similar proportions in Europe, with 15% -23% of 
Europeans being diagnosed with the MS (Hu et al., 2004). 
The sex, age, race, ethnicity and the level of socio-economic transition of the population 
being studied are also determinants of MS prevalence (Ford et al., 2003), with a 
concurrent increase in prevalence being documented with obesity (Cornier et al., 2008). 
South Asians have a 20 - 25% prevalence of MS, with a substantially higher prevalence 
observed in Asian Indians (Eapen et al., 2009). The increasing prevalence of insulin 
resistance and DM have been purported as one of the main drivers of MS in Asian 
Indians, with the Chennai Urban Population study (Mohan et al., 2003) reporting the 
frequency of MS varying from 41.1 to 49.2% (Wasir et al., 2008) in urban Asian Indian 
adults. The prevalence of the MS in migrant Asian Indians has been reported to vary from 
31.6% (Misra et al., 2005) to 38.2% (Misra et al., 2010). These current estimates of 
prevalence are a cause for concern, with the projected escalation even more worrying, as 
the conglomeration of CV risk factors (like obesity, insulin resistance and hypertension) 
become increasingly common. There is general agreement that adverse outcomes are 
more likely when risk factors occur simultaneously (Kahn et al., 2005), although the 
usefulness of the syndromic nature of the  MS  in predicting CV risk has become a topic of 
much debate in recent years. 
 





1.3.4.3 CURRENT CONTROVERSIES REVOLVING AROUND THE METABOLIC 
SYNDROME 
The American Diabetes Association and the European Association for the Study of 
Diabetes published a joint statement in 2005 questioning whether the components of 
MS, as was currently defined, implied any unique pathophysiology by calling it a 
‘syndrome’ (Kahn et al., 2005). They also questioned whether additional risk was 
conferred beyond its individual components, and if there was any medical value in 
diagnosing these risk factor components as a ‘syndrome’. The main points that were 
raised in the joint statement (Kahn et al., 2005) were: 
a. Lack of a common definition which has resulted in discrepant results on its 
association with CVD morbidity and mortality,  
b.  The criteria for inclusion is ambiguous and the rationale for the cut-offs are not 
clearly defined 
c. The unifying role of insulin resistance as the main aetiological basis for the 
syndrome is unsure, and the value of including DM in the definition is questioned 
d. CVD risk is based on the presence of specific risk factors only, with no clear 
rationale for including or excluding these factors 
e. The CVD risk associated with MS appears to be the sum of its components and 
treatment options are geared towards treating individual risk factors, and not the 
‘syndrome’ per se 
In 2010, the WHO Expert Consultation report (Simmons et al.) echoed similar opinions, 
questioning the practical utility of MS as a clinical tool for diagnosis or disease 





management.  A corroboration of two prominent studies (PROSPER and BHRS) showed 
that MS was not associated with vascular risk in the elderly (Sattar et al., 2008), nor was 
CV risk greater in MS as compared to the sum of its individual components (Stern et al., 
2004). In fact, a recent article documenting the ‘rise and fall of the Metabolic Syndrome’ 
(Borch-Johnsen & Wareham, 2009) claims that in spite of all the research done on MS, 
clear reasons underlying the susceptibility to developing CVD or DM still remain vague.  
 
In spite of the lack of a unified definition of MS, a large body of literature supports an 
association between MS and CVD. Irrespective of the diagnostic criteria used, there have 
been many recent epidemiological studies that have supported the increased risk for CVD 
in subjects with MS (Bayturan et al., 2010; Cabre et al., 2008; Hu et al., 2004; McNeil et 
al., 2005; Ford, 2004; Alexander et al., 2003). A meta-analysis by Ford et al. (2005) which 
examined the relative-risk for all-cause mortality, CVD and DM from the general 
population using the WHO and NCEP ATP III MS definitions found that the population-
attributable fraction for MS was 12-17% for CVD and 20-52% for DM. Similarly, in Asian 
Indians patients, Lakka et al. (2002) showed that the presence of MS predicted CVD in 
middle-aged men, and was associated with a two-fold risk for developing cardiovascular 
mortality. More recently, a large, internal, multi-ethnic study from INTERHEART reported 
a >2.5-fold increase in the risk for acute MI in subjects with MS (Mente et al., 2010). An 
increased all-cause mortality (RR=1.35; 95% CI) for CVD, CAD and stroke was also 
reported in a meta-analysis (Galassi et al., 2006), where the authors highlighted the 
importance of detecting, preventing and treating the underlying risk factors which make 





up MS in the general population. A similar recommendation was made by the authors of 
another meta-analysis of 37 longitudinal studies comprising 43 cohorts (Gami et al., 
2007). They showed that individuals with MS were at an increased risk of cardiovascular 
events, particularly when compared with those studies which followed up subjects 
without CAD. Such was the strength of their findings that they recommended primary 
intervention programmes to address MS as a single entity, in addition to treating 
individual CV risk factors. 
 
The metabolic syndrome is also an important risk factor for subsequent development of 
DM and/or CVD. This was borne out from a study by the Third National Health and 
Nutrition Examination Survey (NHANES III, 2003) data, which graded subjects for CVD risk 
based on the presence of MS and DM. Subjects without MS were found to have the 
lowest risk for CVD events, with those having MS being at intermediate risk, while 
diabetic subjects had the highest level of risk for CVD events. Similarly, Meigs et al. 
(2003), when using the Framingham cohort, found that irrespective of the criteria used, 
those individuals with MS were at a higher risk of CVD. These authors, like Galassi et al. 
(2006) further advocated the importance of early detection, prevention and therapy for 
MS. 
 
More recently, these associations have been supported by the International Diabetes 
Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood 
Institute; American Heart Association; World Heart Federation; International 





Atherosclerosis Society; and International Association for the Study of Obesity (2009). 
They found that subjects with the MS were twice as likely to develop CVD over 5-20 
years, and had a 5-fold increased risk for developing DM, as compared to those without 
the MS. A joint statement from the International Diabetes Federation proposed a new set 
of unifying criteria for MS in 2009. These were cognisant of the limitations associated 
with the current definitions mentioned above, with the new definition being called the 
“Harmonizing criteria”. In spite of the disagreements amongst the different expert panels 
regarding the definitions and the criteria, there emerged a consensus from this group 
that the term “metabolic syndrome” was acceptable for the condition describing 
clustering of metabolic risk factors for DM and CVD (Alberti et al., 2009). This group also 
proposed that central obesity, as measured by waist circumference measurement, was 
no longer obligatory (as per IDF definition), but formed one of the risk factors for the 
definition. In an attempt to unify the criteria, they proposed the ‘Harmonized criteria’ in 
which 3 out of the 5 risk factors was needed for the diagnosis of MS (see Methods for 
elaboration).  
Therefore, a diagnosis of the metabolic syndrome appears to be valuable when 
attempting to delay the development of DM and atherosclerosis. This would involve 
timeously identifying a patient who needs aggressive lifestyle modification focused on 
weight reduction and increased physical activity (Rozenzweig et al., 2008; Eckel et al., 
2005), and hence a reduction of multiple risk factors (Alberti et al., 2009). For this 
strategy to be most effective, it would be particularly important to ascertain the 
frequency of risk factor clustering and the most influential components, particularly in 





ethnic groups with a traditionally high CV risk factor prevalence.  One such group in 
whom this would be especially relevant is the Asian Indian group in whom a high CV risk 
factor profile, with a consequently high predisposition for premature CAD, has been well 
established.  
 
1.3.4.4 THE METABOLIC SYNDROME IN SOUTH ASIAN INDIANS 
The metabolic syndrome has been extensively researched in the South Asian Indian 
population in India, and in some parts of the diaspora. Cardiovascular risk factor 
clustering has been reported to be on the increase in Asian Indians (Enas et al., 2007), 
with Misra & Khurana (2009) recently reporting an MS prevalence of 38.2% in urban 
Asian Indians. The SHARE study (Anand et al., 2000) reported a 41.1% prevalence of MS in 
urban Indians when applying the ATP III criteria with the modified waist circumference 
cut-off, with MS being present in 27.9% of participants with normal blood glucose 
profiles. Using the ATP III criteria only, Gupta et al. (2004) reported a 31.6% prevalence of 
MS in urban Indians, to name a few studies. The exact reason for this excess in Asian 
Indians still remains unclear, hence the existence of many possible mechanisms currently 
being postulated. 
As discussed above, there is a high incidence of CV risk factors and CAD found in Asian 
Indians, particularly, insulin resistance, essential hypertension and DM (McKeigue et al., 
1994) as compared to other Western population groups. The exact mechanism for this 
excess risk is not known, but one, which has been reaffirmed by Misra et al. (2004), is 





that Asian Indians tend to gain fat in the abdominal area, with consequent development 
of central obesity rather than generalised obesity. At the biochemical level, Das (2003) 
suggested that the increased expression of 11ß-HSD-1, which is triggered by high levels of 
TNF-α and IL-6 (which are elevated even in healthy Asian Indians) may be responsible for 
the development of abdominal obesity. 
Additionally, the initial trigger for the development of CV risk factors and MS may be 
present even during the foetal phase (Das, 2002), as studies on children of Asian Indian 
origin have shown that insulin resistance occurs early in childhood (Whincup et al., 2002)  
or infanthood, with a degree of heritability. The components of MS are highly heritable in 
Asian Indians, with recent studies showing a heritability (h2) value of between 0.27 and 
0.53 (Zabaneh et al., 2009). It has been suggested that the risk factor profile of migrant 
Asian Indians might be higher than the native populations of their adopted countries, 
even higher still than subjects in India (McKeigue et al., 1989).   
 
1.3.4.5 THE METABOLIC SYNDROME IN SOUTH AFRICANS  
Currently, there is no data available on the national prevalence of insulin resistance, DM 
or MS. What is known from data collected in 1990’s, is that the prevalence of DM is the 
highest in the Indian population (13%), and followed by a lower prevalence in the Black 
(5-8%) and in the White (4%) populations (Huddle & Kalk, 1994).  In South Africa, 
particularly, there is limited information regarding MS in Black subjects.  A recent study, 
looking at randomly selected rural Black South Africans of Zulu descent (Motala et al., 





2011) reported an overall prevalence of 22% when using the 2009 Joint Interim 
Statement (JIS) criteria. A lower prevalence of 10% and 13% was reported by Jennings et 
al. (2009), who studied 209 normal and overweight Black female subjects without known 
disease, using ATP III and IDF criteria, respectively.  Another study looked at a group of 
Black and White corporate executives and reported a MS prevalence of 31% (Ker et al., 
2007) for both population groups. The only recent local report on MS in Asian Indians is a 
study by Ranjith et al. (2008) who found that the MS was prevalent in 60% of subjects in 
their cohort of young patients, hospitalised with myocardial infarction.  
Although the MS has become increasingly common as part of an epidemic of obesity, 
hypertension and insulin resistance, few studies have examined the effects of the MS on 
early changes in cardiac structure and function. There is evidence that the MS is 
associated with an increased LV mass as well as early changes in LV diastolic function, but 
little local data is available on how these risk factors together increase CV risk, or how 
they interplay to alter cardiac structure and function.   
 
1.3.5 The use of echocardiography as a diagnostic tool for early detection 
of cardiac structural and functional abnormalities 
The detection of preclinical changes in cardiac structure in response to the presence of 
CV risk factors may allow timeous intervention before permanent, irreversible changes 
occur (Mogelvang et al., 2009). The STRONG Heart Study (Drukteinis et al., 2007) 
analysed clinical characteristics and left ventricular structure and functions in 1940 





participants of American Indian heritage in the 14 to 39 age group. There was a 35% 
prevalence of prehypertension with concomitant greater LV wall thickness and LV mass. 
They reported that these prehypertensive subjects were more likely to develop left 
ventricular hypertrophy (LVH) than normotensive subjects were. Prehypertension has 
also been associated with higher rates of CVD in older subjects (Devereux et al., 2000). 
Early detection of prehypertension would permit appropriate intervention and prevent 
left ventricular hypertrophy with its sequelae of ischaemic stroke (Fox et al., 2007) and CV 
events (Levy et al., 1990).  
Early changes in myocardial function which are associated with CV risk factors are 
characterized by a normal ejection fraction and subtle changes in the diastolic 
parameters. Diastolic abnormalities have also been associated with the presence of 
insulin resistance, with overt changes being documented in the presence of DM. A 
decrease in ventricle filling during the initial phase of diastole (Nagueh et al., 2001), 
prolongation of the isovolumic myocardial relaxation time (measured by the isovolumic 
relaxation time [IVRT]) and an increase in the left atrial (LA) filling pressure confirm a 
worsening degree of diastolic filling, eventually deteriorating into diastolic dysfunction. 
Common structural changes that occur in the presence of overt DM are characterised by 
such diastolic abnormalities and significant increases in the LV mass, independent of the 
effects of other traditional risk factors (de Marco et al., 2012). For example, Shapiro, et 
al. (1981) reported that left ventricular dysfunction was a common finding in 
asymptomatic diabetic subjects, which was related to the degree of microvascular 





complications with myocardial involvement in diabetes. The STRONG heart study 
(Devereux et al., 2000) also reported similar findings, with diabetic American Indian 
subjects having significantly increased LV mass, left ventricular wall thickness, as well as 
reduced myocardial function, as compared to subjects with normal glucose tolerance.  
Diastolic dysfunction (DD) does not always present with symptoms of heart failure, yet it 
is currently regarded as one of the first markers of imminent CVD (Paulus et al., 2007). 
The prevalence of diastolic heart failure (DHF) has risen dramatically to over 50% (Owan 
et al., 2006), and accounts largely for heart failure admissions in the elderly (Graves et al., 
1994). DHF is also referred to as heart failure with normal left ventricular (LV) ejection 
fraction (HFNEF)(Zile et al., 2004), with older subjects, females, hypertensive subjects, 
diabetic subjects, obese and subjects with LV hypertrophy being at increased risk. 
Diastolic dysfunction is also believed to be the first stage of the diabetic cardiomyopathy 
(Cosson & Kevorkian, 2003), and is related to the duration of DM (Kim et al., 2011). 
However, the subtle changes that occur during the progression of diastolic dysfunction to 
diastolic failure, which, in its normal course precedes systolic dysfunction, may not be 
detected with conventional echocardiography. The loss of longitudinal motion, one of the 
most common functional changes that occur with ageing and diastolic dysfunction, is 
associated with subendocardial interstitial fibrosis, increased conduit arterial pressures 
and increased central arterial pressures (Fraser, 2009). These subtle changes may be 
detected by myocardial velocity measurements, using Tissue Doppler imaging (TDI),  and 





has been used to diagnose DD with greater sensitivity and specificity than 2-D and M-
Mode echocardiography (Poirier et al., 2001).   
Although TDI indices are a reflection of diastolic filling pressures at an instant, an 
increased LA size has been reported to better reflect the cumulative effect of filling 
pressures over time (Prichett et al., 2003).  Enlargement of the LA is a concurrent finding 
in systolic and diastolic dysfunction and in overt CVD (Tsang et al., 2002) with LA 
remodelling being predictive of CV events. Since the LA expands in three dimensions and 
eventually assumes a more spherical shape, Prichett et al. (2003) proposed that the left 
atrial volume index (LAVI) was a better indicator of LA remodelling than the LA size. 
Furthermore, it was recently reported that the LAVI measurement is a more accurate 
clinical prognosticator for cardiac disease (Kedia et al., 2008), with a similar predictability 
as the EF for heart failure hospitalisation and mortality in ambulatory adults with CAD 
(Ristow et al., 2008). In the absence of conclusive TDI findings (i.e. diastolic filling ratios 
Em/Ea ≥ 15) a LAVI measurement > 40 ml/m2 is indicative of LV diastolic dysfunction 
(Paulus et al., 2007). 
Since there are limited community-based studies providing information regarding cardiac 
structural and functional changes in subjects with preclinical disease, particularly in the 
young, this project sought to determine a non-invasive assessment of these parameters 
using echocardiography. The degree of structural alteration associated with the risk 
factors profile, as well as risk factor clustering, was ascertained.   
 





1.3.6 The Metabolic syndrome and cardiac structure 
The growing incidence and prevalence of obesity in South Africa and worldwide has led 
to the metabolic syndrome becoming an increasing public health concern. Population-
based studies exploring the effect of MS on cardiac structural and functional 
abnormalities are limited, and few studies have included quantitative assessment of LV 
diastolic function. A recent study by Aijaz et al. (2008) found that metabolic syndrome 
was associated with an increased LV mass index and LV diastolic dysfunction in American 
Caucasian women. Also, it has been observed that obese adolescents with MS often have 
increased LV mass suggesting that this is a response not only to increased haemodynamic 
load but also to possible neurohormonal effects relating to clustering of metabolic risk 
factors (de Marco et al., 2012). Similar findings were described by Sundstrὃm et al. 
(2006), who reported an increase in the LV mass in subjects with MS in a large group of 
elderly subjects, with these changes related to the contributory effects of insulin 
resistance. The STRONG Heart study (Chinali et al., 2006) reported on a group of young 
Native American Indian subjects (24% prevalence of MS in this cohort), and found that 
MS was associated with LA dilation, LV hypertrophy, reduced systolic and impaired 
diastolic function.  
What emerges from these studies is that there are clear structural changes that occur in 
the presence of MS. According to our knowledge, no such study has been performed on 
subjects in South Africa, particularly in a population group with a traditionally high CV risk 
factor profile. Furthermore, the cardiac structural and functional changes in MS subjects 





with milder forms of obesity, insulin resistance and hyperlipidaemia, especially in this 
community setting, remain unclear. This study therefore planned to explore the 
association of MS with changes in cardiac structure and function across genders in a 
broad range of age groups in a community setting, using Doppler imaging as well as an 
estimation of epicardial fat. The measurement of the sub-epicardial adipose tissue 
thickness was also made to determine its value as a composite marker of the metabolic 
syndrome. 
 
1.3.7  Echocardiography and SEAT thickness 
Obesity, particularly visceral obesity, is regarded as one of the main determinants of MS 
(Bosello et al., 2000). Although waist circumference is a surrogate measurement of 
visceral fat, its limitation lies in its inability to delineate subcutaneous from visceral fat. 
The detection of sub-epicardial adipose tissue [SEAT] using echocardiography, has been 
demonstrated and validated using MRI (Iacobellis, 2003) and CT (Ahn et al., 2008), where 
echocardiographically-derived measures of epicardial fat correlated strongly with visceral 
abdominal fat. SEAT thickness has also been associated with the clinical parameters of 
the MS (Chaowalit et al., 2006), as well as anthropometric (body mass index and waist 
circumference) [Ding et al., 2009], insulin resistance and obesity (Iacobellis & Leonetti, 
2005).  Pericardial fat is also predictive of incident CAD, independent of conventional risk 
factors, after adjustment for BMI and other CV risk factors (Baik et al., 2007). SEAT is 
significantly thicker in patients with unstable angina in comparison to those with stable 





or atypical angina (Ahn et al., 2008), with recent studies (Park et al., 2010; Eroglu et al., 
2009) reporting similar findings in subjects with MS and CAD, as compared to those with 
normal coronary arteries. A Turkish study (Kaan et al., 2008), confirmed a close 
relationship between subepicardial adipose tissue and the MS in a small cohort of 123 
patients, with these authors suggesting that an assessment of SEAT thickness might be 
valuable in the routine echocardiographic examination to predict the presence of MS.  
 
In this study, we used Doppler echocardiography to evaluate cardiac structural and 
functional changes in all subjects, together with two-dimensional echocardiography for 
the visualising and assessment of visceral adipose tissue. We also studied selected gene 
polymorphisms in these subjects to ascertain a possible genetic predisposition. 
 
 
1.3.8 Single Nucleotide Polymorphisms and the Metabolic syndrome 
There is a substantial body of evidence that supports the concept of a genetic basis for 
CVD and DM (Motulsky & Bruznell, 2002), as has been shown in family studies (Levy, 
2003). Although large genetic epidemiological studies have identified gene 
polymorphisms that confer increased susceptibility to CVD, few studies have examined 
these polymorphisms in ‘normal’ subjects to determine their propensity to metabolic 
alterations (such as MS) and to atherosclerosis. Furthermore, although varying 
associations between cardiovascular disease and genetic polymorphisms in different 





populations have been documented, the general emphasis still remains on the need and 
importance of ethnic-specific investigations (UKPDS, 1998). Most common diseases, like 
DM and atherosclerosis, are accompanied by disturbances in the biochemical traits. The 
inheritance of biochemical traits, which may serve in risk factor stratification, may be 
more influenced by genetic variation (Wallace et al., 2008), rather than their related 
diseases. 
 
Corella (2002) suggested that the population-attributable risk for CVD was determined by 
the high allelic frequencies of a mutation or single nucleotide polymorphism (SNP), which 
manifested significantly only at population-level. Kathiseran et al. (2008) further 
emphasized the value of SNPs that were able to influence the variation in (for example) 
lipid levels amongst individuals in a population, providing information about CV risk 
beyond the lipid level itself. Therefore, one of the fundamental questions underlying this 
aspect of the project was to determine whether environmental or genetic factors are 
associated with particular biochemistries or phenotypes. Furthermore, it was important 
to know the extent to which these phenotypes were modulated by CV risk factors. As this 
analysis forms part of a larger genetic component related to the Phoenix Lifestyle Project, 
this study focusses on the genetic associations in relation to CV risk factors related to the 
metabolic syndrome only.  
Although the expression of each of the major component of MS is known to be caused by 
the complex interaction of environmental and genetic factors, understanding the role of 





the genetic factors still remains unclear, since the literature provides limited description 
of the genetic mechanisms underlying the pathophysiology of MS (Nugent, 2004). A large 
number of genetic association and linkage studies reviewed by Joy et al. (2008) and 
Zabaneh et al. (2010) could not provide any confirmed associations with MS. Since 
adipose tissue has been reported to play a central role in the pathogenesis of MS, by 
interacting with genetic variants at candidate genes for dyslipidaemia, hypertension and 
insulin resistance, candidate gene polymorphisms that were related to these conditions 
were studied.  Since oxidative stress has been implicated as a cause of endothelial injury, 
which in turn, has been proposed as the aetiology for DM, candidate gene 
polymorphisms related to endothelial injury were also studied. On this basis, common 
polymorphisms in the Lipoprotein Lipase (LPL) and the Human Paraoxonase-1 (PON-1) 
genes were chosen. The rationale for choosing these genes is explained below.  
 
1.3.8.1 LIPOPROTEIN LIPASE  
Circulating lipids are carried in lipoproteins, which consist of esterified and unesterified 
cholesterol, triglycerides, phospholipids and protein (Preiss-Landi et al., 2002). 
Lipoprotein lipase (LPL) is the major rate-limiting enzyme that catalyses the hydrolysis of 
triglyceride from circulating triglyceride-rich lipoproteins, very low density proteins and 
chylomicrons (Wang, 2009). During this process, surface-free cholesterol and 
phospholipids are transferred to HDL particles, increasing the concentration of HDL 





(Preiss-Landi et al., 2002). The products from these catalytic reactions, like fatty acids, are 
taken up by the tissues and processed differentially; hence LPL acts as a bridging protein 
which mediates the cellular binding and up-take of lipoproteins (Stein, 2003).  
Lipoprotein lipase is found throughout the body, with the highest activity and mRNA 
levels found in the heart, skeletal muscle, adipose tissue, and to a lesser degree, in the 
lungs and brain (Zechner, 1997). It is expressed in the adipocytes, macrophages, smooth 
muscle cells, and most importantly, on the luminal surface of the capillary endothelium 
(Zechner, 1997). Since LPL plays a pivotal role in overall lipoprotein metabolism, it is 
involved in forward cholesterol transport and contributes to the maturation of high-
density lipoprotein (HDL) precursors, which are themselves involved in reverse 
cholesterol transport (Pillarisetti, 2003). Lipoprotein lipase also controls the delivery of 
triglyceride-derived free-fatty acids to muscle, adipose tissue, and vascular wall 
macrophages, where lipid uptake influences peripheral insulin sensitivity, central obesity, 
and foam cell formation (Mead, 2002).  
Most of the identified SNPs with functional effects have been reported to lead to loss of 
enzymatic function, and hence, higher triglyceride and lowered HDL levels (Kathiresan et 
al., 2008). A reduction in LPL activity could result in adverse metabolic consequences and 
contribute to the clinical phenotype (Zhang et al., 1996), which is supported by the strong 
association that has been reported between reduced LPL activity, major cardiovascular 
risk factors (Mead, 2002) and MS (Aguilera et al., 2008). Therefore, diminished LPL 
activity is suggested to be one mechanism that results in impaired clearance of circulating 





lipoproteins, with subsequent hypertriglyceridemia (Wang et al., 2009). An increase in 
LPL activity, however, is associated with a favourable lipid profile, namely, a lower 
triglyceride and higher HDL levels (Preiss-Landi et al., 2002). Hayden et al. (1991) 
reported that lipid abnormalities have genetic determinants, with other researchers 
postulating that the metabolic parameters that determine serum lipid and lipoprotein 
levels are modulated by multiple gene-gene and gene-environmental interactions 
(Corella et al., 2002; Lee et al., 2004).  
 
1.3.8.1.1 The Lipoprotein lipase gene 
The gene that codes for LPL is located on chromosome 8p22, spans close to 35 kb, and 
contains 10 exons (Oka et al., 1990). Most of the over 100 identified LPL gene mutations 
are rare, with 20% occurring in the non-coding regions (Murthy et al., 1996). Three 
common exonic variants, namely, D9N, N291S and S447X have been identified (Van 
Bockxmeer, 2001).  
Abnormalities of LPL function are associated with adverse pathophysiological conditions 
like hyperlipidaemia. Prospective case-control studies have shown a strong and 
consistent association of LPL polymorphisms with raised triglyceride levels and CAD 
(Sagoo et al., 2008). A recent cross-sectional and longitudinal study of 2045 African 
Americans and 2116 Europeans was undertaken by Tang et al. (2010) to determine the 
association of eight LPL polymorphisms with the lipid profile. Apart from the population-





related heterogeneity that was observed over the 20 year follow-up, they reported that 
lipid variations were influenced by the effect of ageing on the LPL polymorphisms. LPL 
variants have also been associated with obesity in South Indian Asians (Radha et al., 
2007).  
Since raised triglyceride levels and lowered HDL levels make up two of the defining 
features of MS the study of the LPL gene was considered important in this project. 
Furthermore, since there are clearly mechanistically opposing effects of LPL 
polymorphisms on lipid profile, the S447X polymorphism (which has been found to have a 
favourable effect on lipid profile), and the N291S polymorphism (which has been 
reported as having an adverse association with HDL and triglyceride levels) were studied.  
 
1.3.8.1.2 Polymorphisms in the LPL gene 
The S447X polymorphism that is located on exon 9 is reported as being one of the most 
common polymorphisms, with a frequency of 5.6% to 21.1 % (Sagoo et al., 2008; 
Humphries et al., 1998). This SNP is characterized by a C-G transversion, where the X- 
allele encodes a prematurely truncated LPL protein, Serine, converting the 447 codon 
prematurely to a termination codon (Rip et al., 2006). In contrast to other LPL SNPs, the 
S447X variant is an exception within the coding region, and has been linked to increased 
lipolytic activity (Ross et al., 2005). Hokanson (1999) suggests that the functional 
properties of this truncated protein results in an enhanced bridging function, which leads 





to increased clearance of triglyceride-rich lipoproteins. In a case-control study of subjects 
with combined hyperlipidaemia, Wung et al. (2006) showed that individuals with this 
mutation had significantly lower triglyceride, low-density lipoprotein cholesterol and 
TG/HDL-C ratio, which are established risk factors for CVD (Hokanson et al., 1996) in 
contrast to individuals without the SNP. This was also shown in a recent meta-analysis 
(Kathiresan et al., 2008), and has been supported in a large cohort of 1577 Chinese 
Canadian subjects (McGladdery, 2001), and in other twin and candidate gene association 
studies (Huang et al., 2006; Groop, 2001). 
There have been subsequent studies which show that carriers of the X447 allele have a 
higher degree of protection against developing MS (Jensen et al., 2009). For example, in 
the Turkish Adult Risk Factor (TARF) study, Komurcu-Bayrak et al. (2007) evaluated the 
relationship of the S447X variant with serum lipid levels and MS. They found that 
individuals with this variant had higher levels of HDL and lower fasting glucose when 
compared to those with the wild-type. Furthermore, in a study of two hundred Egyptian 
patients with acute myocardial infarction, S447X was found to be associated with a 
favourable lipid profile. Conversely, this profile was reversed with the addition of DM 
(Tarek et al., 2011) as a risk factor. Another study examining the association between the 
S447X variant, hypertension-induced LV growth and CAD risk, showed that the 
hypertensive carriers of the variant were at an increased risk of LVH and risk for CAD. This 
was in contrast to the protective trend observed in normotensive subjects with the 
variant (Talmud et al., 2007).  





Since considerable variation has been reported between study populations (Kathiresan et 
al., 2008) in the association of the S447X polymorphism with plasma lipids, its association 
with risk of CHD, in addition to genetic factors (Corella et al., 2002) and environmental 
exposures like smoking (Lee et al., 2004), we investigated the association between S447X 
with MS and its components. Furthermore, the influence of this SNP on the lipid profile 
or on the MS has not been studied in a community-based cohort of randomised men and 
women. This is particularly pertinent to the Phoenix community, in South Africa, whose 
inhabitants, being of predominantly Asian Indian origin, are known to have a high 
propensity for adverse lipid profiles and DM (Seedat et al., 1990). 
 In contrast to the cardio-protection conferred by the S447X mutation, the N291S 
polymorphism has been associated with low lipoprotein lipase enzymatic activity, and 
hence, an unfavourable lipid profile (Zhanget al., 1996; Hayden et al., 1991), since 
identified in 1994.  This may be due to the location of the N291S SNP in a heparin-binding 
cluster, which is thought to affect the interaction of LPL with the cell wall 
glycosaminoglycan, as well as the result of the substitutions of the amino acid in the N-
terminal domain of LPL which is responsible for catalytic function (Mead et al., 2002).  
A large meta-analysis comprising 17 630 subjects (Hokanson et al., 1996) showed that 
this mutation was associated with a marginal risk for CVD, with stronger associations 
reported in certain populations. Another meta-analysis of 13 studies by Wittrup et al. 
(1999) reported that this mutation was associated with a significant increase in 
triglyceride levels and low HDL, with Souverein et al. (2005) reporting a significant 





association between this mutation and triglyceride levels in a study of 512 males with 
CAD. This was also shown in EARS study (Humphries et al., 1998) where younger subjects 
with N291S mutation were more likely to have elevated TG and decreased HDL 
concentrations, potentiated by moderate obesity. The N291S SNP has also been 
associated with increased atherosclerotic risk, as reported by the Framingham Offspring 
study (Kastelein, et al., 1999). A meta-analysis by Yaomin et al. (2006) found that this 
mutation conferred additional risk for a dyslipidaemia profile and was associated with 
DM and CAD, with López-Ruiz et al. (2009) and Sagoo et al. (2008) reporting that N291S 
could identify  subjects with a high CV risk and was associated with adverse lipid profiles.  
Therefore, in view of the high propensity of Asian Indians for dyslipidaemia and DM, the 
study of the associations between this polymorphism, DM and dyslipidaemia in this 
sample was determined to ascertain if additional CV risk for MS was conferred by the 
presence of the N291S polymorphism. 
 
1.3.8.2 THE HUMAN PARAOXONASE ( PON) AND THE PON-1 GENE  
The generation of excess reactive oxygen species (ROS) with a loss of reduction-oxidation 
(redox) homeostasis has been reported to play an important role in the pathogenesis of 
DM, hypertension, and consequent CVD (Whaley-Connell et al., 2011). The generation of 
excess free radicals has also been reported to contribute to proinflammatory and 
profibrotic pathways, which promote insulin-signalling impairment, reduced endothelial-





mediated vaso-relaxation, and associated CV and renal structural and functional 
abnormalities (Martinelli et al., 2005). Clinical and experimental studies have suggested 
that oxidative stress with a concurrent decline in anti-oxidant defence mechanisms, could 
lead to cell organelle and enzyme damage, with a resultant increase in lipid peroxidation 
and insulin resistance (Maritim, 2003). Oxidative stress and higher concentrations of lipid 
peroxides have also been reported in prediabetic subjects (Senti et al., 2003), linking 
oxidative stress to insulin resistance when endothelial dysfunction was found to be an 
underlying cause for insulin resistance. It has also been suggested that high oxidative 
stress promotes impaired insulin action, which further increases the degree of oxidation, 
resulting in subsequent impairment of insulin action on adipocytes (Rudich et al., 1997). 
There appears, therefore, to be a close relationship between insulin resistance, obesity 
and oxidative stress, which is more apparent by the elevated markers of systemic 
oxidative stress which have been documented in subjects with insulin resistance and DM 
(Meigs et al., 2007). Elevated levels of oxidative stress are also accompanied by a 
decrease in the expression of PON-1, an enzyme which is reported to have considerable 
anti-oxidant properties. 
Human serum paraoxonase (PON-1) is a calcium-dependant esterase, and a polymorph 
enzyme, which is a 45-kDa molecular weight enzyme, composed of 355 amino acids, 
synthesized and expressed by the liver, and bound to HDL.  High density lipoprotein (HDL) 
is the serum transport vector for PON-1, and is essential for its metabolism as it is 
involved with the stimulation, secretion and stabilisation of PON-1.   Impairment of the 





anti-oxidative activity of HDL (Hansel et al., 2004) increases oxidative stress, which, in 
turn, contributes to the development of atherosclerosis. 
One of the main functions of PON-1 is to decrease lipid peroxidase generation during LDL 
oxidation by destroying the biologically active phospholipids in oxidatively modified LDL 
(Li et al., 2003).  PON-1 is also involved with the reduction of the ability of oxidized LDL to 
trigger monocyte-endothelial cell interactions and hydrolysis of oxidised LDL-associated 
compounds (Watson et al., 1995), which triggers the inflammatory response and 
promotes foam cell formation (Aviram et al., 1999). This process, due mainly to the anti-
atherogenic activity and the anti-oxidative effects of HDL (Getz, 2004), negates the 
effects of oxidised lipids which are responsible for the pathogenesis of atherosclerosis 
(Florentin et al., 2008; Mackness et al., 1993.)  
PON-1 is also associated with the high-density lipoprotein sub-fraction that contains 
apolipoprotein A1 (Mackness et al., 1993), which is believed to have an important role in 
protection and preservation of cell membrane integrity (Durrington et al., 2001). It has 
also been reported to have an important additional protective function on LDL, by 
preventing the transformation of LDL into biologically active atherogenic particles, and 









1.3.8.2.1 Polymorphisms in the Human Paraoxonase-1 gene  
The PON-1 gene has been identified as a potentially important candidate gene as it 
appears to have an important role in promoting or protecting against oxidative stress 
(Levy, 2003), with a direct effect on the pathophysiology and acceleration of CVD. PON-1 
activity is thought to be modulated by CV risk factors, as well as by environmental and 
lifestyle factors (Balcerzyk et al., 2007). Decreased PON-1 activity is associated with a 
greater risk of disease that involves lipid peroxidation and oxidative damage (Veiga et al., 
2011), for example, DM, renal disease, liver cirrhosis and CVD. Leviev et al. (2001) found 
lower PON-1 activity in non-diabetic subjects with abnormal fasting glucose, as compared 
to higher PON-1 activity in those subjects with normal glucose levels. Furthermore, initial 
studies examining PON-1 activity on transgenic mice (Tward et al., 2002) found an 
overexpression of PON-1, which was related to a decrease in atherosclerotic lesion 
formation as compared to PON-1 knock-out mice, strongly suggesting that PON-1 is a 
major determinant of atherosclerosis. There is clear evidence which indicates that PON-1 
activity regulation is strongly influenced by genetics. This is further supported by the fact 
that there is wide variation in terms of the enzymatic activity of PON-1 in humans, which 
has been explained partly by the genetic variation (genetic polymorphisms) in the coding 
region of the PON-1 gene. 
The PON-1gene is part of a paraoxonase family of genes, located on chromosome 7q21.3-
22.1 (Primo-Parmo, 1996). The PON-1 gene has 9 exons spanning 26 kb, with two 
common missense polymorphisms being identified, namely, the Gln192Arg (Q192R) and 





Leu55Met (L55M). These variants have been reported to confer risk to CAD in varying 
degrees (Watzinger et al, 2002). PON-1 enzymatic activity for paraoxon is modulated at 
the PON-1 locus by the polymorphism Q192R on codon 192, which creates an amino acid 
substitution of arginine (R) for glutamine (Q), resulting in the mutation known as the 
192R allele. This variant displays opposing effects on PON-1 enzymatic activity, which has 
been reported to be determined by alleles: low paraoxonase activity is determined by the 
Gln allele (Q192), whereas high paraoxonase activity is determined by the Arg allele 
(Adkins et al., 1993). What this translates into is that the HDL particles from the 
Gln/Gln192 variant appear more effective in protecting LDL from oxidative changes 
(Mackness et al., 1999).  
The Q192R SNP (Arg192) has been linked with an increased risk for DM (Flekak et al., 
2008), CAD (Watzinger et al., 2002) and with ischaemic stroke (Dahabreh et al., 2010) and 
has been associated with lower PON-1 serum activity (Kim et al., 2007). The Arg192 
mutation has been reported as being less effective in protection from the effects of 
oxidative stress (Aubo et al., 2000). This is possibly attributed to the decreased affinity of 
this SNP to HDL, leading to decreased protein stability and activity (Gaidukov et al., 2006), 
and has been linked with coronary artery spasm in Japanese subjects (Fujihara et al., 
2011). This was also shown in a study of 156 Spanish patients, where diabetic subjects 
with the 192R allele demonstrated a 2.5 fold increase in the odds ratio (OR) for 
myocardial infarction (Aubo et al., 2000), with the 192R allele reported as being an 
independent risk factor for CAD in non-diabetic subjects as well (Imai et al., 2000). Low 
PON-1 activity and the 192 RR genotype has also been associated with the severity of 





CAD (Kerkeni et al., 2006) in a Tunisian population, and with conventional CV risk factors 
(Balcerzyk et al., 2007). Studies by Pati & Pati (1998) and Jian Ping et al. (2005) reported 
higher frequencies of the Arg- allele in patients with CAD and MI, as compared to a higher 
frequency of the Gln- allele in controls, with increased risk of MI in subjects that were 
diabetic and/or obese. They suggested that these conditions which were associated with 
high oxidative stress had a modifying effect on the association, as Q192R was not 
independently associated with MI. 
In contrast, a recent case-control study of 650 subjects, of whom 350 had severe (>70%) 
coronary artery stenosis, from North-west Punjab, showed that the Q192R SNP was 
independently associated with CAD (Gupta et al., 2011). Additionally, there was a 
significant association reported between the R allele and the development of CAD in a 
group of Egyptian subjects (Mohamed et al., 2010).  
 
The second common PON-1 polymorphism, the L55M mutation, results from the 
nucleotide substitution on codon 55. This substitution produces an amino acid 
substitution of methionine for leucine, resulting in the mutation known as the 55M allele. 
The L55M mutation has been reported to be of importance to paraoxonase function 
because of its association with paraoxonase serum concentrations, but with small effects 
on enzyme activity (Blatter-Garin et al., 1994), although Mouhamed et al. (2011) reported 
low PON- activity associated with this polymorphism. 





Previous studies have associated this allele with less protection from oxidative stress, and 
hence increased risk of CVD (Imai et al., 2000, Watsinger et al., 2002).  The L55M 
polymorphism has also been associated, although to a lesser degree, with ischaemic 
stroke (Banerjee, 2010). In a study of 222 case-controlled subjects, Taşkiran et al. (2009) 
reported that the frequency of PON-1 55M allele was significantly higher in subjects with 
premature CAD than normal subjects, with a significant relationship demonstrated 
between the PON-1 M/L55 polymorphism and premature CAD (p=0.017).  
What emerges is that the PON-1 polymorphisms are associated , with varying degrees 
with CV risk factors and disease, since Leu55 and Arg 192 have been associated with CAD 
in some, but not all, clinical studies. These inconsistencies were highlighted in a recent 
meta-analysis (Christiansen et al., 2004), who showed a weak, but significant association 
with CAD in the Gln192Arg variant. Martinelli et al. (2005), in their study of PON-1 
polymorphisms, pointed out the inherent limitations of this meta-analysis, which were 
related to high heterogeneity of the population groups and clinical outcomes, to name a 
few. In spite of these controversies, it appears that the studies which show the strongest 
association with CV risk were the ones with high-risk populations, like diabetics 
(Martinelli, et al., 2005), where the effects of oxidative stress and risk factor clustering 
(like the metabolic syndrome) are more apparent. 
The two prominent components of the MS, namely, glucose intolerance and obesity, are 
contributors to oxidative stress. This may be explained by the role of oxidative stress 
pathways and a reduction in antioxidant defences, with consequent impairment of insulin 





signalling, and resultant insulin resistance (Martinelli et al., 2011).  Another hypothesis, 
proposed by Grundy (2007) is that the MS manifests in subjects with a specific metabolic 
susceptibility, most likely insulin resistance, and with an accumulation of excess of body 
fat. The MS itself has also been reported to contribute to elevated levels of oxidative 
stress, as it is considered to be associated with a proinflammatory and prothrombotic 
state, thus contributing to the acceleration of CVD and atherosclerosis (Kim & Younossi, 
2008).  
Increased oxidative stress and lower PON-1 activity has been associated with a greater 
severity of risk factor clustering (Senti et al., 2003). This association was strengthened by 
findings from the Verona Heart Project (Martinelli et al., 2005), where a significant 
association was documented between the Leu55 and Arg 192 alleles, in subjects with MS 
and CAD. They also reported that subjects with MS and both alleles had significantly 
increased risk of CVD, as compared to subjects without MS, but with the 55Met/Met and 
192Gln/Gln genotype. This was also borne out by Oliviera et al. (2004) who reported that 
the Met/Met55 allele, like the Gln/Gln192 allele had  protective effects against oxidative 
stress, with the MM genotype being associated with lower triglyceride levels, hence, 
conferring protection against CAD. 
Recent genetic analysis in young South African Indian males (≤ 45 years old) have 
reported gene-gene and gene-environment interactions (Ranjith et al., 2008) and found 
that the interplay between environmental risk factors and genetic factors may be more 
important in contributing to the development of MI in young Indians.  Although such 





ethnic-specific data on the contribution of LPL and PON-1 activity and polymorphisms to 
the development of CVD is steadily growing, there have been few data on these 
polymorphisms on communities with high risk factor profiles. Hence the objective was to 
study these polymorphisms in a sample with known elevated CV risks, to determine 
whether these polymorphisms conferred increased risk for the development of the MS.  
 
 






It is understandable that the metabolic syndrome causes an exponential increase in the 
risk of cardiovascular disease (de Las Fuentes, 2007) because of the multiplicity of risk 
factors that together constitute the syndrome. However, very few studies (none to our 
knowledge in the Asian Indian community, to date) have evaluated the relationship 
between MS and the associated changes in LV structure and functions (Chinali et al., 
2006; Aijaz, 2008). In this study, the objective was to investigate whether MS was 
associated with changes in cardiac structure and/ or function. In particular, it was 
important to know whether early functional changes, as assessed by diastolic indices, 
worsened progressively with increasing burden of MS. Furthermore, the presence and 
implications of SEAT thickness in these subjects and its value as an early diagnostic 
marker in the development of MS, using echocardiography, was evaluated. 
The LPL gene has emerged as an important candidate gene for the components of the MS 
(Goodarzi et al., 2004). Triglyceride-rich lipoprotein metabolism is impaired in diabetics, 
and LPL has been reported as the culprit for the alterations found in these patients (Carr, 
2004). We investigated the associations between polymorphisms and risk factors, as well 
as the allele frequency in normal subjects with MS in this cohort.  
Furthermore, since MS is associated with increased oxidative stress, which appears to be 
modulated by PON-1 polymorphisms, it was important to define the genetic patterns 
relating to risk factor profile in those individuals with the MS.   





1.5 Outline of the thesis 
Chapter 1 incorporates the Introduction, followed by the review of the current Literature 
(above), which touches briefly on conventional cardiovascular risk factors. The focus is 
then turned to cardiovascular risk factors in Asian Indians, particularly in South Africa. 
Risk factor clustering, in particular, the metabolic syndrome, is then discussed. The 
current controversies surrounding the relevance of the metabolic syndrome are then 
briefly explored, with some motivation to support the decision to study this syndrome in 
this population group. A brief pathophysiology of the metabolic syndrome, the 
atherogenic phenotype in Asian Indians, and its varying prevalence world-wide is then 
discussed. 
The next portion of the review of the literature is allocated to the importance and utility 
of echocardiography as a screening tool for the detection of early structural and 
functional changes in the heart, associated with cardiovascular disease. Of particular 
importance would be the acquisition of echocardiography values in normal subjects, and 
comparison of these with subjects with the metabolic syndrome or its individual 
components. The role of novel echocardiography measurements, like the use of tissue 
Doppler Imaging for the assessment of diastolic dysfunction and the measurement of 
sub-epicardial adipose tissue (SEAT) thickness is then discussed. 
The genetic portion of this project aims to describe the frequency, association and 
patterns of single nucleotide polymorphisms in subgroups of participants based on age, 





gender, anthropometry and certain lifestyle habits, as well as presence or absence of the 
metabolic syndrome or its individual components. This includes an in-depth discussion of 
each of the gene polymorphisms investigated and their intermediate expressions in this 
study. 
Chapter 2 consists of a detailed description of the study design, methodology and 
experimental procedures. This is followed by the results (Chapter 3), which include the 
risk factor prevalence, the prevalence of metabolic syndrome and echocardiographic 
changes, and finally the genetic analysis of the PON-1 and lipoprotein lipase 
polymorphisms studied. The discussion and conclusion are found in Chapter 4 and focus 
on the molecular mechanisms for the development of the metabolic syndrome, as well as 














 Materials and Method 





2.1 Study design 
This was an analytical, cross-sectional study where a random sample of participants from 
the Phoenix community was selected and sub-divided into two categories based on the 
presence or the absence of the metabolic syndrome (outcome). The various exposures 
such as echocardiography and genotyping were then compared between the two 
outcome groups. 
 
2.1.1 Study population and location 
The study was carried out on subjects residing in the Phoenix area (EThekwini 
Municipality, Durban, Kwazulu-Natal), made up of predominantly South African Asian 
Indians.  
The latest census data indicate that Indians make up 2.5% (Stats SA P0302, 2011) of South 
Africa’s population.  The history of this population has been documented as being 
descendants of indentured sugar-cane workers, who were brought to Kwazulu-Natal 
between 1860 and 1911 (Seedat, 2005). The community of Phoenix is a culturally 
heterogeneous one, with inhabitants of varying socio-economic status. Although the 
prevalence and incidence of Type 2 Diabetes Mellitus (DM) has been studied on limited 
occasions in the Indian population, there has been no recent community-based 
evaluation of the inhabitants of the community of Phoenix. It is believed that the 





transition in the socio-economic status of the community has deleteriously contributed to 
the acceleration of atherosclerotic disease.  
 
2.1.2 Classification of normal controls 
Subjects who were not documented with cardiovascular or metabolic risk factors were 
classified as normal.  
 
2.1.3 Study period 
Data collection began in 2007 as part of the Phoenix Lifestyle Project (Ethics number: 
E336/05). D R Prakaschandra was responsible for the major portion of the data collection, 
including the performance of the echocardiography examination and the genetic analysis 
(Nucleic acid extraction, Allele-specific Polymerase Chain Reaction, sequencing and 
analysis).   
 
2.1.4 Sampling strategy  
A map of Phoenix which showed the households was used to select these by using simple 
random sampling. Individuals within the target age group were then selected using the 
Kish method (Appendix 1) of sampling. Participants were stratified by gender and age:  
the rationale being that the risk factors and disease prevalence differ among age groups 





and genders. Participants (age 15 to 64 years) were divided into  each of the 10 strata, 
stratified for age (15-24, 25 – 34, 35 – 44, 45 – 54, 55 - 64,) and gender (male and female). 
 
2.1.4.1 SAMPLING 
Only one member from each household was included in the study to improve 
generalizability to the Phoenix population. In order to obtain adequate numbers in all 
strata without enrolling more than one individual in the household, the field-worker 
followed a prescribed guideline (Appendix 1) when visiting a randomly selected 
household.   
 
2.2 Statistical planning  
2.2.1 Sample size 
The sample size calculation was performed by Mrs T Esterhuizen, Biostatistician from the 
University of Kwazulu-Natal. The sample size calculation was adjusted for sub-group 
analysis (taking into account the smallest subgroup size) with sufficient power (80%) to 
detect clinically significant differences based on the findings of de Las Fuentes (2007). 
Based on this, and for the genetic analysis, a sample size of 724 subjects was required to 
detect significant differences between groups.  
 
  





2.2.2 Exclusion criteria: 
I. Bedridden or physically disabled  
II. Pregnant and lactating women 
III. Inability to give informed consent 
IV. Cancer patients having received treatment within the last year   
 
2.3 Data collection methods and tools 
2.3.1 Recruitment process and administration of the STEPS Questionnaire 
Advertising for this project inviting interested participants was done in the local 
newspaper and radio station. The recruitment was done by trained personnel.  Informed 
consent was obtained from subjects who agreed to participate in the study, after detailed 
information about the study was given by trained field workers (Appendix 2). A 
questionnaire tool, validated by the World Health Organisation (WHO) STEPS was used to 
record the demographic information and behavioural measurements at the subjects’ 
homes (Appendix 3), this being a modified STEPS Instrument for Non-communicable 
Disease (NCD) Risk Factors, Version 1.3a  questionnaire. The subjects were then 
telephonically given an appointment for the next phase of the study. On the stipulated 
date and time, subjects were collected from their homes and taken to the Lifestyle Centre 
at the Inkosi Albert Luthuli Central Hospital (IALCH) in Cator Manor, Durban. 
 





2.3.2 Questionnaire parameters 
The demographic information included age, gender, education, income, number of 
people with living in the household activity profiles, as well as dietary patterns. Other 
information included a history of DM, hypertension or an immediate family history of 
cardiovascular risk factors. These responses were entered into Step 1 of the STEPS 
questionnaire. 
 
2.4 The Clinical Examination 
At the Lifestyle Centre, the blood pressure and heart rate was recorded, and thereafter, 
anthropometric measurements (height, weight, mid-upper-arm, waist and neck 
circumferences and triceps skin fold thickness) measurements were made. Blood and 
urine samples were taken for biochemical analysis. An electrocardiogram was recorded 
and a comprehensive echocardiogram was performed. The following methods for 
measurements that were recorded are explained below.  
 
2.4.1 Blood pressure and heart rate 
Subjects were seated for at least 5 minutes prior to recording the blood pressure using a 
mercury manometer connected to a standard 12.5 x 23 cm cuff (a larger cuff (15.5 x 32.5 
cm was used for those with a mid-upper arm circumference above 33 cm).  The blood 
pressure was taken on 3 occasions at 1-minute intervals. The mean diastolic and systolic 
measurements were used for analyses.  





2.4.2 The diagnosis of systemic hypertension and pre-hypertension 
Systemic hypertension was defined according to Joint National Committee VII (JNC VII) 
criteria as a BP ≥140/≥90 mmHg and/or current antihypertensive therapy (Chobanian et 
al., 2003), or a self-report of previously diagnosed hypertension. 
Pre-hypertension was defined using the JNC VII guidelines as a systolic blood pressure of 
120-139 mm Hg systolic or a diastolic blood pressure of 80- 89 mm Hg (Chobanian et al., 
2003). 
 
2.4.3 Anthropometry measurements 
2.4.3.1  HEIGHT 
This was measured to the nearest 0.1 cm using a metal measuring tape applied to a wall 
and a flat headboard at right angles to the wall to ensure correct reading.  The subjects 
were measured without shoes, heels against the wall and the angle of the eye level with 
the external auditory meatus.  
 
2.4.3.2  WEIGHT 
This was determined to the nearest 0.5kg on a balance scale with the subject in light 
clothing and without shoes.  The scale was standardised at the beginning of the study. 
 
 





2.4.3.3  WAIST CIRCUMFERENCE 
This was measured according to standardized guidelines with the subjects standing 
comfortably.  The smallest circumference between the xiphisternum and the umbilicus 
on expiration was taken as the waist circumference. 
 
2.4.3.4 BODY MASS INDEX 
The body mass index (BMI) was calculated automatically by computer software according 
to the WHO (http://www.who.int/bmi/index.jsp) as weight (kg)/ height (m) 2, and was 
further classified according to the WHO guidelines:  
a. BMI : 18.50 kg/m2 – 24.99 kg/m2= normal weight 
b. BMI  ≥25 kg/m2 -29.99 kg/m2 = overweight  
c. BMI ≥30 kg/m2 = obese   
In response to evidence that Asian populations had have different associations between 
BMI, distribution and percentage of body fat and CV risks than European populations,  
the WHO Expert Consultation revised the cut-offs for obesity from  25 kg/m2 to 23 kg/m2 
for Asian Indians (WHO Expert Consultation, 2004).  The classification for adult Asians was 
as follows: 
a.  <23.0= normal weight 
b. 23.0 to 24.9 kg/m2 = overweight  
c.  ≥25.0 kg/m2 = obesity 





These cut-offs were also used together with the current international WHO guidelines in 
our analysis.  
 
2.5 Biochemical measurements 
After a ten hour overnight fast, whole- blood samples were collected, drawn from the 
cubital vein with minimal stasis in all subjects by trained phlebotomists or the attending 
physician. Plasma was assayed for total cholesterol, HDL-cholesterol, and triglycerides. 
Fasting blood glucose was measured using spectrophotometry and plasma insulin was 
measured by radioimmunoassay. A whole-blood sample was also collected for genetic 
analyses. 
 In subjects who did not self-report DM, a 75g glucose monohydrate in 250ml water was 
ingested over two minutes.  An additional blood sample for glucose and insulin 
estimation was drawn two hours later. Blood samples were delivered within one hour of 
collection to the Chemical Pathology Laboratory at IALCH for estimation of the lipid 
profile, glucose and insulin levels. 
 
2.5.1 Definition of Impaired fasting glucose concentration, prediabetes, 
insulin resistance  and Type 2 Diabetes Mellitus 
The impaired fasting glucose (IFG) concentration was defined using guidelines published 
by the American Diabetes Association (2010) by fasting plasma glucose concentration > 
5.6mmol/l -6.9mmol/l. Impaired glucose tolerance (IGT) was defined by fasting plasma 





glucose concentration after the 2-hour glucose tolerance test being in the range of 
7.8mmol/l – 11.0mmol/l.  
 
Subjects with IFG and IGT, without a prior history of DM, were classified as those in the 
prediabetic stage, according to the guidelines from the International Expert Committee 
Report on the role of the A1C assay in the diagnosis of DM (2009). The summarised 
guidelines (Buysschaert & Bergman, 2011) classified those with FBG: 5.6–6.9 mmol/L or 
IGT: 7.8–11.0 mmol/L as having prediabetes. 
 
The diagnosis of DM was made from a self-report of previously diagnosed DM. Subjects 
who did not have a previous history of DM but had a fasting plasma glucose 
concentration ≥7.0 mmol/L (Genuth et al; 2003), a 2-hour fasting glucose concentration 
of ≥11.1mmol/l and/or current medical therapy with an oral hypoglycaemic agent and/or 
insulin, were classified, according to the American Diabetes Association’s (2006) set 
criteria for the definition of DM, as diabetic. 
 
2.5.1.1 THE DIAGNOSIS OF INSULIN RESISTANCE 
The Homeostatic model of Insulin resistance (HOMA-IR) has been reported to serve as a 
surrogate measure of the insulin resistance phenotype (Cheal et al, 2004). Although the 
HOMA-IR index is inferior to the clamp technique in terms of accuracy, the utility of this 
index makes it possible to study a large number of subjects in a fasting state, with a single 





glucose and insulin measurement. We calculated the HOMA-IR values as follows 
(Matthews et al., 1995): 
HOMA-IR = fasting insulin (µU/m) x fasting glucose (mmol/l) 
22.5 
A HOMA-IR value > 2.6 was used as a diagnosis for insulin resistance (Ascaso et al., 2003). 
 
2.5.1.2 DEFINITION OF DYSLIPIDAEMIA 
Using the National Cholesterol Adult Panel (NCEP) guidelines (Grundy et al., 2001), the 
following cut-offs were used to define elevated total cholesterol, triglyceride and 
decreased HDL levels: 
a. Elevated total cholesterol: > 5.17mmol/l 
b. Elevated triglycerides: > 1.69mmol/l 
c. Decreased HDL: < 1.04mmol/l  
 
2.6 The diagnosis of the Metabolic Syndrome 
There are several definitions that propose criteria for the diagnosis of the metabolic 
syndrome (MS), namely that recommended by the WHO (Balkau et al., 1999), whose 
criteria were simplified by the National Cholesterol Adult Panel (NCEP) Adult Treatment 
Panel III (ATP III) (Adult Treatment Panel, 2002). Later, the International Diabetes 
Federation (IDF) replaced the WHO criteria for the diagnosis of MS, with the mandatory 
inclusion of ethnic-specific waist circumference cut-offs (Alberti et al., 2005). More 
recently, Alberti et al. (2009) proposed unifying criteria for the definition for MS, which is 





a composite of the ATP III and IDF criteria: this wass aptly named the ‘Harmonizing 
criteria’.We therefore decided to use the three common definitions of MS in our study, as 
the previous definitions have either been modified or replaced. 
 
2.6.1 Diagnosis using the  NCEP ATP III criteria 
The presence of metabolic syndrome as stipulated by the NCEP APTIII criteria was defined 
as 3 or more of the following 5 risk factors in Table 2-1. 
Table 2-1: NCEP criteria for diagnosis of the Metabolic Syndrome 
NCEP ATP III criteria 
 
Waist circumference measurement     
Men       > 102 cm  
Women      > 88 cm   
Triglycerides      ≥1.7  mmol/L 
HDL cholesterol      
Men      <1.03  mmol/L 
Women     <1.29  mmol/L 
Blood pressure      ≥130 / ≥85 mmHg 




2.6.2 Diagnosis using IDF criteria 
The IDF proposed ethnic-specific cut-offs for waist measurement and defined the 
metabolic syndrome as the presence of central obesity plus any two other risk factors. 
The criteria are shown in Table 2-2.  Subjects who were on medical therapy for 





hypertension or DM were included, irrespective of the values obtained during the clinical 
examination or biochemistry. 
Table 2-2: IDF criteria for diagnosis of the Metabolic Syndrome 
IDF criteria  
Waist circumference measurement for South Asians:       
Men     Waist   ≥ 90cm  
Women    Waist ≥ 80cm 
Raised triglyceride     >1.7mmol/L  
Reduced HDL cholesterol*   
Men      <1.03mmol/L,  
Women     <1.29mmol/L  
Blood pressure*     ≥130 / ≥85mmHg  
Raised fasting plasma glucose*  ≥5.6mmol/L  
 
2.6.3 Diagnosis using the “Harmonized” criteria 
In 2009, the joint statement from the International Diabetes Federation Task Force on 
Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart 
Association; World Heart Federation; International Atherosclerosis Society; and 
International Association for the Study of Obesity (Alberti et al) proposed world-wide 
unifying criteria for the clinical diagnosis of the metabolic syndrome, calling it the 





‘Harmonized definition’. This definition is identical to that of the NCEP ATP III definition, 
except that ethnic-specific cut-points (IDF waist circumference) for the waist 
circumference measurements are included. The definition comprises a minimum of 3 risk 
factors and is summarised in Table 2-3.  
Table 2-3: Harmonized criteria for diagnosis of the Metabolic Syndrome 
Harmonized criteria  
Waist circumference measurements for South Asians      
Men      Waist   ≥ 90cm  
Women     Waist ≥ 80cm 
Triglyceride      ≥1.7 mmol/L 
HDL cholesterol      
Men      <1.03 mmol/L 
Women     <1.29 mmol/L 
Blood pressure      ≥130 and/ ≥85 mmHg 












Each subject underwent a transthoracic two-dimensional (2D) guided M-mode 
echocardiogram, and a comprehensive Doppler echocardiogram. Echocardiograms were 
performed with a Siemens CV70 instrument (Siemens, New York, NY) using a 3.5 MHz 
transducer with subjects lying in the left lateral decubitus position.  
 
2.7.1 Two-dimensional and M-Mode measurements 
M-Mode measurements were performed for the measurements of the aortic root and 
left atrial (LA) size according to published guidelines (Schiller et al., 1989). The  left atrial 
volume (LAV) was calculated according to the American Society of Echocardiography 
(Sahn et al., 1978; Pritchett et al., 2003) as an ellipse using the formula: 
𝜏/6(𝑆𝐴1 𝑥 𝑆𝐴2 𝑥 𝐿𝐴) where SA1 = the M-mode LA dimension and SA2 and LA are 
measurements of short- and long-axis in the apical four-chamber view  (Figure 2.1).  
The LAV was then indexed to BSA to calculate the left atrial volume index (LAVI). The LAVI 
was considered to be dilated if the index was more than 29ml/m2 (22±6ml/m)2 (Lang et 
al., 2006). 





Figure 2.1: Measurement of LA dimension using M-Mode and 2-D
  
 Figure 2.1.(a) Measurement of SA1: the widest LA diameter in the parasternal long axis view by 2-D     
from the inter-atrial septum and the lateral boundary of the left atrium 
 
 
Figure 2.1. (b):  Measurement of SA2 and LA: distance of the perpendicular line measured from the 
middle of the plane of the mitral annulus 
 
 





The left ventricular (LV) internal dimensions and the thickness of the posterior and septal 
wall were measured according to published guidelines (Schiller et al., 1989). The left 
ventricular mass (LVM) was estimated by using by the M-mode-derived cubed method 
and divided by height2.7 to correct for body habitus (Devereaux et al., 1986). This was 
termed the left ventricular mass index (LVMI).  
The Fractional Shortening (FS) was calculated using the modified Simpson’s formula. The 
ejection fraction (EF) was measured using a monoplane image in the 4-chamber view, by 
tracing the contours of the LV internal diameter during peak systole and peak diastole. 
The ejection fraction was calculated automatically by computer software using the 
Teichholz formula. The ejection fraction was further confirmed by eye-balling, and was 
used as the measure of LV systolic function.  
 
2.7.2 Doppler Echocardiography 
Trans-mitral inflow velocities were used to detect and quantify diastolic dysfunction and 
were obtained using Pulsed-wave (PW) Doppler in the apical 4-chamber view with the 
sample volume placed between the tips of the mitral valve leaflets (Quinones et al., 
2002). The trans-mitral early diastolic (Em) and atrial (Am) velocities were measured and 
were used to calculate the trans-mitral E/A ratio. The isovolumic relaxation time (IVRT) 
was also measured from the cessation of LV outflow to the onset of LV inflow. 
Tissue Doppler imaging (TDI) was used to obtain left ventricular (LV) myocardial velocities 
in the apical  chamber views with a 2 mm sample volume placed at the septal and lateral 





mitral annulus (Oh, 2006).  The early myocardial velocity (Ea), myocardial velocity 
associated with atrial contraction (Aa) and the systolic (Sa) velocities were measured 
(Dumesnil et al., 2002). In subjects where regional wall motion abnormality was not 
detected, the mitral annular velocity was measured on the lateral side.  All 
echocardiographic measurements were averaged over three consecutive cardiac cycles, 
measured by a single investigator (DRP) blinded to all other variables.  
 
2.7.2.1 CALCULATION OF THE LEFT VENTRICULAR END DIASTOLIC PRESSURE USING 
TDI 
The calculation of the LV end diastolic pressure (LVEDP) was done according to the 
recommendations by Nageuh et al (1997) and Ommen et al (2000), who reported a 
strong correlation between the LVEDP and the diastolic filling ratios, in simultaneous 
cardiac catheterization and echocardiographic studies i.e. the ratio of the mitral inflow E 
wave to the tissue Doppler Ea wave (Em/Ea) [Figure 2.2]. We classified the estimation of 
the LVEDP using their criteria, as follows: 
a. Em/ Ea (lateral) >10 or Em/Ea (septal) >15 is correlated with an elevated LV end-
diastolic pressure 
b.  Em/Ea<8 is correlated with a normal LV end-diastolic pressure.  
 





Figure 2.2. Calculation of TDI Em/Ea (using pulsed-wave and tissue Doppler) 
 
Figure 2.2 (A): Pulsed-wave Dopller across mitral valve leaflets 
 
 
Figure 2.2 (B): Tissue Doppler tracing on the lateral mitral annulus 
 
 





2.7.3 Definition of diastolic abnormalities and diastolic dysfunction 
Diastolic abnormalities were identified using the guidelines proposed by the European 
Study Group on Diastolic Heart Failure (1998). In the presence of preserved ejection 
fraction, diastolic abnormalities were identified using the criteria tabulated below in 
Table 2.1. The presence of any Doppler abnormality was considered a feature of diastolic 
abnormality.  
 
Table 2-4: Age-specific diastolic abnormality criteria 
Age <30 years  30-50 years  >50 years  
E/A ratio <1 <1 <0.5 
IVRT (ms) >92 >100 >105 
  
The diagnosis of diastolic dysfunction (DD) was made when the subject had 
echocardiographically-derived diastolic abnormalities (Table 2-4) and was on current 
diuretic therapy and/or exhibited features of left atrial dilation. Left atrial enlargement 
was classified as the mean LA diameter of more than 45 mm. 
 The diagnosis of DD has been recently revised and according to Nagueh et al (2009) are 
summarised as follows:  
a. PW Doppler criteria: E/A ratio <1 if age <55 or <0.8 if age >55, and/or 
Deceleration time (DT) >240ms 





b. TDI criteria: Ea ≤12.9 cm/s if age <40; Ea ≤10.2 cm/s age 40–59; and Ea ≤7.2 
cm/s if age ≥60 (Alam et al; 1999) 
c. Em/ lateral Ea>10 or Em/ septal Ea>15 (suggests elevated LV end-diastolic 
pressure; Nagueh et al., 2009). 
However the recent guidelines from the Heart Failure and Echocardiography Associations 
of the European Society of Cardiology (Paulus et al., 2007) report that a diagnosis of LV 
diastolic dysfunction is ‘preferably derived from myocardial TDI (Em/Ea ≥ 15).’ In the 
absence of these tissue Doppler findings,   i.e., if the Em/Ea was ≥8≤ 15, they suggested 
that concentric LV remodelling as a potential surrogate for direct evidence of diastolic LV 
dysfunction, and recommended that, an LV wall mass index of 122 g/m2 in females or an 
LV wall mass index of 149 g/m2 in males be used as evidence for the diagnosis of HFNEF. 
They also recommended that a measurement of the LAVI be used with the cut-off, 
according to the Heart Failure and Echocardiography Associations of the European 
Society of Cardiology (Paulus et al., 2007) guidelines, with a LAVI > 40 ml/m2 being 
indicative of LV diastolic dysfunction. 
Therefore, in this study, the diagnosis of LV diastolic dysfunction was made if the criteria 
according to European Study Group on Diastolic Heart Failure (1998) was satisfied i.e. 1 
or more diastolic abnormalities and current diuretic therapy and/or LA enlargement. This 
was then compared to the newer criteria as proposed by the European Society of 
Cardiology (Paulus et al., 2007): 
a. E/lateral Ea>10 or E/septal Ea>15 or, 





b. If  Em/Ea was ≥8≤ 15,and LVMI 122 g/m2 in females or an LV wall mass 
index of 149 g/m2 in males or, 
c. If  Em/Ea was ≥8≤ 15 and LAVI > 40 ml/m2  
 
2.7.4 Sub-epicardial adipose tissue thickness measurement 
The thickness of the epicardial fat was measured in the free wall of the right ventricle in 
the parasternal long and short axis as proposed by Iacobellis et al (2003)[Figure 2.3]. 
Epicardial adipose tissue appears as an echo-free or hyper-echoic space, and has been 
validated as an indicator of visceral fat (Iacobellis, 2003). The measurement of epicardial 
fat on the right ventricle was chosen, as this point is recognised as having the highest 
absolute thickness of epicardial fat (Schejba, 1989). The parasternal long-axis and short-
axis views allow the most accurate measurement of epicardial adipose tissue on the right 
ventricle, with the best cursor-beam orientation in each view (Iacobellis, 2003). 
 
2.7.5 Intra-observer variability 
It is established that intra-observer variability is low, when the echocardiograms are 
performed by 1 experienced echocardiographer (Ogah et al., 2006), as is the case in our 
study.  Furthermore, each measurement was performed according to the ASE guidelines 
to ensure standardization. At least 3 cycles were recorded, and the average was 
documented. Measurements of SEAT thickness was made at two sites, and an average of 
3 cycles at these 2 sites were taken. 





Measurement of intra-observer variability was calculated from samples recorded on the 
same subject at different intervals.  A coefficient of variance of 4%, 5%, 4%, 4%, 2% and 
9% was found for the mean LA, LVM, EDD, ESD and EF, SEAT measurements, respectively. 
The Doppler parameters yielded an intra-user variability of 4% for transmitral filling 
velocities (Em/Am), 7% for the mean Ea velocity and 11% for the mean Em/Ea ratio on 
tissue Doppler imaging, respectively. All measurements were stored on computer, and 
printed as hard copies. The images were reviewed off-line by two experienced observers 




















Figure 2.3: Measurement of Sub-epicardial Adipose Tissue 
 
  Figure 2.3.(A): SEAT measurement in parasternal long axis 
 
 














2.8 The Genetic analysis 
2.8.1 Sample collection 
The samples for the genetic analysis were collected in ethylenediaminetetraacetic acid 
(EDTA) tubes and sent to the Chemical pathology Department for centrifuging. They were 
stored as aliquots in 500 µl cryo-tubes and frozen at -80°C until DNA isolation. 
 
2.8.2 Selection of genes and SNPs for analysis 
The genes selected for this study forms part of a larger investigation of the same cohort 
of South African Asian Indians in Kwazulu-Natal. The candidate was responsible for 
performing most of the DNA isolation and all of the genotyping, gel electrophoresis and 
sequencing techniques described and analysed in this study.  
The criteria for selection for the genes and SNPS being studied have been discussed 
under the literature review and rationale.  
2.8.3 DNA isolation 
Total nucleic acid (TNA) was isolated from whole blood using the automated MagNA Pure 
Instrument (Roche Applied Science) according to the manufacturer’s instructions. A brief 
description of the procedure, which is based on magnetic bead technology, is as follows: 
• The MagNA Pure instrument was programmed to extract total nucleic acid from 
whole blood.  





• The extraction involved loading of the sample into the Sample Cartridge.  
• In order for cell lysis to occur, the MagNA Pure instrument (using the automated 
program) added the Lysis/Binding Buffer to each sample, releasing all nucleic 
acids.  
• The nucleases were denatured and the addition of Proteinase K digested the 
proteins. 
• Due to the chaotropic salt conditions, isopropanol, and the high ionic strength of 
the Lysis/Binding Buffer, the TNA bound to the silica surface of the added 
magnetic glass particles (MGPs).  
• The MGPs with bound TNA were magnetically separated from the lysed sample, 
and then washed with Wash Buffer to remove unbound substances (such as 
proteins, cell membranes, PCR inhibitors) and to reduce the chaotropic salt 
concentration.  
                    Figure 2.4: Extraction of total nucleic acid 
 
                                       Downloaded from: www.roche-applied-science.com 





The purified TNA was then eluted at 70°C into the Elution Cartridge, while the MGPs were 
retained in the reaction tip and discarded.  
The isolated TNA was made up into aliquots and stored in 2ml screw-in cryo-tubes and 
stored at -80°C until the DNA quantification measurements were done.  
 
2.8.3.1. DNA QUANTIFICATION 
The determination of DNA concentration and purity was performed using the NanoDrop 
2000 Spectrophotometer (Thermo Fischer Scientific, Inc) by measuring the absorbance of 
the diluted DNA at 260 and 280 nm. The generally accepted extinction coefficients for 
nucleic acids are: 
• Double-stranded DNA: 50 ng-cm/μL 
• Single-stranded DNA: 33 ng-cm/μL 
• RNA: 40 ng-cm/μL (NanoDrop 2000/2000c Spectrophotometer; V1.0 User 
Manual) 
The extracted total nucleic acid was made up into 25µl aliquots using a 1:5 ratio of 










2.8.4.1 RATIONALE FOR CHOICE OF THE GENOTYPING METHOD 
Sequence-non-specific methods of genotyping (based on the capture, cleavage or 
mobility change during electrophoresis or liquid chromatography) are commonly used in 
the detection of polymorphisms. However, these methods have been reported as being 
suboptimal due to the uncertainties that exist regarding the inferred genotype being the 
true genotype, as the reaction is not sequence-specific (Kwok et al., 2003). Sequence-
specific methods are able to reliably discriminate between alleles, using allele-specific 
hybridisation, nucleotide incorporation, oligonucleotide ligation and invasive cleavage 
(Kwok, 2003). This method, which is known for its simplicity and accuracy for SNP 
genotyping, was used in this study.  
 
2.8.4.2 PRINCIPLES FOR HOMOGENOUS REAL-TIME SNP GENOTYPING USING 
HYBRIDIZATION PROBES  
Fluorescence monitoring using hybridization probes employs the use of allele-specific 
probes that are designed to hybridise to the target sequence only when there is a perfect 
match between probe and target DNA (Kwok 2003). Two probes, each labelled with a 
different reporter fluorophore are used in the same reaction, and this allows both SNP 
alleles to be detected in a single tube (Syvänen, 2001). The one base mismatch (Figure 
2.5) is able to destabilise the hybridization to prevent the allelic probe from annealing to 
the target sequence.  





In this study, hybridization probes and the principle of fluorescence energy transfer 
(FRET) was used, where a fluorescence signal is generated if fluorescence resonance 
energy transfer (FRET) occurs between two adjacent fluorophores (Didenko, 2001). The 
first hybridization probe (Figure 2.5), which is labelled with fluorescein as donor 
fluorophore (R1) on its 3' end, can hybridize in close proximity to a second hybridization 
probe that is labelled with the acceptor fluorophore, labelled with LC Red 640 at its 5' end 
(R2). The fluorescein becomes excited by the LED light source from the LightCycler 
system, and transfers energy to the acceptor fluorophore. The acceptor fluorophore then 
emits light of a longer wavelength that can be measured with a photodiode. This 
detection strategy allows monitoring of the amplification process on a per-cycle basis 
because the intensity of the FRET signal depends on the amount of specific PCR product 
generated (Nauck, 1999). Continuous monitoring of the fluorescence as the temperature 
is raised from annealing to denaturation produces a sharp decrease in fluorescence when 












Figure 2.5: The principle of fluorescence energy transfer (FRET) 




2.8.4.3 PRINCIPLES FOR AND MELTING CURVE ANALYSIS  
When heated during the Melting Curve stage, the probes melt away from the template 
sequence, resulting in the loss of fluorescence. The melting temperature (Tm) at which 
probes melt is specific to the particular mutation that it was designed for (Pont-Kingdon 
& Lyon, 2005). The fluorescence signal (F) is plotted in real- time against temperature (T), 
producing melting curves for each sample (F vs T). Melting curves are then converted to 
derivative melting curves by plotting the negative derivative of the fluorescence with 
respect to temperature against temperature [-(dF/dT) vs T] (Gordon et al., 1998). 
Therefore, wild-type, heterozygote and /or variants are observed by the fluorescence 
pattern observed at increasing temperatures, as different curves (Figure 2.6).  
FRET only occurs when hybridization probes (R1 and R2) bind to their target sequences i.e. when 
there is a match 





Figure 2.6: The principle of Melting curve analysis  
 
 
2.8.4.4  REAL-TIME POLYMERASE CHAIN REACTION AND MELTING CURVE ANALYSIS 
The real-time polymerase Chain reaction (PCR) was performed according to the 
manufacturer’s instructions using the Roche LightCycler 480 System. A summary of the 
primer and probes used for the PCR amplification and the melting curve analysis is shown 
in Table 2.5 below. All primer and probe sets were manufactured by Roche Applied 
Science and the melting temperature (Tm) for each SNP was calculated as shown in Table 
2-5. The melting temperature would have been calculated as a function product length, 
GC content and sequence composition so subtle differences in the sequence composition 
will result in a shift in the Tm. The different variants under the probe will then result in 
Downloaded from https://www.roche-applied-science.com/sis/rtpcr/htc/index.jsp?id=htc_0107010103 





different probe stabilities, with specific alleles being distinguished by their Tms (Ririe et 
al., 1997). The LightCycler 480 machine that was used bases its Genotyping algorithm on 









Table 2-5: Primer and Probe sequences for the selected candidate genes and polymorphisms 
Pon1: Human Paraoxonase Gene 1; LPL: Lipoprotein lipase gene; FL: Fluorescein; PH: Phosphate end; f: forward primer; r: reverse primer 
Gene: SNP Primer sequences Probe sequences Mutation 
PON-1:L55M (f):AAAGAAAACACTCACAGAGCTA 
(r):TCAAGTGAGGTGTGATAAAGAAAT 
LC Red 640-CTGGCTCTGAAGACATGGAGATACTG-PH 
ACCTGTACTTTCTGTTCTCTTTTCTGGCAGA-FL 
A to T 
PON-1:Q192R (f):TATTGTTGCTGTGGGACCT 
(r):ACATACTTGCCATCGGG 
LC Red 640-CCCAAATACATCTCCCAGGATCGTAAGTA-PH 
CTTGGACTATAGTAGACAACATACGACCACGCTA-FL 
A to G 
LPL:S447X (f):TTCTGTTCTAGGGAGAAAGTGT 
(r):CATGAAGCTGCCTCCCTTA 
LC Red 640ATTCAGAGACTTGTCATGGCATTTCACAAATACCG-PH 
AATGCTCACCAGCCTCACTTC-FL 
C to G 
LPL:N291S (f):TGAGTTGTAGAAAGAACCGC 
(r): GGACTCCTTGGTTTCCTTATT 
LC Red 640-TTTGGCTCTGACTTTACTGATCTCATAGC-PH 
GAACGAGTCTTCAGGTACATTTTGCTGCTT-FL 
A to G 




Table 2-6: Melting curve temperature calculation for selected candidate genes and 
polymorphisms 
Gene: SNP Amplicon 
length (bp) 
GC % Mutation 
position 
WT Tm(°C) Mutation 
Tm(°C) 
PON-1:L55M 152 40.3 301 61.1 64.9 
PON-1:Q192R 198 42.4 301 58.7 66.1 
LPL:S447X 164 48.8 401 64.7 55.1 
LPL:N291S 152 44.7 301 60.7 64.9 
Tm: melting curve temperature; WT: wild-type 
 
Polymerase chain reaction was performed by rapid cycling in a reaction volume of 10 µL 
with 0.5 µmol/L each primer, 0.2 µmol/L anchor and detection probes, 50 ng of genomic 
DNA and LightCycler 480 Genotyping Master. This is a ready-to-use hot-start reaction 
master mix designed specifically for single nucleotide polymorphisms detection with 
Melting Curve analysis, using allele-specific hybridization probes. The master mix is 
supplied as a 10-times concentrated stock solution containing nucleotides, Thermus 
aquaticus DNA polymerase, and 10 mmol/L Mg2+. The PCR mix was pipetted into a 96-
well Lightcycler Multiwell PCR reaction plate, to which were added 2, 5 µl of DNA 
template. The Multiwell plate was then sealed, centrifuged and then transferred to the 
plate holder of the Roche Light Cycler 480 Instrument, and the real-time PCR reaction was 
initiated.  
 
After pre-incubation at  95 °C  for 10 minutes, amplification was performed using 35 
cycles of denaturation (95°C for 10 seconds), annealing (55°C for 10 seconds), and 




extension (72 °C for 10 seconds). Observation of real-time amplification was possible as 
fluorescence was measured at the end of the annealing period of each cycle. When target 
amplification was completed, a melting curve stage was recorded by cooling the reaction 
mixture to 45°C, holding it at 45°C for 2 minutes and then slowly reheating it to 95°C. 
Fluorescence was measured continuously during the slow temperature ramp to monitor 
the dissociation of the fluorescein-labelled detection probe. A final cooling stage cooled 
the reaction mixture to 40°C in 30 seconds. The entire run took approximately 75 minutes 
in a homogenous setting.  
 
2.8.4.5 NEGATIVE CONTROLS 
At least two negative controls were run with each plate, by replacing the DNA template 
with PCR-grade water. This was done to detect contamination, if it was present. 
 
2.8.5 Gel electrophoresis 
In order to investigate whether PCR amplification was successful, 2µl of each PCR product 
was mixed with 5µl Gel red loading buffer (2 mg/ml Gel red and 35% (w/v) sucrose). The 
solution was loaded onto a 3% (w/v) horizontal agarose gel [6g agarose in 100 ml 1TBE]. A 
100 base pair (bp) ladder was also loaded onto the gel to confirm PCR amplification of the 
correct fragment size. Electrophoresis was performed at 80 V for 90 minutes in 1TBE 
buffer solution. The bands were then visualised by ultraviolet light transillumination 
(GeneSnap MultiGenius Bio Imaging System, Syngene).  




2.8.6 Genotyping by sequencing 
2.8.6.1 PURIFICATION OF PCR PRODUCTS 
PCR products were purified using the Qiagen Gel extraction Kit, according to the 
manufacturer’s guidelines following gel electrophoresis, which was performed using a 
low DNA mass ladder, and run at 100 V for 60 minutes. The DNA fragment was then 
excised from the agarose gel with a scalpel, using the SynGene (Vacutech) 
transilluminator. The excised gel was weighed, to which was added 3 volumes of Buffer 
QG, and incubated at 50°C for 10 minutes until the gel dissolved. After following the 
manufacturer’s protocol, the DNA was aliquoted into Eppindorf tubes and stored at -20°C 
until the sequencing reaction. 
 
2.8.6.2 SEQUENCE REACTION 
The SOP that was referred to, was designed by the Hasso Plattner Laboratory at the 
University of Kwazulu Natal (SEQ 002; Version 001).The method is summarized briefly as 
follows: 
A master mix was prepared using the Terminator Ready Reaction Mix (Applied 
Biosystems) (0.4µl), 5 x concentration sequencing buffer (2.0 µl), primers for the specific 
SNPs (3.2pmol) and deionised water (up to 10 µl). The master mix was centrifuged and 
aliquoted into the 96-well plate. The purified PCR template was then added to the wells, 
centrifuged and placed in the thermal cycler under the conditions in Table 2-7.  
 




Table 2-7: Stages for the sequence reaction 
No of cycles Temperature Time Process 










 4°C HOLD - 
 
The PCR products were stored at 4°C, protected from light. Purification of the sequencing 
products were performed on the same day as the sequencing reaction. 
 
2.8.6.3 PURIFICATION OF SEQUENCING PRODUCTS (PLATE CLEAN-UP)  
The SOP that was referred to was designed by the Hasso Plattner Laboratory at the 
University of Kwazulu Natal (SEQ 003; Version 001), and was added to each well, as 
shown in Table 2-8. 
Table 2-8: Purification of sequence products 
Reagent Per well 
125mM EDTA pH8.0 1 µl 
3M NaOAc Ph5.2 1 µl 
100% Ethanol 25 µl 
 




The plate was securely sealed with adhesive foil, vortexed briefly and centrifuged for 20 
minutes at 3000 x g. The plate was then inverted onto a paper towel and centrifuged at 
150 x g for 1 minute, to which 35 µl of 70% fresh cold ethanol was added to each well. 
Centrifuging, inverting and re-centrifuging were repeated as above, and samples were 
dried in the thermal cycler for 1 – 5 minutes at 50 °C. The plate was then sealed with an 
adhesive cover, wrapped in foil and stored at -20°C until sequencing.  
 
2.9 Statistical analysis 
The data was captured onto Microsoft Excel spread sheets, cleaned and transferred into 
SPSS Version 17 software package. 
The distributional properties for all variables were investigated, and those that were not 
normally distributed were log-transformed, or analysed using non-parametric testing. 
Means and standard deviations (Mean±SD) and median values and inter-quartile ranges 
(IQR) (non-Gaussian distributed variables) were calculated for continuous variables and 
frequencies for categorical variables for descriptive purposes.  
Categorical data was summarized as a percentage of the group total with corresponding 
95% confidence intervals (CIs). Comparison among groups was made by the Chi-square 
test. Comparisons among groups were based on analysis of variance models. Post hoc 
analysis of variance comparisons of continuous variables were based on the t- test. 
Frequency analysis was performed to determine the prevalence of risk factors in this 
population, as well as their relationships with each other and with echocardiographic 




parameters. Echocardiographic parameters and genetic patterns were analysed in the 
entire sample, and further sub-group analyses were performed between the genders and 
the age groups. Subjects were then classified into those with and without the MS based 
on the ATP III, IDF and Harmonized criteria. Statistical differences were sought from 
clinical parameters, echocardiographic parameters and polymorphisms in all subjects, 
and then in sub-groups depending on age, gender, presence or absence of MS or each of 
its components.  Differences were considered statistically significant when p <0.05.  
 
Logistic regression analysis, stratified for age and sex, was performed for prevalence of 
echocardiographic abnormalities among subjects with isolated MS and compared with 
those without the MS. Spearman’s Rho was used to determine the strength of the 
correlation. 
Linear models were constructed in order to investigate the association between each MS 
trait, and echocardiography variables. The Analysis of covariance (ANCOVA) was used to 
compare levels of echocardiographic variables (LVMI, LVM, LVPW, LVS, LVEDD, Em/Am 
and SEAT) between subjects with and without MS. SEAT values (in mm) were used in 
logistic regression to determine its contribution to the diagnosis of MS.  
Receiver operator characteristic (ROC) curve analysis was used to determine the 
discriminating capacity of biochemical, anthropometry measurements, genotypes and 
echocardiography parameters in determining the presence of MS. The area under the 
curve (AUC) was used determine the predictive efficiency of each of these variables.  
 




The genetic analysis was performed on coded subjects identified by study number. The 
analysis was performed without prior knowledge of the grouping of subjects into those 
with and without MS.Gene counting was used for the estimation of genotype and allele 
frequencies and was expressed as percentages of the totals.   
Cross-tabulations were constructed with MS and the MS components with the genotype 
category.  Non-parametric variables were expressed as mean ranks and the Kruskal-Wallis 
test was used to determine the significance. Median values for MS components as well as 
echocardiography variables were compared between the three genotype groups. Hardy 
Weinberg equilibrium was calculated once the allele frequencies in the population were 
known. 
 
2.10 Ethical considerations 
The applicant received full ethical clearance for this study from BREC for 
echocardiography and blood storage for genetic studies, and this was received on 23rd 
October 2009 (BE 172/09). Recertification of ethics for the Phoenix Lifestyle Project has 
been granted by the University of KwaZulu-Natal Bioethics committee. Ethics number: 
E336/05. 





CHAPTER THREE  
Results 




3.1 Demographic data 
The study comprised 1428 randomly selected subjects from the suburb of Phoenix, which 
is situation in the EThekwini Municipality of KwaZulu-Natal. The sample was dominated 
by females, making up 72% of the sample, whilst the male component comprised 28%.  
The mean age (±SD) of the sample was 43 (±15) for males and 46 (± 12) for females. The 
mean age of the total sample was 45.5 (±13). The highest number of subjects within the 
sample was in the 45-54 year age group (Table 3-1). 














 Age group n Males (n % ) Females (n %) 
15-24 140 (10%) 58 (41%) 82(59%) 
25-34 165 (12%) 63(38%) 102(62%) 
35-44 304 (21%) 76(25%) 228(75%) 
45-54 442 (31%) 89(20%) 353(80%) 
55-64 377 (26%) 116(31%) 261(69%) 
TOTAL 1428 402(28%) 1026 (72%) 
Mean age 45.5 ± 13 43.43(±15) 46(± 12) 




3.2 Prevalence of cardiovascular risk factors 
There were 543 (38%) subjects who did not exhibit any of the 5 common cardiovascular 
(CV) risk factors (elevated total cholesterol and triglyceride levels, decreased high-density 
lipoprotein [HDL], impaired fasting glucose and hypertension) that were tested for. The 
remaining 62% of subjects in the sample presented with 1 or more CV risk factors (Figure 
3.1). There was an increase in the proportion of subjects with CV risk factors with 
advancing age. The median and interquartile range (IQR) values for the major risk factors 
for cardiovascular disease in this sample are shown in Table 3-2.  
 















Sample males females 15-24 25-34 35-44 45-54 55-64
0 risk factors
>=1 risk factor
The gender and age distribution of subjects with CV risk factors: subjects with no risk factors are 
shown in blue. The highest proportion of subjects with >1 risk factor is in the 45-54 age group. 
 




3.2.1 Family History of Cardiovascular risk factors 
A positive family history for CV risk factors (obesity, Type 2 Diabetes Mellitus [DM], 
hypertension, myocardial infarction/stroke and heart failure[CHF]) was recorded in all 
subjects. The main disease reported in this sample was a positive family history of 
hypertension (76%) in both males (68%) and females (79%). This was followed DM (67%) 
in both genders (Figure 3.2). Almost half of all subjects (48 %) reported a positive family 
history for heart failure (Figure 3.2).  













obesity DM HYPN MI/Stroke PVD CHF
sample males females
The gender-wise distribution of subjects with a positive family history for CVD: the most 
frequent positive history reported is hypertension. 
 




3.2.2 Anthropometric parameters 
There was a high prevalence of raised BMI (66%) in this population (Table 3-7a). The 
frequency of raised BMI increased from the 1st to the 4th age groups (19% to 39%), and 
decreased by the 5th age group (Table 3-7a). Using the standard guidelines of 
interpretation, 32% of subjects were classified as being overweight (BMI >25<30 kg/m2), 
and remaining 34% were classified as being obese (≥ 30kg/m2) (Table 3-7a). Using the 
ethnic-specific cut-off for BMI for Asian Indians (≥23 kg/ m2) (WHO Expert Consultation, 
2004), the prevalence of obesity (≥25 kg/m2) increased to 64% (Table 3-7a). There were 
significant differences between the genders (p = 0.000), as a raised BMI was more 
prevalent amongst the females (84%). 
The median and inter-quartile range (IQR) waist circumference measurement for males 
was 89 cm (77, 98) and 95 cm (85,105) in females (Table 3-2). Using ethnic-specific 
criteria as specified by the International Diabetes Federation (IDF) [90cm in males and 80 
cm in females], the waist circumference was increased in 51% of males and in 82% of 
females (Table 3-7a). 
 
3.2.3 Lifestyle and behavioural characteristics 
Smoking was reported by 26% of subjects, with the largest number of smokers observed 
in the youngest (29%) and oldest (28%) age groups, respectively (Table 3-7a). There were 
significantly more male than female smokers (p = 0.001).   
 




3.2.4 Clinical observations 
The median (IQR) systolic blood pressure (SBP) was 130 mmHg (118,144) and the median 
(IQR) diastolic blood pressure (DBP) was 79 mmHg (77, 98) in males. In the female group, 
the median (IQR) SBP was 131 mmHg (118, 146) and the median (IQR) DBP being 81 
mmHg (74, 90) mmHg. There were no significant differences observed between the 
genders. There was a gradual increase in both the mean systolic and diastolic blood 
pressure accompanying advancing age (Table 3-2). 
Hypertension was documented in 49% of subjects (Table 3-7a). There was a marked 
increase in the prevalence of hypertension observed from the 1st (6%) to the 5th (71%) age 
groups. There were 211 (15%) subjects who were previously undiagnosed with 
hypertension (Table 3-3). 
Prehypertension (SBP/DBP 120-139 mm Hg/ 80- 89 mm Hg) was found in 676 subjects 
(49%), with the prevalence distributed evenly between males and females. However, 
there was an increase in the frequency of prehypertension observed with increasing age. 
A positive family history for hypertension was recorded in 78% (1072) of participants, of 
whom 40% (551) were hypertensive already. This translated into a doubling of risk for 
hypertension (OR= 2.08; 95% CI=1.6, 2.7) when a positive family history was present 
(Table 3-4). 




Table 3-2: Median and inter-quartile ranges (25th-75th) for physiological, anthropometry and biochemical measurements 
Parameter Males  females P 15-24 25-34 35-44 45-54 55-64 
         
BMI (kg/m2) 24.6(21.2,27.8) 28.6(25,33) 0.001* 21.7(18.3,26.6) 27(22,32) 28(24,32) 28.2(25,32) 27.15(23.8,31) 
WC (cm) 89(77, 98) 95(86,105) 0.001* 77(70, 88) 90(79,104) 94(84,104) 96(88,105) 95(88,103) 
SBP (mmHg) 130(118,144) 131(118,146) 0.83 117(108,125) 122(113,136) 125(114,139) 135(123,148) 140(127,155) 
DBP(mmHg) 79(71,89) 81(74,90) 0.253 70(64,78) 79(72,87) 81(73,90) 82(75,92) 82(75,91) 
FBG(mmol/l) 5.1(4.7,5.9) 5.3(4.8,6.5) 0.008* 4.7(4.5,5.0) 4.9(4.5,5.2) 5.0(4.7,5.7) 5.5(5.0, 6.7) 5.8(5.1,8.1) 
GTT(mmol/l) 6.3(5.2,8.4) 7.2(5.9,9.5) 0.001* 5.5(4.7,6.5) 6.1(5.3,7.7) 6.8(5.9,8.6) 8.0(6.2,10) 7.7(5.9, 10) 
TC (mmol/l) 5.3(4.5,6.1) 5.4(4.6,6.1) 0.219 4.4(3.9,5.0) 5.0(4.5, 5.6) 5.3(4.6,6.0) 5.6(4.9, 6.3) 5.7(5.0, 6.4) 
TG (mmol/l) 1.5(1.1,2.2) 1.5(1.1,2.0) 0.644 0.9(0.7,1.1) 1.4(1.0, 1.8) 1.5(1.1, 2.0) 1.8(1.2,2.1) 1.7(1.3,2.3) 
HDL(mmol/ 1.17(1.0, 1.34) 1.3(1.1, 1.5) 0.001* 1.3(1.09,1.5) 1.2(1.0,1.4) 1.2(1.02,1.4) 1.3(1.1,1.5) 1.3(1.1.,1.5) 
HOMA-IR (iu) 2.09 (1.2,4.1) 3.3(1.9,5.4) 0.50 1.9(1.3,3.3) 2.6(1.7, 4.2) 3.0(1.6, 4.87) 3.2(1.9,5.4) 3.3(1.7,6.0) 
BMI: Body mass index, WC: Waist circumference; TC: Total cholesterol, HDL: high-density lipoprotein; TG: triglyceride, FBG: fasting blood glucose; GTT: 2-hour fasting 
plasma glucose concentration; SBP: Systolic blood pressure; DBP: diastolic blood pressure 
*Significant differences between males and females 
 
 




Table 3-3: The crude prevalence of Hypertension and prehypertension  
 Males  Females Prevalence 15-24 25-34 35-44 45-54 55-64 
n 377 1001 1378 128 161 298 430 374 
Systemic 
hypertension 
157 (42%) 512 (51%) 669 (49%) 8(6%) 39 (24%) 114 (38%) 246 (57%) 266 (71%) 
Self-reported 91(24%) 367(37%) 458 (68%) 5(4%) 12(7%) 61(20%) 168(39%) 214(57%) 
Previously                             
unknown 
66(18%) 145 (14%) 211 (32%) 3(2%) 27(17%) 53 (18%) 78 (18%) 52 (14%) 
Prehypertension 189(50%) 487(49%) 676 (49%) 51(40%) 79(49%) 137(46%) 223(52%) 191(51%) 
 
Table 3-4: Positive family history of Hypertension  
 Males (n) Females(n) Prevalence 15-24 25-34 35-44 45-54 55-64 
n 377 1001 1378 128 161 298 430 374 
Family history 268(71%) 804(80%) 78% 99(77%) 124(77%) 226(76%) 332(77%) 296(79%) 
Prehypertensive#  130(34%) 384(38%) 37% 35(27%) 61(39%) 106(36%) 167(39%) 149(40%) 
Hypertensive* 119(44%) 432(54%) 40% 7(7%) 32(26%) 91(40%) 203(61%) 222(75%) 
#p (trend) =0.847; OR (95%CI) = 1.03(0.8; 1.3) 
* p (trend) =<0.001; OR (95%CI) = 2.08(1.6; 2.7) 




3.2.5 Biochemical parameters 
3.2.5.1. BLOOD GLUCOSE AND INSULIN 
The median fasting blood glucose levels in males was 5.1 mmol/l and significantly higher 
(5.3 mmol/l) in females (p= 0.008) (Table 3-2). There was a steady increase in the fasting 
blood glucose levels observed with increasing age. 
 
There was a total number of 455 (32%) subjects who were classified as diabetic, with the 
highest prevalence (49%) observed in the 55-64 year age group. Of the diabetic subjects, 
16 % of males and 22 % of females self-reported their status, leaving over one third of 
diabetic subjects who did not know their status (Table 3-5).  
The prevalence of DM increased with advancing age and was significantly higher in 
females (p = 0.001). Of note, there was a high prevalence of DM (38%) in subjects who 
had a first-degree diabetic family member, and this was associated with an almost 3-fold 
likelihood (OR= 2.53; 95% CI=1.94, 3.3) of subjects with positive family history developing 
DM themselves (Table 3-6). 
Using the guidelines proposed by the American Diabetes Association (2012) for the 
classification of prediabetes, we found a prevalence of 20% in male subjects and of 25% 
in female subjects with prediabetes, at the time of testing (Table 3-5). 
There was also a high frequency of insulin resistance observed in this sample (58%), 
which increased progressively with advancing age. The highest prevalence was observed 
in the 4th and 5th age groups, with 61% of subjects in each age group being classified as 
insulin resistant, as assessed by the HOMA-IR index (Table 3.7a).  




Table 3-5: The crude prevalence of Diabetes and Prediabetes  
 Males  Females Prevalence 15-24 25-34 35-44 45-54 55-64 
n 377 1001 1378 128 161 298 430 374 
DM prevalence  96 (25%) 349 (35%) 445(32%) 8(6%) 20(12%) 80(27%) 155(36%) 183(49%) 
Self-reported 60(16%) 221(22%) 281(63%) 3 (1%) 5 (3%) 52 (17%) 98 (23%) 123 (33%) 
Previously unknown 36 (10%) 128 (13%) 164(37%) 5 (4%) 15 (9)% 28(9%) 57(13%) 60(16%) 
Prediabetes# 76(20%) 250(25%) 326(24%) 9 (7%) 34 (21%) 74 (25%) 154(36%) 106(28%) 
# using IFG and IGT criteria 
Table 3-6: Positive family history of Diabetes Mellitus 
 Males  Females 15-24 25-34 35-44 45-54 55-64 
N 377 1001 128 161 298 430 374 
Family history 245(65%) 703(70%) 92(72%) 95(59%) 209(70%) 297(69%) 260(70%) 
Median FBG (mmol/l) 6.6 6.7 5.0 5.3 6.3 7.0 7.2 
Prediabetic # 67 (27%) 225 (32%) 7(8%) 16 (17%) 60(28%) 112(38%) 88(34%) 
DM* 73 (19%) 287 (29%) 8(9%) 25(26%) 66(22%) 130(44%) 142(55%) 
#p (trend) =0.21; OR (95%CI) = 1.062(0.83; 1.36) 
* p (trend) =<0.001; OR (95%CI) = 2.53(1.94; 3.3) 




3.2.5.2 LIPID PROFILES 
The median (IQR) value of total cholesterol (TC) was recorded as 5.3 mmol/l (4.5, 6.1) 
(Table 3-2). There was an 18% (cf 17%) prevalence of elevated total cholesterol (≥ 6.5 
mmol/l), when applying the cut-offs used by Seedat et al (1990).  This was most prevalent 
in the 55-64 year age groups (Table 3-7b). This prevalence tripled to 60% in both genders 
when the NCEP cut-off (5.1 mmol/l) was applied. There was a steady increase in the 
prevalence of raised TC levels with advancing age, with 70% of subjects in the 55-64 age 
group recording elevated levels of total cholesterol.  
 
The median (IQR) triglyceride value (Table 3-2) was 1.5 mmol/l (1.1, 2.1), with elevated 
triglyceride levels (> 2.83 mmol/l) being detected in 11% of the sample. The highest 
prevalence was recorded in the 25-34 year age groups, with 16% of subjects presenting 
with hypertriglyceridemia. A higher prevalence of hypertriglyceridemia was observed 
when the new NCEP (Grundy et al., 2001) cut-off (>1.69 mmol/l) was applied, quadrupling 
the prevalence to 44%, with an increasing trend noted with advancing age (Table 3-7b). 
 
The median HDL levels were within normal limits across all age groups, with 14%  of the 
sample presenting with levels lower than <1.0 mmol/l (Table 3-7b).  There was a similar 
dyslipidaemia pattern in the 25-34 year age groups, which recorded the highest 
prevalence of abnormal HDL levels (29%), with males presenting more frequently with 
decreased HDL levels. Using the NCEP cut-off for HDL (< 1.04 mmol/), the prevalence of 




decreased HDL levels increased to 23% (Table 3-7b).  
 
3.2.6 Overall risk factor profile 
There were significant differences between males and females for six out of the nine risk 
factors that were studied (Table 3-7a; 3-7b). Females were more prone to obesity, insulin 
resistance, DM and hypertension (Table 3-7a). There was a higher prevalence of low HDL 
cholesterol in men (24%) compared to women (10%). As mentioned earlier more than 
half the men were smokers. 
The most common risk factor in this sample was an increased waist circumference (using 
the IDF criteria), which was found in 79% of subjects, followed by general obesity in 64% 
of subjects (Table 3-7a). The most common biochemical abnormality was 
hypercholesterolemia, found in 60% of subjects (Table 3-7b). Both men and women were 









Table 3-7a:  Distribution and frequency of selected major cardiovascular risk factors: Clinical characteristics, BMI and waist circumference 
 Males Females p 15-24 25-34 35-44 45-54 55-64 Prevalence 
n= 1378# 377 1001  128 161 298 430 374  
BMI < 25kg/m2  
>25<30 kg/m2 
146 (39%) 323 (32%) ns 86(67%) 58(36%) 78(26%) 80(19%) 103(27%) 469(34%) 
128 (35%) 318 (33%) ns 22(17%) 38(24%) 94(32%) 166(39%) 126(33%) 446(32%) 
>30 kg/m2 51 (14%) 419 (42%)  0.000* 24(19%) 59 (37%) 112 (38%) 160 (39%) 119(30%) 474(34%) 
<23 kg/m2** 



















>25 kg/m2** 179 (47%) 702 (70%) 0.000* 46 (36%) 97(60%) 208(69%) 331(76%) 246(65%) 881(64%) 
Waist***(cm) 192(51%) 856 (82%) 0.000* 47(37%) 103(64%) 233(78%) 368(86%) 297(79%) 1048(79%) 
Diabetes 
HOMA- IR (>2.6) 165 (44%) 626 (63%)         0.000* 52 (41%) 84 (52%) 171 (55%) 261(61%) 227(61%) 795(58%) 
DM (%) 96 (25%) 349(35%)         0.001* 8(6%) 20(12%) 80(27%) 155(37%) 183(49%) 445 (32%) 
Hypertension and smoking 
BP&:≥140/≥90 157 (42%) 512 (51%)        0.001* 8(6%) 39 (24%) 114 (38%) 246 (57%) 266 (71%) 669 (49.5%) 
Smokers (%) 208 (53%) 144 (14%)        0.001* 37(29%) 33(20%) 69 (23%) 93(22%) 103(28%) 235(26%) 
*indicates statistical significance; #n due to missing values; BMI: Body mass index, FBG: fasting blood glucose; SBP: Systolic blood pressure; DBP: diastolic blood 
pressure; **Modified criteria for Asian Indians (WHO Expert Consultation, 2004); ***IDF criteria 




Table 3-7b:  Distribution and frequency of major cardiovascular risk factors: Lipids 
*indicates statistical significance 
TC: Total cholesterol, HDL: high-density lipoprotein; TGL: triglyceride, ^ (Seedat et al., 1990) ;!( NCEP guidelines, 2001); BP&: JNC criteria 
 Males Females p 15-24 25-34 35-44 45-54 55-64 Prevalence 
n= 1378# 377 1001  128 161 298 430 374  
TC > 6.5mmol/l^ 67 (18%) 183(18%) ns 6(5%) 12(7%) 46(16%) 95(22%) 91(24%) 250(18%) 
TC > 5.17mmol/l! 227 (60%) 588 (59%) ns 25(20%) 73(45%) 168(56%) 292(68%) 263(70%) 821(60%) 
HDL (< 1.0mmol/)^ 91(24%) 96(10%) 0.000* 17 (13%) 47 (29%) 47(16%) 46(11%) 29(8%) 187(14%) 
HDL (< 1.04mmol/)! 133(35%) 183(18%) 0.000* 32(25%) 46(29%) 80(27%) 84(20%) 77(21%) 319(23%) 
TGL(>2.83mmol/l)^ 51 (14%) 100(10%) ns 3 (2.1%) 26(16%) 26(9%) 48(11%) 46(12%) 149(11%) 
TG (>1.69mmol/l)! 175(46%) 424(42%) ns 18(14%) 45(28%) 118(40%) 217(50%) 202(54%) 600(44%) 




3.2.4 Correlation between cardiovascular risk factors 
The correlation between individual risk factors is shown in Table 3-8. The analysis, using 
Spearman’s Rho showed a strong correlation (rs > 0.500), shown in darkest purple 
between the BMI, waist circumference, fasting blood glucose and HOMA-IR values.  A 
moderate correlation (rs > 0.300 < 0.500), coded dark purple (Table 3 - 8) was observed 
between triglyceride levels and the waist circumference, FBG, glucose tolerance test 
values, total cholesterol and HOMA-IR values. A moderate inverse correlation existed 
between triglyceride and HDL levels. The remaining associations were weak, but 
statistically significant (rs > 0.100 < 0.300, shown in lightest purple). All correlations with 
HDL were inversely orientated, where a lower level of HDL was moderately correlated 
with higher levels of triglycerides, and weakly correlated with fasting blood glucose, total 















Table 3-8: Spearman’s Rho correlation between risk factor variables 
Parameter BMI WC FBG 2-H TC TGL HDL SBP DBP HOMA-IR 
BMI  1 +++ + ++ + + - + ++ +++ 
WC +++ 1 ++ ++ + ++ - ++ + +++ 
FBG + ++ 1 +++ + ++ - + + +++ 
2-Hr GTT ++ ++ +++ 1 + ++ - + + ++ 
TC + + + + 1 ++ - + + + 
TGL + ++ ++ ++ ++ 1 -- + + ++ 
HDL - - - - - -- 1 NS - - 
SBP + ++ ++ + + + NS 1 +++ + 
DBP ++ ++ + + + + - +++ 1 + 
HOMA-IR +++ +++ +++ ++ + ++ - + + 1 
BMI: Body mass index, WC: waist circumference; FBG: fasting blood glucose, 2-H: 2-hour GTT; TC: Total 
cholesterol, TGL: triglyceride; HDL: high-density lipoprotein; SBP: Systolic blood pressure (mean); DBP: 
diastolic blood pressure (mean); HOMA-IR: values as measured by HOMA-IR index.  
KEY: + (weak); ++ (moderate);+++ (strong) ;    -(weak inverse); -- (moderate inverse);--










3.2.5 The age distribution of cardiovascular risk factors 
The distribution of CV risk factor clustering (elevated total cholesterol and triglyceride 
levels, decreased HDL, impaired fasting glucose and hypertension: WHO cut-off) is shown 
in Figure 3.3 below. There was a proportional inverse relationship between the absence 
of CV risk factors and age, where the proportion of subjects without CV risk factors 
decreased with advancing age. The majority (66%) of subjects in the 15-24 year age group 
presented with no risk factors, as compared to 24% in the 55-64 year age group. Of note, 
we documented 33% of subjects in the 15-24 year age group who presented with a single 
risk factor, with under 2% who presented with 2 CV risk factors. A slightly higher 
percentage was observed in the 25-24 year age group (35% with 1 CV risk factor, 6% with 
2 CV risk factors) and a smaller number (3%) with 3 CV risk factors. The 35-44 year age 
group contained 30% of subjects with 0 risk factors, 40% with 1 risk factor, 21% with 2 
risk factors and 7% with 3 risk factors, with approximately 2% of subjects who had 4 risk 
factors. There were approximately 3% of subjects in the 55-65 year age group who also 
had 4 risk factors. There were no subjects who tested positive for all 5 risk factors.  
 









3.3 The Metabolic Syndrome 
3.3.1 The prevalence of the Metabolic Syndrome 
The crude prevalence of the metabolic syndrome (MS) was 38% (518 subjects) using the 
criteria proposed by the Adult Expert Panel (ATP) III panel, which increased to 46% when 
the International Diabetes Federation (IDF) criteria was applied (Figure 3.4). According to 

























number of risk factors 
15-24 25-34 35-44 45-54 55-64
The highest number of subjects without conventional CV risk factors was in the 15-24 age 
groups. This proportion decreased with advancing age. 




Table 3-9: Gender-wise prevalence of the Metabolic Syndrome according to IDF, NCEP 
ATP III and Harmonized criteria 
 IDF NCEP ATP III Harmonized 
Males 131/398 (33%) 90(23%) 128/398 (32%) 
Females 536/1024(52%) 427(43%) 462/1026 (45%) 
Prevalence 667/1422 (46%) 518/1374 (38%) 590/1424 (41%) 
 
The general trend across all 3 criteria was a higher prevalence of the MS in females, with 
these differences being significant between males and females (p < 0.005).  
 
FIGURE 3.4: Age-wise prevalence of the Metabolic Syndrome according to IDF, NCEP 





































The age-wise pattern of the metabolic syndrome prevalence: apart from the IDF definition, there was a 








The age-wise prevalence showed a corresponding increase in the prevalence of MS with 
increasing age (Figure 3.4), where the 55-64 year age group had the highest prevalence, 
subject to the definitions used [67% (IDF), 53% (NCEP) and 50% (Harmonized)]. There was 
a sharp increase in the prevalence of MS from the 25-34 year age group (27%) to the 35-
44 year age groups  (45%) when the IDF definition was applied, a pattern which was not 
seen with the other criteria.  
 
3.3.2 The Kappa statistic 
Of the total 1422 participants, 619 (43%) had a concordant positive diagnosis according 
to both the IDF and Harmonized definitions of MS, and 720 (51%) were negative 
according to both definitions (Table 3-10). The total percentage of observed agreements 
was in 1339 (94%) of subjects, with 83 (6%) subjects being discordant. Thus the kappa 
statistic indicated a strong level of agreement (almost perfect [Landis and Koch, 1997]) 
between the two tests (Kappa = 0.883).   
The agreement between the NCEP ATP III and Harmonized definitions yielded a Kappa of 
0.812. There was therefore a stronger agreement between the IDF and Harmonized than 








Table 3-10: Degree of agreement between the Harmonized, NCEPA III and IDF criteria 
 Harmonized criteria 
 No yes Total 
IDF            no 









768 654 1422 
 
  Harmonized criteria 
        No yes Total 
NCEP III   no  729  0  729 
                Yes  127  518  645 




3.3.3 The frequency and clustering of MS components 
Figure 3.5 below shows the distribution and clustering of MS components in subjects 
according to age. These subjects were classified with MS using the IDF criteria, which, in 
addition to using ethnic-specific cut-offs, was able to identify the highest number of 
individuals with MS. 
There were 35% of subjects in the youngest age groups having no components for MS 
(Figure 3.5). The 45-54 year age groups prominently displayed the highest percentage of 
subjects with a single MS component and subsequent clustering of MS components. 
Furthermore, a third of subjects in this age group had all 5 components of MS, exceeded 




only by the 55-64 year age groups, where 41% of subjects in this age group showed 
clustering of all 5 risk factors.  
 
The most frequent components contributing to the diagnosis of MS using the NCEP 
criteria was an increased waist circumference ([males >102 cm] [females >88 cm) in 
84.2% of subjects, followed by elevated triglycerides levels (> 1.7 mmol/l) in 78% of 
subjects (Figure 3.7). There was an increase in the frequency of abdominal obesity in all 
subjects (100%) with MS as defined by the IDF criteria ([males ≥ 90 cm][females ≥ 80cm]), 
followed by elevated triglycerides levels (> 1.7 mmol/l) which was observed less 
frequently, but significantly, in 67% of subjects with MS (Table 3-11). 
A similar trend was observed when the Harmonized criteria was applied, with an 
increased waist circumference ([males ≥ 90 cm] [females ≥ 80cm]) seen in 84.2% of 
subjects, followed by elevated triglycerides levels (> 1.7 mmol/l) in 78% of subjects with 
MS (Table 3-11). 
Impaired fasting glucose and hypertension were the least common abnormalities 
observed across all three criteria. As a result of the application of the IDF criteria, the 
greatest number of subjects with MS was identified. Hence, we present subsequent 
analysis for the IDF criteria only in this population with a high propensity for CVD. 
 
 















































The clustering of MS components according to age: the youngest age group had the largest 
proportion of subjects with no MS components, while the oldest group had the largest proportion 
with all 5 MS components. 
 
 








NCEP ATP III  
Yes (n = 518) No (n = 856) 
Fasting Glucose ≥ 6.1 mmol/L 310 (60%) 86 (10%) 
TG ≥ 1.7 mmol/L 396 (78%) 186 (21.7%) 
HDL [males <1.03] [females <1.29] mmol/L 376 (72.6%) 230 (26.9%) 
Waist Circumference[males >102cm][females 
>88cm] 436 (84.2%) 317 (37%) 
Blood Pressure ≥130 / ≥85 mmHg 301 (60.1%) 143 (16.7%) 
 
 International Diabetes Federation 
Yes (n = 667) No (n = 755) 
Waist Circumference[males ≥ 90 cm][females ≥ 
80cm] 
667 (100%) 381 (51%) 
Fasting Glucose ≥ 5.6 mmol/l 423 (63.4%) 111 (14.7%) 
TG > 1.7mmol/l 447 (67%) 140 (19%) 
HDL [males <1.03] [females <1.29] 427 (64%) 188 (25%) 
Blood Pressure ≥ 130 / ≥ 85 mmHg 325 (51%) 118 (16.3%) 
 
Harmonized Criteria 
Yes (n = 518) No (n = 856) 
Fasting Glucose ≥ 6.1 mmol/L 329 (56%) 256 (43%) 
TG ≥ 1.7 mmol/L 446 (76%) 140 (24%) 
HDL [males <1.03] [females <1.29] mmol/L 417 71%) 170 (29%) 
Waist Circumference[ males ≥ 90 cm][females ≥ 
80cm] 565 (96%) 25 (4%) 
Blood Pressure ≥130 / ≥85 mmHg 327 55%) 244(75%) 




3.3.4 The frequency of individual MS components in males and females 
Analysis of the frequency of the MS components between the genders in Figure 3.6, using 
the IDF criteria indicated that there was a significantly higher prevalence of MS in 
females, as compared to males (p < 0.05); with females more likely to present with  
abdominal obesity (p < 0.05). There were also significant differences between males and 
females for the prevalence of impaired fasting glucose levels (p = 0.000), with females 
having a higher frequency of elevated triglycerides, elevated blood pressure and 
decreased HDL levels (p= 0.000).  
Analysis of males and females showed differing trends in terms of the most common MS 
component. In male subjects with MS, the most common MS component was an elevated 
triglyceride level, present in 79% of subjects (Figure 3.6). In addition, all of them had an 
increase in waist circumference measurements in accordance with the IDF criteria. In 
females, hypertension (76%) was the most common components of MS, followed by 











FIGURE 3.6: Gender-wise distribution of Metabolic Syndrome components in subjects 




3.3.5 Clinical and metabolic criteria in relation to the glycaemic profile 
The prevalence of CVD risk factors and the MS (IDF criteria) are described in males and 
females, as well as in subjects with normal blood glucose, impaired fasting glucose (IFG) 
and DM (Table 3-12). There were significant inter-gender differences, as a significantly 
higher proportion of females were diagnosed with MS (p < 0.05), with the median FBG (p 
= 0.013), BMI and waist circumference measurements (p = 0.000) being significantly 
higher in females than males.  
In the total sample, there were 600 subjects with a normal glycaemic profile, 328 with 



























Although the prevalence of MS was significantly higher in females, distribution of the MS components 
was almost equally distributed in both genders, aside from the elevated triglyceride levels, which was 
more frequent in males. 




DM (53%), with 25% of subjects with MS being prediabetic and 20% normoglycaemic 
(Table 3-12). 
There was a worsening of the lipid profile as the glycaemic profile changed from normal 
to prediabetic, and then to DM. The median systolic and diastolic blood pressures were 
also higher in diabetics as compared to those with normal and prediabetic blood glucose 
profile. Similarly median BMI and waist circumference increased with the transition from 
normoglycaemia to prediabetes and DM (Table 3-12). 




Table 3-12: IDF criteria for Metabolic Syndrome (median IQR) according to glycaemic levels (median plasma glucose levels) 
*indicates statistical significance: p < 0.05
 Gender Blood glucose profile(n=667) 
Parameter Males(n=398) Females(n=1024) p-value Normal Prediabetic Diabetic 
Prevalence of MS (n=667) 131 (33%) 536(52%) <0.05* 131(20%) 166(25%) 370 (55%) 
Total cholesterol (mmol/l) 5.5(4.8,6.2) 6.1(5.2,8.6) 0.355 5.1(4.4,6.8) 5.4(4.7,6.1) 5.6(4.9,6.4) 
Fasting Glucose (mmol/l) 6(5, 9.1) 6.1(5.2,8.6) 0.013* 4.9(4.6,5.1) 5.8(5.4,6.2) 14.6(9,21) 
Triglycerides (mmol/l) 2.3(1.8,3.0) 1.9(1.5,2.4) 0.79 1.3(0.9,1.7) 1.6(1.2,2.1) 1.9(1.4,2.6) 
HDL (mmol/l) 1(0.9,1.15) 1.2(1.04,1.33) 0.000* 1.3(1.1,1.5) 1.24(1.1,1.4) 1.2(1.02,1.4) 
Systolic Blood Pressure (mmHg) 142(128,155) 139(127,153) 0.63 123(114,137) 135(123,149) 138(127,153) 
Diastolic BP (mmHg) 89(80,97) 86(77,93) 0.12 77(69,86) 82(75,91) 85(76,92) 
HOMA-IR 4.2(2.6,6.6) 4.7(2.9,7.5) 0.356 1.9(1.2,2.99) 3.5(2.2,5) 5.3(3.2,9.2) 
Waist Circumference (cm)  99.5(94,105) 100.5(93,109) 0.000* 88(77,98) 97(89,105) 97(89,106) 
BMI (kg/m2) 27.8(26,30.1) 30(26.7,34.8) 0.000* 25(21,30) 29(26,33) 28.5(25,33) 




3.4 The Echocardiographic analysis 
There were 1420 subjects who yielded optimal image quality for the evaluation of two-
dimensional measurements, and for pulsed-wave (PW)-Doppler evaluation of diastolic 
indices. Tissue Doppler indices (TDI) and measurement of the sub-epicardial adipose 
tissue (SEAT) thickness were taken from a subset of 582 subjects.  
Table 3 -13 shows the median values (IQR) in the population for chamber size, systolic 
and diastolic parameters, and the prevalence of contractile and valvular abnormalities. 
The ejection fraction (EF) was within the normal range for the cohort, but 24 subjects 
(<2%) presented with an EF < 50%. Of these subjects, five showed characteristics of 
dilated cardiomyopathy, while the remaining subjects had normal ventricular dimensions, 
but with contractile dysfunction.  
Using the gender-specific ranges recommended by Lang et al (2006, Appendix 4), the 
median values for the chamber dimensions and wall thickness were found to be within 
normal limits. The median values as well as the inter-quartile ranges in men [138g 
(112,171)] and in women [119g (95,152)] were well within in the normal ranges for LVM. 
The LVMI (LVM indexed to BSA) was also in the normal range for men [78.4g/m2 (64, 93)] 
and women [69.5 g/m2 (58, 87] [Appendix 4 for normal values range].The median LVMI, 
indexed to height2.7  was higher in women (35.5m2.7[29, 46]) than in men (34 m2.7 [27, 42]) 
and were in the normal range, with the 75th percentile being slightly higher than 
prescribed by Lang et al (Appendix 4). This median value increased proportionally with 
increasing age. 




Table 3-13: Echocardiographic chamber dimensions and wall thickness (median [IQR])  
Variables Males Females 15-24 25-34 35-44 45-54 55-64 
n 397 1023 165 303 444 372 397 
LA mean (mm) 30(24,33) 28(26,30) 31(29,34) 34(30,37) 34(31,37) 35(31,38) 35(32,39) 
LAVI(ml/m2) 14.5(1,18) 16(12,18) 12(16,14) 14(11,16) 15(11,17) 16(12,18) 17(12,19) 
LVEDD(mm) 49(45, 52) 46(43, 50) 46(43,50) 47(47,51) 47(44,50) 47(44,50) 47(43,51) 
LVESD(mm) 30(27,32) 27(24,30) 28(25,31) 29(27,32) 28(25,30) 28(25,31) 28(24,31) 
PW (mm) 6 (6,8) 6 (6,8) 6 (5,6) 6 (5,7) 6 (6,8) 7 (6,8) 7 (6,8) 
IVS(mm) 8 (8,9) 7 (6,9) 6 (6,8) 7 (6,8) 7 (6,8) 8 (6,9) 8 (6,9) 
LV M (g) 138 (112,171) 119 (95,152) 104 (85,131) 117 (97,149) 118 (95,148) 129 (104,164) 135 (105,176) 
LVMI( g/m2) 78 (64,93) 69.5 (58,87) 64 (54,77) 66 (57,82) 67 (56,82) 73 (63,92) 78 (64,98) 
LVMI (h2.7) 34 (27,42) 35.5 (29,46) 27.8 (23,35) 31.5 (26,39) 33 (27.5,42) 37.6 (31,47) 38.6 (30.7,50) 
SEAT (mm) 3.9 (3.5,4) 4 (3.5,4) 3.5 (3.0,3.5) 3.5 (3.0,4.0) 4 (3.0,4.0) 4 (3.5,4.5) 4 (3.5,4.5) 
LA: left atrial; LAVI: left atrial volume index; LVEDD: left ventricular end-diastolic dimension; LVESD: left ventricular end-systolic 
dimension; PW: posterior wall; IVS: interventricular septum; LVM: left ventricular mass; LVMI: left ventricular mass index; SEAT: 
sub-epicardial adipose tissue 
 




 Table 3-13: Echocardiographic chamber dimensions and wall thickness (median [IQR]) ..continued 
Median echocardiography variable values in the sample: systolic and diastolic parameters 
 Males Females 15-24 25-34 35-44 45-54 55-64 
EF (median) 
   ≥ 50 % (n) 






































IVRT 104(88,128) 104(88,120) 96(80,112) 99(88,112) 104(88,120) 109(88,120) 111(96,128) 
TDI:  Em/Ea 7(6,8) 7(6,9) 7(6,9) 7(6,8) 7(6,8) 7(6,8) 7(5,9) 
EF: ejection fraction; Em: early transmitral inflow velocity; Am: transmitral atrial contraction wave; Ea: early myocardial 
velocity; IVRT: isovolumic relaxation time; TDI: Tissue Doppler indices; RWMA: regional wall motion abnormality; VHD: valvular 
hear disease 
Prevalence of cardiac disease in the sample 
 
RWMA (n/%) 8 (2%) 16 (2%) 0% 0% 4(1%) 5 (1%) 15(4%) 
VHD (n/%) 1(0.3%) 5 (0.5%) 0% 0% 0% 0% 6 (2%) 
Other. (n/%) 5(1%) 3(0.2%) 0% 0% 2(0.6%) 3 (0.7%) 3 (0.8%) 




The Doppler Em measurements decreased with advancing age, while a corresponding 
attenuation of the trans-mitral ratio (Em/Am) was observed. The isovolumic relaxation 
time (IVRT) increased with advancing age, while the tissue Doppler diastolic ratio 
(Em/Ea), remained fairly consistent across the age groups. 
There was an increase in SEAT thickness, with advancing age, mostly evident from the 
increases in the 25th and 75th percentile values. The median values were increased in 
females as compared to males.  
3.4.1 Echocardiography and Cardiovascular risk factor profile 
Since 62 % of the subjects in this sample presented with 1 or more CV risk factors, we 
compared the echocardiographic parameters in subjects with, versus those without CV 
risk factors. Table 3-14 shows the median (IQR) values in subjects with and without CV 
risk factors. In the presence of CV risk factors,  mean left atrial (LA) dimension, left atrial 
volume index (LAVI), left ventricular mass (LVM), left ventricular mass index (LVMI), and 
SEAT thickness were significantly higher (p < 0.05). Similarly the transmitral flow 
velocities (Em and Em/Am) were lower in subjects with CV risk factors. The tissue Doppler 
diastolic filling ratio (Em/Ea) was higher in males with CV risk factors, while the IVRT was 
longer in females with CV risk factors.  
Significant differences were observed between those with and without CV risk factors in 
the thickness of the posterior wall, the LV mass and LVMI in subjects from 25-64 years of 
age. The SEAT thickness was significantly higher in the 55-64 year age groups (p= 0.003).  




Table 3-14: Comparison of median echocardiographic variables in subjects with and 
without CV risk factors  
Echo 
parameter 
No CV risk factors ≥ 1 CV risk factor 
 Males Females Males Females 
LA (mm) 36(32,40) 36(32,39) 37(34,40) 37(34,40)* 
LAVI (ml/m2) 13(10,17) 14(11,17) 14(11,18) 15(12,19)* 
LVEDD (mm) 49(45,52) 45(43,48) 48(45,52) 46(43,50) 
LVESD (mm) 30(28,32) 27(24,30) 29(27,32) 27(24,30) 
LVS (mm) 8(6,9) 7(6,8 8(8,9) 8(6,9)* 
LVPW (mm) 6(6,8) 6(5,7) 6(6,8) 7(6,8)* 
EF (%) 68(64,72) 69(64,75) 67(71,82) 70(64,75) 
LVM (g) 135(114,159) 109(89,138) 139(110,177) 125(102,163)* 
LVMI (g/m2) 77(65,90) 65(55,78) 79(64,95) 73(61,94) 
Em 1.34(0.11,1.8) 1.2(1.0,1.5) 1.2(0.9,1.5)* 1(0.8,1.2)* 
Em/Am 0.14(0.1,0.16) 0.12(0.1,0.16) 0.11(0.1,0.14) 0.1(0.08,0.14)* 
IVRT (ms) 112(96,120) 96(88,112) 104(88,128) 104(88,120)* 
SEAT (mm) 3.5(3,4) 3.5(3,4) 4(4,3.5)* 4(3.5,4.5)* 
TDI (Em/Ea) 5(1.0,7.0) 4(1.0,7.0) 6(1.4,7.0) 4(1.3,7.0)* 
*indicates statistical significance between groups i.e. subjects with and without CV risk factors 
Em: early transmitral inflow velocity; Am: transmitral atrial contraction wave; Ea: early myocardial 
velocity; Aa: myocardial velocity associated with atrial contraction; LA: left atrium; LVEDD: left 
ventricular end-diastolic dimension; LVESD: left ventricular end-systolic dimension; LVPW: left ventricular 
posterior wall; SEAT: sub-epicardial adipose tissue thickness; LVMI: left ventricular mass index; LAVI: left 
atrial volume index 
 




3.4.2 Correlation co-efficients between echocardiography variables 
When echocardiography variables were compared to each other (Table 3-15), the 
strongest associations using Spearman’s rho (rs) (indicated by rs > 0.500), were observed 
between the LVEDD and LVESD (rs = 0.654), the EF and LVESD (rs = -0.698), LV septal 
thickness and LV Mass (rs = 0.713) and between the posterior wall (PW) and LV mass (rs = 
0.640).  There were moderate relationships (rs > 0.300 < 0.500) between SEAT and the 
following parameters: LV septal thickness (rs = 0.356), posterior wall thickness (rs =0.360), 
LV Mass (rs =0.372), and an inverse relationship with the early transmitral flow velocity 
(Em) (rs =- 0.385). Statistically significant (rs > 0.100 < 0.300), albeit weaker relationships, 
existed between SEAT and the following parameters: presence of CV risk factors (rs = 
0.207), LA size (rs =0.287), and an inverse relationship with the trans-mitral ratio (Em/Am) 














Table 3-15: Correlation co-efficient of echocardiography variables and their association 
with each other (rho-values)   
Parameter LVEDD LVESD LA LAVI EF LVS PW LVM LVMI Em E/A Em/Ea SEAT 
Risk          -   + 
LVEDD  ++      ++      
LVESD     ___   ++      
LA      +  +  - -  - 
LAVI  + +++  - ++ + ++ ++  - - + 
EF  ___            
LVS       +  ++  +  + 
PW      +   ++     
LVM ++ ++         +  + 
 LVMI       ++      + 
Em -             
Em/Am -     +  +    ++ - 
TDI:Em/Ea           ++   
SEAT   -   +  + +  -   
KEY: + (weak); ++ (moderate);+++ (strong) ;    -(weak inverse); -- (moderate inverse);--










3.4.3. Diastolic abnormalities and dysfunction in the sample 
Diastolic abnormalities were identified using the criteria set by the European Study Group 
on Diastolic Heart Failure (1998). The diagnosis of diastolic dysfunction (DD) was made 
according to the guidelines set by the Heart Failure and Echocardiography Associations of 
the European Society of Cardiology (Paulus et al., 2007). Based on these guidelines (see 
Methods), 436 subjects (31%) were classified as having diastolic abnormalities. Only five 
subjects (< 1%) fulfilled the diagnosis for diastolic dysfunction (Table 3-16).  
Subjects with diastolic abnormalities were predominantly female (78%). They also 
presented with higher waist circumference measurements and an increased prevalence 
of DM. These subjects were also more likely to be smokers. 
Echocardiography showed an increase in the LVMI, diminution of the trans-mitral ratio, a 
prolonged IVRT and an increase in Tissue Doppler diastolic indices, consistent with the 
deviation from normality. 
The diagnosis of DD was made when the subject had echocardiographically-derived 
diastolic abnormalities (Table 2-1 in Methods) and exhibited features of left atrial dilation 
(> 45 mm). In the absence of these criteria, subjects with TDI diastolic filling ratio (Em/Ea) 
≥ 15 were classified as having diastolic dysfunction. If the Em/Ea was ≥8≤ 15, then the 
LVMI > 122 g/m2 in females or > 149 g/m2 in males was used to diagnose DD. In this 
manner, there were 5 (< 0.5%) subjects who were classified with DD in this sample. These 
subjects presented with a higher BMI and a larger waist circumference (Table 3-16). 




The accompanying echocardiographic changes shown in the table below (Table 3-16) 
showed an elevated LAVI and LVMI, with the transition from diastolic filling abnormalities 
to the entity of diastolic dysfunction. Subjects with DD also had an increased IVRT, and a 
decreased trans-mitral Doppler ratio (Em/Am). Further subgroup analysis revealed 
elevated TDI diastolic filling ratio (Em/Ea) (7 in subjects with diastolic abnormalities to 8 
















Table 3-16: Clinical, echocardiographic and anthropometric median values (IQR): 
subjects with and without diastolic abnormalities 
n* Normal : n =(988) Abnormalities (n= 436) Dysfunction (n=5) 
Age 48(38,55) 45(35, 54) 55(54, 59) 
Women (%) 695 (70%) 331(76%) 4 (80%) 
BMI (kg/m2) 27(24,32) 27(23,32) 37(31,39) 
Hypertension 481(49%) 192(44%) 3(60%) 
WC 92(83,103) 95(84,105) 115(102,120) 
DM 316 (22%) 140(32%) 2 (40%) 
Smokers 241(17%) 114(26%) 0 
LVMI(g/m2) 64(53, 78) 75(63,92) 85(75, 100) 
LAVI(ml/m2) 15,4(12,19) 12(10,15) 30(23,38) 
LVPW(mm) 6(6,8) 6(6, 8) 7(7,9) 
LVS(mm) 8(8,9) 6(6, 8) 7(6,10) 
IVRT(mm) 68(64, 88) 104(88, 120) 96(96,96) 
Em/Am 2.5(0.6,) 0.11(0.8,0.15,) 0.1(0.1,0.2) 
TDI: Em/Ea 1.4(1.1,1.8) 7(6,8) 8(5,11) 
*varying n due to missing values
Independent determinants of diastolic abnormalities on univariate analysis were age, 
BMI, LVMI and LAVI (Table 3-17). Multivariate step-wise logistic regression analysis 
indicated that the odds of having diastolic abnormalities using the echocardiographic 




criteria was 0.658 in females, and the odds increased by 0.986 per year of increasing age. 
Furthermore, the likelihood of diastolic abnormalities increased by 0.73 for every mmHg 
increase in the blood pressure, and by 0.882 for every ml/m2 increase in the LAVI. 
Table 3-17: Univariate and Multivariate independent risk factors for diastolic 
abnormalities  
Risk factor Univariate Multivariate 
 p-value Odds ratio p-value 
Age 0.000* 0.986(0.975;0.998) 0.025* 
Gender (female) 0.544 0.658(0.48,0.900) 0.009* 
Hypertension 0.072 0.73(0.533;0.999) 0.049* 
DM 0.065 0.782(0.577;1.06) 0.114 
BMI 0.03* 0.760(0.534; 1.08) 0.129 
LVMI 0.001* 0.992(0.981;0.975) 0.137 
LAVI 0.000* 0.882(0.882;0.854) 0.000* 







BMI: Body mass index; LVMI: Left ventricular mass index; LAVI: left atrial mass index 
 




3.4.4 Echocardiography and the Metabolic Syndrome 
The LVEDD, LVESD and the EF were within the normal limits for both subjects with and 
without MS, with significant differences observed in the LVEDD and EF between the two 
groups (Table 3-18). The LA dimension, LAVI, LVPW and LVS were significantly increased 
in subjects with MS. This was accompanied by an increase in the LVM and LVMI in these 
subjects (p= 0.001). The sub-epicardial adipose tissue thickness was also significantly 
higher in subjects with MS (p< 0.005), and this was evident in both males and females.  
Trans-mitral Doppler flow velocities showed that the Em (early mitral filling velocity) as 
well as the Em/Am (trans-mitral filling ratio) was significantly increased (p< 0.005) in 
subjects with MS as compared to those without. Further sub-group analysis and 
interrogation using TDI also showed significant differences between the 2 groups (p= 
0.001), where subjects with MS had higher TDI diastolic filling ratio than those without 
MS. 
Since hypertension by itself is a major determinant of LV mass, adjustments were made 
for blood pressure. The significant differences in echocardiographic parameters between 
those with and those without MS persisted (Table 3-18). However, these differences were 








Table 3-18: Median echocardiographic values by presence or absence of the Metabolic 
Syndrome (IDF criteria) 
 Metabolic Syndrome (IDF criteria) 
 MS present MS absent p p#(adjusted) 
LA  35(39,32) 34(37,30) <0.005* 0.000* 
LAVI 17(19,12) 14(17,10) 0.001* 0.027* 
LVEDD  47(51,44) 46(50,43) 0.004* 0.074 
LVESD  28(31,25) 28(31,25) 0.651 0.363 
LVPW  7(8,6) 6(7,5) 0.001* 0.000* 
EF 70(75,64) 69(73,64) <0.005* 0.015* 
LVS 8(9,6) 7(8,6) <0.005* 0.026* 
LV Mass  138(176,110) 114(144,91) 0.001* 0.000* 
LVMI 39.4(50,32) 32(39,26) 0.001* 0.000* 
Em 0.99(1.2, 0.8) 1.27(1.6, 1.02)  0.001*  
Em/Am 0.11(0.12, 0.08) 0.12  0.023* 0.000* 
IVRT 104(120,88) 120 0.539 0.274 
SEAT  4.0(4.5,3.5) 3.5(4,3) <0.005* 0.000* 
TDI Em/Ea 5.26(7, 1.2) 3.2(6.36,1,2) 0.001* 0.424 
*indicates statistical significance p < 0.05  
# adjusted for hypertension 
 
 




Table 3-19: Relationship of echocardiography variables with the Metabolic Syndrome 
and its components* 
 Metabolic Syndrome components  
Fasting 
Glucose 
TG ≥ 1.7  
mmol/L HDL WC BP MS 
LA dimension  + +  + + + 
LAVI(ml/m2) + + + + + + 
LVEDD (mm) +    +  
LVESD (mm)       
LVPW (mm) + + + + + + 
LVS (mm) + +   + + 
LV Mass (g) + +  + + + 
LVMI(g/m2) + + + + ++ ++ 
SEAT (mm) ++ +  + ++ ++ 
Em/Am -- -  - -- + 
IVRT(ms)     +  
TDI:Em/Ea - - - - - + 
*only correlation co-efficient with statistically significant p-values shown 
KEY:+ (weak); ++ (moderate);+++ (strong) ;    -(weak inverse); -- (moderate inverse);--- 
(strong inverse) 




The strength of the relationship between the echocardiographic parameters and the 
diagnosis of MS, as well as its individual components were determined. Statistically 
significant relationships are shown in Table 3-19. The strongest correlations were 
observed between the LV mass and hypertension, and the LV mass and the presence of 
MS (rs =0.337 and 0.319, respectively). Another significant relationship was observed 
between SEAT, the fasting blood glucose levels, hypertension and the presence of MS (rs 
= 0.318, 0.301 and 0.355 respectively). There was also an inverse relationship between 
the fasting blood glucose and the Em/Am ratio (rs = - 0.324). The TDI diastolic filling ratio 
showed a weaker, but significant correlation (rs =0.206) with the presence of MS.  
Further comparisons within subgroups (Table 3-20) showed that there was a significant 
increase in the SEAT thickness in the presence of insulin resistance, DM, hypertension, 
smoking, as well as general and abdominal obesity (p = 0.000). 
Bivariate analysis between SEAT and clinical, biochemical and echocardiography 
parameters showed that the strongest correlations existed between SEAT and other 
measures of adiposity, i.e. the BMI (rs = 0.416) and the waist circumference (rs = 0.415). 
There were also moderate correlations (rs = 0.301) between SEAT and the presence of MS 
and hypertension using the IDF cut-off (Table 3-20).  Weaker, but statistically significant 
relationships were observed between SEAT thickness and DM (rs = 0.249) and insulin 
resistance (rs = 0.287). 
 
 




Table 3-20: Comparison of SEAT thickness (means +/- SD) in sub-groups 
Variable Group SEAT  
(mean) 
rs p 
Gender Males 3.8±0.8 0.059 0.350 
Females 3.9±0.8  
Hypertension No 3.6±0.7 0.301 0.000* 
yes 4.1±0.8  
Diabetes Mellitus No 3.7±0.7 0.249 0.000* 
yes 4.1±0.8  
Smoking No 3.7±0.8 -0.052 0.208 
yes 3.9±0.8  
Abdominal obesity No 3.5±0.7 0.415 0.000* 
yes 3.9±0.8  
General obesity No 3.4±0.7 0.416 0.000* 
yes 4±0.8  
Insulin resistance No 3.6±0.7 0.287 0.000* 
 
yes 4.0±0.8  








Table 3-21: Univariate and multivariate biochemistry, anthropometry and 
echocardiography prediction models for detection of MS (IDF criteria) 
 Univariate analysis  Multivariate analysis 
 OR 95% CI p  OR 95% CI p 
IDF BP 10.6 8.2,13.6 0.000*  16.1 8.2,31.2 0.000* 
BMI 1.17 1.14,1.9 0.000*  1.01 0.92,1.11 0.797 
WC 1.1 1.09,1.12 0.000*  1.092 1.04,1.14 0.000* 
TG 4.18 3.4,5.1 0.000*  5.007 2.8,8.9 0.000* 
FBG 1.45 1.37,1.57 0.000*  1.44 1.2,1.67 0.000* 
HDL 0.18 0.13,0.27 0.000*  0.03 0.008,0.121 0.000* 
SEAT 2.9 2.19,3.8 0.000*  1.17 0.699,1.9 0.558 
LAVI 1.06 1.04,1.08 0.000*  1.08 1.007,1.16 0.031* 
LVMI 1.01 1.009,1.02 0.000*  1 0.986,1.015 0.972 
Diast.Abn 0.928 0.85,1.35 0.526     
Diast. Abn# 1.070  0.582     
Diast.Abn: diastolic abnormalities present; # age adjusted 
*indicates statistical significance 
 
Using linear regression we found that a 1mm in SEAT thickness was associated with a 3 
times likelihood of being diagnosed with MS. (Table 3-21).  However, subjects with blood 
pressure ≥130 / ≥85 mmHg were 11 times more likely to have the MS. An increase in 
triglyceride level of 1mmol/l predicted a 4- fold increase for the diagnosis of MS. Subjects 
with diastolic abnormalities was not conferred with additional risk for MS, even after 
adjusting for age (Table 3-21). After multivariate stepwise linear correlation, the greatest 




odds of being diagnosed with MS was the IDF blood pressure cut-off (OR= 16), as well an 
increase in every unit of triglyceride (OR= 5; Table 3-21). 
In order to determine whether MS was an independent predictor of diastolic 
abnormalities, logistic regression was performed to disentangle the effects of several 
other predictor variables including age, gender, hypertension, diabetes and 
anthropometry (Table 3-22). After adjustment, gender, age and both anthropometry 
parameters (BMI and waist circumference) emerged as significant predictors of diastolic 
abnormalities. Using the crucial Wald statistic, we found that age, which showed the 
highest Wald statistic, made the most significant contribution to the outcome.  
 
Table 3-22: Logistic regression for independent predictors of diastolic abnormalities 
















.230 1.078 .631 
1.380 1.193 .240 
1.142 .833 .285 
23.010 .959 .000* 
13.785 1.075 .000* 
19.507 1.025 .000* 
*indicates statistical significance 




We tested the discriminating capacity of all MS components (IDF), as well as 
echocardiographic and biochemical variables, to detect the presence or absence of the 
MS, by constructing receiver operator curves (Figure 3.7). Indices relating to glycaemia 
control yielded the highest area under the curve (AUC): fasting blood glucose levels (AUC 
= 0.822), followed by HOMA-IR values (AUC = 0.816). The waist circumference had an 
AUC = 0.807, followed by the triglyceride levels (AUC = 0.806), while the mean LA 
dimension was the echocardiographic measure with the highest AUC = 0.745. Blood 
pressure categorized into >or <130/85 yielded an AUC= 0.792.    
 
FIGURE 3.7: Receiver operator curves for detection of Metabolic Syndrome (IDF) 
 




3.4.5 The determination of normal echocardiography values in the Phoenix 
population  
This study sought to propose normal echocardiography ranges in healthy subjects in the 
Phoenix population, as this has not been done previously (refer to the Literature review 
for rationale). From the 1428 subjects who underwent echocardiography, there were 38 
subjects who were found to have structural and functional abnormalities. There were 667 
subjects who were diagnosed with the MS (IDF criteria), and these were excluded from 
the analysis. There were 377 subjects with CV risk factors who did not meet the criteria 
for the diagnosis of MS: these subjects were also excluded. Therefore, the measurements 
from 346 subjects (89 males and 257 females) were analysed and are presented in Tables 
3-23 and 3-24 below. 
The physical and anthropometric characteristics of the normal subjects are shown in 
Table 3-23, and are stratified for gender. The raw data showed significant differences 
between male and female height, BSA and mean systolic blood pressure. Males were 
significantly taller, with a higher BSA, and recorded a higher mean systolic blood 
pressure. The BMI was significantly higher in females. There were no gender differences 
for weight and mean diastolic blood pressure. 
Inter-gender differences were significant for echocardiography variables, where males 
had larger chamber dimensions, wall thickness and higher Doppler (Em) measurements 
(Table 3-24). 




When the echocardiographic dimensions were indexed to height, these differences were 
not apparent, and were replaced by significantly larger LA dimensions in females, higher 
LVMI and thicker SEAT in males (Table 3-25). These changes persisted when 
echocardiographic variables were indexed to the BSA, but SEAT thickness was higher in 
females (Table 3-25). 
Table 3-23: Gender stratification of physiologic and anthropometry parameters 
(median, IQR) 
 Males (n=89) Females (n=257) p 
Age 32 (18,46) 40 (30,49) 0.01* 
Height 169 (165,176) 156 (152,161) 0.000* 
Weight 67 (57,76) 63 (55,75) 0.373 
BSA 1.78 (1.62,1.85) 1.6 (1.5,1.8) 0.000* 
BMI 22.7 (19,26) 26 (22,31) 0.000* 
Systolic BP(mean) 125 (115,135) 119 (111,129) 0.036 
Diastolic BP(mean) 75 (69,81) 76 (70,83) 0.169 










Table 3-24: Echocardiographic parameters (raw data) in men and women (mean/95th 
percentile)   

















LVEDD (mm) 48 56  46 55 0.000* 
LVESD 30 37  28 35 0.000* 
LA dimension 35.65 44  35.36 44 0.53 
EF 67 78  69 80 0.094 
LVS 8 11  7 10 0.000* 
LVPW 6 8  6 9 0.003* 
LV Mass (g) 134 200  110 180 0.000* 
SEAT 3.3 4.0  3.5 5.0 0.263 
E(mitral) 1.55 2.5  1.4 2.3 0.005* 
E/A (transmitral ratio) 1.2 1.9  1.1 1.9 0.319 
IVRT 101 144  100 128 0.294 
TDI: Em/Ea 7 11  7 11 0.272 
LAVI (ml/m) 13.90 22.8  14.42 22.5 0.334 
 



















*indicates statistical significance 
 
 HEIGHT  BODY SURFACE AREA 
Parameters  Males Females   Males Females  Mean 95th Mean 95th  p  Mean 95th  Mean 95th p 
LVEDD (mm/m) 29 33 29 34 0.365  28 33 28 33 0.787 
LVESD (mm/m) 18 22 17.5 22.5 0.5  17 21 17 22 0.169 
LA dimension (mm/m) 21 26 23 28 0.000*  20 25 21.5 26 0.000* 
LVS (mm/m) 4.6 6.5 4 6 0.173  4 6 4 6 0.450 
LVPW (mm/m) 3.8 4.9 3.8 5.5 0.932  3.6 5 3.5 5.3 0.478 
LV Mass Index (g/m) 80 120 70.5 113 0.000*  76 112 67 108 0.000* 
SEAT(mm/m) 2.2 4 2.2 3.2 0.003*  2 2.5 2 3 0.019* 
LVMI (h2.7) 36 45 33 56 0.511       




3.5 The analysis of gene polymorphisms 
3.5.1 The Hardy-Weinberg Equilibrium 
The genotype and allele frequencies for the polymorphisms investigated were computed 
by gene counting and are presented in Table 3-26. There were no polymorphisms which 
were in Hardy-Weinberg equilibrium in this sample. All four polymorphisms showed an 
almost equitable distribution of frequencies of the genotypes and alleles between males 
and females with no significant differences observed. The frequency of the heterozygous 
variant genotype of the S447X, Q192R and L55M polymorphisms were higher than the 
homozygous wild-type genotypes.  
There were no heterozygous or homozygous mutant genotypes found in this sample for 
















3.5.2. LPL polymorphisms 
The frequency of the homozygous wild-type genotype (SS) of the S447X polymorphism 
was found in 25% of subjects (Table 3-26). There was a much higher prevalence of the 
heterozygous variant, which was found in 73% of subjects with a small number (2%) 
presenting with the homozygous mutant genotype (Figure 3.8). There was a dominance 
of the c-allele, detected in 62% of the sample, as compared to the g-allele, which was 
found in 38% of participants.  
 







         Single peak red- homozygous:  mutant (55°)/ wild-type (65°) 
         Double-peak green: heterozygous 
 




Table 3-26: Genotype and allele frequencies in the sample  
 genotype n % Allele frequencies 
Lipoprotein Lipase 
S 447 X 
SS 226 25 c : 0.62 
g: 0.38 SX 662 73 
XX 16 2 
Total  904 100 1 
Lipoprotein Lipase 
N291S 
NN 903 100 a:1 
NS 0 0 g:0 
SS 0 0  
Total  903  1 
PON-1 
L55M 
QQ 288/843 34 a: 0.66 
QR 537/843 64 g: 0.34 
RR 18/843 2  
Total  843  1 
PON-1 
Q192R  
LL 290 35 a: 0.67 
t: 0.33 LM 524 63 
MM 15 2 





The distribution of genotypes and alleles in the sample shows that a third of subjects presented with 
mutations. 




3.5.3 PON-1 polymorphisms 
3.5.3.1 THE L55M POLYMORPHISM 
The frequency of the homozygous wild-type (LL) genotype of the L55M polymorphism 
was 34% in this sample (Table 3-26), with a high prevalence of the heterozygous (LM) 
variant (64%). There were only 2% of subjects with the homozygous mutant (MM) 
genotype (Figure 3.9).   
There was a dominance of the a-allele (0.66), as compared to the g-allele (0.34) in the 
sample. 
 






         Single peak red: homozygous mutant (61.1) 
         Double-peak green: heterozygous 
 


























Polymorphism genotype MS (n/%) No MS (n/%) p 
Lipoprotein Lipase 
S 447 X 
 
 













N# (%) 407 422  
0.537 QQ 135(33%) 155 (37%) 
QR 265 (65%) 259 (61%) 
RR 7 (2%) 8 (2%) 
 
L55M N# (%) 447 440  
0.518 LL 297 (66%) 300 (68%) 
LM 134 (30%) 127 (29%) 
MM 16 (3%) 13 (3%) 
The distribution of genotypes shows no significant differences in the frequencies of genotypes 
between subjects with and without the metabolic syndrome 




3.5.3.2. The Q192R polymorphism 
The frequency of this polymorphism in our sample was 35% for the wild-type, 63% for the 
heterozygous variant and 2% for the homozygous mutant (Table 3-27). There was a 
dominance of the a-allele (0.67) as compared to the t-allele (0.33).  









      Single peak red: homozygous wild-type (66.1°)/mutant (61.1°) 
      Double-peak green: heterozygote  




3.5.4 Distribution of polymorphisms in subjects with/without Metabolic 
Syndrome 
There was a very similar distribution of the genotypes in those subjects with and without 
MS (Table 3-27), with no significant associations detected (p = 0.599) between males and 
females, even when the heterozygous and homozygous mutant variants were combined.  
The diagnosis of MS and the distribution of the S447X mutation were analysed, with no 
significant statistical significance (Table 3-28) detected. Similarly, the L55M and the 
Q192R genotypes were almost equally distributed between subjects with and without 
MS, with a consequently non- significant association (Table 3-27) detected. Associations 
were also sought between the variant polymorphisms and the individual components of 
the MS.  
Although the variants were distributed equally between subjects with and without MS 
(Table 3-27), non-parametric testing using the Mann-Whitney test showed a statistically 
significant difference in the Q192R genotype. Subjects with this mutation (Table 3-28), 
were more inclined to have decreased levels of HDL (p= 0.026) as  









Table 3-28: Associations between median values of MS components and genotype 
 
3.5.5 The association between polymorphisms and obesity 
Considering that obesity was very prevalent in this sample, the frequency of gene 
polymorphisms in obese subjects using both the WHO and Pan-Asian cut-off, was 
determined. Statistical significance was found in obese women using the Pan-Asian cut-
off with the PON-1 polymorphisms, as a higher number of these obese subjects were 




 S447X L55M Q192R 
MS component Mean rank p Mean rank 
 
p Mean rank p 
Triglyceride 429 452 0.682 439 453 0.364 406 420 0.322 
Increased WC  523 451 0.127 440 452 0.348 426 409 0.197 
FBG 500 453 0.397 444 447 0.822 407 429 0.365 
HDL 383 451 0.226 443 440 0.827 391 425 0.026* 
Elevated BP  475 440 0.533 434 430 0.841 410 406 0.805 
*indicates statistical significance  




Table 3-29: Frequency of polymorphisms in obese subjects 
 BMI 
(kg/m2)   
Wild-type  Mutants 



















































*p < 0.05 
#: Asian cut-off 
The frequency of the presence of wild-types and mutations in obese subjects using the WHO and Asian 
cut-offs: there were a significantly higher number of female subjects with the Q192R mutation 
 























This is the first community-based study of South African Asian Indians which documents 
CV risk factor prevalence and clustering, and relates them to structural and functional 
changes using echocardiography. This study also determined the relationships and 
patterns between CV risk factors and single nucleotide polymorphisms (SNPs) of the 
Lipoprotein Lipase (LPL) and the Human Paraoxonase (PON-1) gene.  
The results show that there is a very high prevalence of cardiovascular (CV) risk factors 
and the metabolic syndrome (MS) in this population, which are associated with 
alterations in cardiac structure and physiology. Genotyping revealed significant 
associations between HDL levels and the Q192R polymorphism of the PON-1 gene, 
which also showed an association with obesity in women. 
 
4.1 Cardiovascular risk factor profiles and Lifestyle patterns  
The high prevalence of cardiovascular risk factors in urban Asian Indians has been well 
documented previously (Balarajen, 1991; Enas et al., 1992; Cappucio, 1997; Yusuf et al., 
2001). Although there is limited data on CV risk factor profiles in South Africa, especially 
in Asian Indians (Rheeder, 2006), this study shows that the magnitude of change has 
been of epidemic proportions, from what has been previously reported (Seedat et al., 
1990).  
 
Currently, there is a global increase in the prevalence of obesity (Rheeder, 2006; 
Goedecke et al., 2005), particularly in developing countries. Recent estimates from the 
South African Demographics and Health Survey published in 2002 (Puoane et al., 2002) 




reported that 29.2% of men were overweight or obese (≥ 25kg/m2), and over half of all 
South African women (56.6%) were obese. Our study showed that the frequency of 
raised BMI (> 25 kg/m2), using the World Health Organisation (WHO) Expert 
Consultation (2004) criteria, was 66% in our sample (Table 3-7a). Of note, there was a 
steep increase in the prevalence of raised BMI from the 1st (15-24 years old) to the 2nd 
(25-34 year olds) age groups. We attributed the reasons for this significant increase in 
weight to socioeconomic changes that occur at this age, namely, financial independence, 
dietary changes, transition from an active to sedentary working lifestyle, as well as 
psychological factors related to the individual’s social environment (Marmot, 2000).  
The frequency of increased BMI in our study is also substantially higher than what has 
been reported in a study of the coloured community in Mamre (23%), Cape Town (Steyn 
et al., 2004). More worryingly, it is also in excess of what was reported on in a cohort of 
Asian Indians in the Durban Metropolitan area by Seedat et al in 1990, where 48% of 
subjects were recorded as having a BMI > 25kg/m2.  This translates into a 50% increase 
in the prevalence of overweight subjects with similar environmental exposure in a span 
of under 20 years.    
 
It is known that both general and central obesity is associated with a simultaneous 
increase in CV risk factor development, like hypertension, as well as glucose and lipid 
abnormalities (Gupta et al., 2007). Therefore, it is no surprise that the WHO, amongst 
other bodies (National Institute of Health 1998; Seidell et al., 2001) still recommend the 
BMI and waist circumference measurements for risk scoring. One of the main limitations 




associated with these parameters in Asian Indians is that Asian Indians are known to 
have higher levels of CV risk factors compared to Caucasians at any given BMI value (Low 
et al., 2009). The WHO subsequently redefined the criteria for obesity to be population-
specific: in Asians, the cut-off for obesity has been reduced to 23kg/m2 from 
25kg/m2 (WHO Expert Consultation, 2004).  
In our sample the prevalence of raised BMI (>23 kg/m2) changed from 66% to 77% with 
the application of Asian cut-offs for BMI. These results are very similar to what was 
reported by the Heart and stroke statistics from the American Heart Association (2011), 
where 67% of subjects tested were overweight; and 37% of these were classified as 
being obese. The increased prevalence of obesity, higher than what has been previously 
documented in this sample, may reflect the effects of a community that is undergoing an 
epidemiological transition. The consumption of a high-calorie diet and the adoption of a 
more sedentary lifestyle, together with ensuing obesity, is likely the driver for the 
development of other associated CV risk factors like hypertension, Type 2 Diabetes 
Mellitus (DM) and dyslipidemia (Tibazarwa et al., 2009). 
One of the important uses of the waist circumference measurement in CV risk 
stratification lies in its strong correlation with insulin resistance (Fonseca et al., 2004), 
therefore serving as a surrogate for the measurement of intra-abdominal fat. Since this 
was a study of subjects of Asian Indian ethnicity, we used the IDF ethnic-specific criteria 
for the measurement of the waist circumference (male ≥ 90 cm/female ≥ 80cm) as an 
obligatory component for the diagnosis of MS.  There were 1048 (79%) subjects who had 
an increased waist circumference in this sample, which was most apparent in females 




(82%) and in the 45-54 age groups (Table 3-7a). This prevalence is much higher than has 
been documented in urban Indians in India (Gupta et al., 2007), where only 22% of 
males, and 42.2% of females were documented with increased waist circumference. 
There was a clear increase in abdominal obesity prevalence within industrialised 
settings, as shown by Kaur et al (2007), where improvement in socio-economic status 
accompanied the increasing prevalence of abdominal obesity (50%) in men.  
 
4.1.1 Smoking 
South Africa is one of the six countries in Africa that has adopted a national smoke-free 
legislation, where a ban on tobacco advertising, sponsorship and promotion was 
implemented in 1993 (Tobacco Products Control Act, 1993). In spite of this, there was a 
prevalence of 26% of subjects in the sample who continued to smoke, with almost half 
the males in this study being smokers (Table 3-7a). This was comparable with other 
studies in India, where the prevalence of smoking ranged from 10% in industrialised 
samples (Mohan et al., 2003) to 24.3% in an urbanised sample (Gupta et al., 2007). 
Although there is extensive research (Jonas et al., 1992; Ockene & Miller, 1997) that 
links smoking with CV disease, as well as clear diminution of CV risk with cessation of 
smoking, these figures suggest that there still remain barriers to intervention in this 
community.   
 





There was a high prevalence of hypertension in the present study - recorded in almost 
half (49%) of the sample (Table 3-7a): this was higher than what was reported in the 
United States, where 44% of subjects were recorded as being hypertensive. The 
prevalence in our study was also higher than recent estimates in Asian Indians, where a 
prevalence of 37% was recorded in urban subjects in Kumarokam in 2006 (Thankappen 
et al., 2006). The fact that these significant differences exist in Asian Indians in different 
parts of the world suggest that environmental and behavioural factors may be important 
underlying factors for promoting the development of hypertension in our sample.  
 
4.1.3 Diabetes                   
According to the American Diabetes Association (2012), individuals with impaired fasting 
glucose (IFG) and/or impaired glucose tolerance (IGT) are regarded as having 
prediabetes, which in itself, confers a relatively higher risk for the development of future 
DM. It is now well established that DM, in association with other CV risk factors, 
increases the risk of macrovascular complications. In fact, the risk of a diagnosis of DM 
has been likened to having a previous myocardial infarct (Heller, 2005) by the American 
College of Cardiology and the American Heart Association.  
The present study found a prevalence of 20% in male subjects and 25% in female 
subjects with prediabetes (24% in total), with a third (32%) of the sample being classified 
as being diabetic. Sixty three percent (63%) of these diabetics self-reported their status. 




Using fasting blood glucose testing and the two-hour glucose tolerance test, we 
identified 37% of subjects with DM who were previously unaware of their status (Table 
3-5).  
The prevalence of DM has almost quadrupled since an investigation by Omar et al. in 
1993 (11%), which showed an increase of 2% (from 9%) in 1988 (Omar et al.) in Asian 
Indians in Durban. Using the biochemical cut-off described by Seedat et al. (1990), there 
was an almost 20% increase in DM prevalence in women from 16% in 1990 to 35% in the 
present study, and a 10% increase in men from 15% in 1990 to 25% in the present study. 
The overall prevalence has increased markedly from 16% (Seedat et al., 1990) in 1990 to 
32% in our study, and re-affirms previously documented evidence that the prevalence of 
DM in South Africa is highest (13%) in Indians (Omar et al., 1994). The extent of the 
excessive prevalence becomes clearly evident when compared to other population 
groups of similar socio-economic demographics, like the coloured population in Mamre, 
where only 10% of subjects were reported to be diabetic (Steyn et al., 2004).   
Research shows that the common strand in most of the studies conducted on Asian 
Indians living in India as well in the diaspora (for example Africa, United Kingdom, 
Mauritius and the West Indies) is the high prevalence of DM. However, comparison of 
our diabetic prevalence shows that it is exceedingly higher than reported by Cappuccio 
(1997) for Asian Indians in Trinidad (20%) and Mauritius (21%). The same was evident 
when compared to the prevalence of DM in Asian Indians (17.4%) in the United States as 
reported by Misra et al (2010). Furthermore, analysis of previous studies of CV risk in 
India show that there were substantially more subjects in our cohort who were diabetic 




as compared to urban Asian Indians (12.3%) in Jaipur (Gupta et al., 2007). This was 
further highlighted when compared to recent data from the Heart and Stroke Statistics 
from the American Heart Association (Roger et al., 2011), which indicated that the 
prevalence of DM in our sample (32%) is significantly higher than that which is reported 
(8%) in the United States.    
 
4.1.4 Positive family history for cardiovascular risk factors 
All subjects reported a positive family history for at least one of the CV risk factors that 
was recorded, with hypertension being the most frequently reported positive family risk 
factor, in 76% of subjects. In these subjects with a positive family history for 
hypertension, 37% of these subjects were found to be prehypertensive (Figure 3.2; Table 
3-4). Data from the Framingham  cohort (Vasan et al., 2001) reported that 
prehypertension was associated with an increased relative and absolute risk for CVD 
outcomes across the age spectrum, where prehypertensive subjects were 1.65 times 
more likely to have 1 or more adverse CV risk factor than those with normal blood 
pressure (Greenlund et al., 2004). Prehypertension, in our sample, was associated with 
an odds ratio of 1.03 (95% CI= 0.8; 1.3) of these subjects developing hypertension 
themselves (Table 3-4). Furthermore, a positive family history of hypertension was also 
associated with a doubling of the odds (Table 3-4) of subjects developing hypertension 
themselves (OR= 2.08; 95% CI=1.6, 2.7).  




Similarly, from the 24% of subjects who were prediabetic (Table 3-5), 90% (292) of these 
had a positive family history for DM, translating into an odds ratio of 1.062 (95% CI= 
0.83; 1.36) for these subjects developing frank DM themselves.   
 
4.1.5 Lipid profiles 
Hypercholesterolemia is a common feature in Asian Indians, with recent estimates 
documenting as many as 41% of Asian Indians in an industrial setting with the condition 
(Mehan et al., 2006).  The prevalence is higher in migrant Indians, as reported by Misra 
et al. (2010), with almost 44% of subjects presenting with elevated cholesterol levels. 
Using the conventional cut-offs of > 6.5mmol/l (Seedat et al., 1990), only 18% of subjects 
in the present study were documented with elevated total cholesterol levels; these 
numbers being marginally lower (18%) than what was reported by Seedat et al. (20%) in 
1990 (Table 3-7b). However, when the NCEP criteria (Grundy et al., 2001) was used (> 
5.17 mmol/l), the prevalence of elevated total cholesterol escalated dramatically to 60% 
(Table 3-7b). This prevalence was also substantially higher when compared to subjects 
tested in the United States (15%), according to the Heart Disease and Stroke Statistics 
from the American Heart Association (2011).    
There was a 14% prevalence for decreased HDL concentrations (Table 3-7b) observed in 
our sample when using conventional cut-offs (<1.0mmol/l). This prevalence increased to 
23% when using the NCEP cut-points (Grundy et al., 2001), but was still lower when 
compared to the significantly higher prevalence of 55% reported in India in urban 




subjects (Gupta et al., 2007) and in 87.2% of subjects in rural areas (Chow et al., 2007). 
Misra et al. (2010) reported a 42.3% prevalence of low HDL levels in Asian Indians in the 
United States.  
 
4.1.6 Summary of cardiovascular risk factors and clustering 
Although Asian Indians share similar cardiovascular risk profiles with other ethnic groups 
(McKeige et al., 1991), these risk factors do not clearly account for the marked excess in 
risk for CHD that has been consistently demonstrated in Asian Indian subjects (Gupta et 
al., 2004; Misra & Khurana, 2011; Chahal et al., 2010). This suggests that the 
mechanism/s underlying the development of CVD may therefore be different in this 
ethnic group, portending a possible genetic aetiology. Furthermore, previous 
population-based studies show inter-correlated metabolic abnormalities (like 
hypertriglyceridemia, low HDL levels, hyperinsulinaemia and central obesity), related to 
DM, unique to Asian Indians (Cappaccio, 1997; Misra et al., 2003; Misra & Khurana, 
2011). Possible explanations revolve around low birth-weight and childhood under-
nutrition (Victora et al., 2008), which were proposed as risk factors for elevated blood 
pressure, high glucose concentrations and abnormal lipid profiles once these babies 
gained weight rapidly during the postnatal period. This stems from the “thrifty 
phenotype” hypothesis alluded to by Neel in 1962, most evident in those that are 
undergoing socio-economic changes from poverty, which, in the presence of excessive 
calories, becomes disadvantageous and leads to obesity and glucose intolerance (Hales 




& Barker, 2001, Misra et al., 2004). In addition, the theory of a prothrombotic state in 
Asian Indians has been suggested (Anand et al., 2000; Hoogeveen et al., 2001), 
promoted by higher homocysteine, lipoprotein (a), and plasminogen activator inhibitor-
1 levels than are observed in Black (McKeige et al., 1991; Kain et al., 2008) or Caucasian 
populations. 
The high CV risk profile observed in our study may be explained by the mechanisms 
discussed above, and particularly by the changes in socio-economic status with resultant 
changes in dietary patterns to more high-fat-and highly processed carbohydrate-based 
meals and a sedentary lifestyle. Consequently, these were the factors that were 
suggested to have accelerated the development of over-weight and obesity in the Indian 
diaspora in Mauritius (Dowse et al., 1995) and in Trinidad (Gulliford et al., 2001; 
PAHO/WHO, 1999). Similar conclusions have also been made previously in subjects 
sharing the same environmental exposure in KwaZulu-Natal (Motala et al., 2011; Seedat 
et al., 1990; Omar et al., 1988, Ranjith et al., 2002). Our study has drawn attention to the 
very high risk profile in the same community developing only two decades later, which 
has been signaled by a surge in the prevalence of obesity, dysglycaemia and DM 
beginning in early adolescence.  
 
4.2 The Metabolic Syndrome 
The clustering of biochemical, anthropometric and physiological abnormalities that 
constitute the metabolic syndrome is known to amplify an individual’s risk for CVD. 
Subjects with MS are considered to have a twofold increased risk for CVD (Scholl, 2012) 




even before the development of overt DM. Currently there still remains disagreements 
about the diagnostic criteria of MS and debate about whether MS is a true syndrome or 
a mixture of various phenotypes (Alberti et al., 2009). The current research, however, 
suggests that the components may have common genetic mechanisms as they tend to 
occur concomitantly, or cluster together. 
 
4.2.1 The prevalence of the Metabolic Syndrome  
The present study shows that there is a very high prevalence of MS in the Phoenix 
community, with the varying prevalence attributed to the definitions that were used.  
The crude prevalence of MS was found to be 38%, 46% and 41% when the NCEP ATP III, 
IDF and Harmonizing criteria were applied, respectively (Table 3-9). The increase in 
prevalence using the different criteria was mainly attributable to the ethnic-specific 
waist circumference cut-offs used in the IDF and Harmonizing criteria, which, in this 
case, identified more subjects with the syndrome than did the NCEP ATP III criteria.  
This prevalence was higher than what has been reported recently in the United States 
(34%) by the American Heart Association (2011), and much higher than those reported 
for other population groups in South Africa, namely, 30% in Caucasians (Ker et al., 2007) 
and 23%  in the African population (Motala et al., 2011). By whatever criteria used, our 
sample showed a much higher prevalence when compared to the 24.9% which was 
reported for an urban Asian population in India (Gupta et al., 2004)  and in also excess of 
that reported recently in Asian Indians in the United States (Misra et al., 2010) as 26.7% 
and 38.2 % for the NCEP and IDF criteria respectively. This study therefore highlights the 




importance of determining ethnic-specific analysis of the prevalence of the syndrome, 
and not just extrapolating results from other studies (Al-Shaer, 2005). 
The present study also shows significant differences in the prevalence of MS amongst 
men and women, as females were almost twice as likely to have the syndrome as males 
(Table 3-9), in contrast to the general view that MS is equitably distributed between the 
sexes (Grundy, 2008). This finding was not altogether unexpected and may be ascribed 
to the greater frequency of general and abdominal obesity, as well as DM (Table 3-11) in 
females. This pattern has also been reported in other Asian Indian migrants by Misra & 
Khurana (2009), and by Ford et al. (2002) who described a higher prevalence of MS in 
the females of their respective cohorts. Recent studies in Asian Indian males (Chow et 
al., 2007; Deepa et al., 2007), in Germany (Dekker et al., 2005) and in Greece (Skoumas 
et al., 2007) have begun to show increasing prevalence data for MS in males.   
 
The prevalence of MS also increased with ageing (Figure 3-4), and is probably due to the 
increased exposure of ageing individuals to CVD risk factors to a point where they are 
clinically evident. The increase in prevalence with advancing age was most discernible in 
females (Figure 3-4), and has also been reported in females from other ethnicities (Ford 
et al., 2004; Ford 2005). The pattern seen in males was different, with the prevalence of 
MS peaking in the 4th age groups (45-54 age groups), and decreasing in the 5th age 
groups (55-64 age groups).  This pattern has also been recently described by Misra et al. 
(2010), who describes it as the characteristic Asian Indian male pattern, where 
dysmetabolism is observed early in life.  




The trends with regards to MS and ageing were also different when compared to a 
recent study conducted in Botswana on health personnel, where the researchers 
(Garrido et al., 2009) found that highest prevalence was in the 35-54 age groups. 
Interestingly, this was attributed to the changing lifestyle patterns to Westernisation, 
which the authors believed, afflicted the young more than the old (who remained set in 
their traditional habits). Their findings therefore underscored the importance of early 
detection and intervention in the younger subjects of the sample. 
 
4.2.2 The distribution and relationship of individual MS components 
McNeill et al., (2005) describes a gradient of risk for the development of CVD that is 
associated with increasing numbers of MS components.  The 45-54 age groups appear to 
be the worst affected in terms of the number of MS components, as this group 
comprised of the largest number of subjects with more than 1 MS component (Figure 
3.5). The greatest number of subjects with all 5 MS components was in the 55-64 age 
groups. This is probably attributed to the increased exposure of these older individuals 
to CVD risk factors, developing from the effects of a sedentary lifestyle, a cholesterol-
rich diet and the genetic contribution (Grundy, 1997), with ensuing insulin resistance 
and obesity, which are regarded as the main contributors of MS.  What was also 
emerged from our study was that the MS was not confined to those subjects with DM, 
but was also present in subjects with prediabetes and even normal glucose tolerance. 
 




The MS in prediabetic subjects is characterised by dyslipoproteinaemia (small-dense 
LDL, high ApoB, low HDL, low Apo-A1, high triglycerides) and fasting, as well as 
postprandial hyperinsulinaemia (NCEP ATPIII, 2001), with hypertension being a common  
finding. Our results showed a worsening of the lipid profile in the transition from the 
normal glycaemic profile to prediabetes, to DM (Table 3-12).  Subjects with prediabetes 
and DM had markedly high HOMA-IR values, waist circumference measurements and 
BMI values as compared to those with normal fasting blood glucose.  
Our study also showed that there were a high proportion of subjects (63.4%) with MS 
who had an impaired fasting glucose value (Table 3-11); the underlying mechanism 
which may be related to the impaired fasting glucose forming the intermediate stage in 
the pathogenesis of DM (Pietropaolo & Roith, 2001). Further decline in beta-cell 
function leads to more loss of insulin secretion, and eventual insulin resistance.  
Insulin resistance is known to be strongly associated with MS (NCEP ATPIII, 2001; IDF, 
2005) and may not be a condition exclusive to the obese, as was reported by Whincup et 
al. (2002) who found insulin resistance in non-obese subjects. There was a high 
prevalence of insulin resistance in our study, which correlated strongly (rs > 0.500) with 
the fasting blood glucose, BMI and the waist circumference measurement (Table 3-8).  
 
Our study also showed that there were 20% of subjects with MS who were 
normoglycaemic (Table 3-12), with 25% of MS subjects manifesting with prediabetes and 
55% of subjects classified with MS being diabetic. A previous study on young Indian 
subjects presenting with acute myocardial infarction (MI) performed at the R K Khan 




hospital in 2008 (Ranjith et al., 2008) reported a 57% prevalence of MS in his cohort, 
with 91% of subjects with MS in that cohort having impaired fasting glucose. Similarly, 
studies on other ethnic groups with DM in South Africa (Joffe & Kalke, 2008), found that 
MS was present in 46.5% of African and in 74.1% of Caucasian patients. This increasing 
trend has been observed in the US as well, as shown by the NHANES study (Lin et al., 
2007), with 69.9% being reported in Whites, 64.8% for Blacks and 62.4% for Mexican 
Indians. The lower number of MS subjects with DM in our sample may be explained by 
the fact that apparently healthy, non-hospitalised subjects were recruited for our study. 
Other studies on Asian Indians (Misra et al., 2010) reported a higher prevalence of 
impaired fasting glucose and DM in their cohort of subjects with MS. Since these 
conditions were detected much more frequently in their participants than obesity, 
insulin resistance and DM were considered as the key drivers for the development of 
MS.  
While obesity is known to contribute towards the development of metabolic risk factors 
and MS (Wasir et al., 2008), its value as a contributor to CVD risk, independent of the 
accompanying metabolic abnormalities is not well elucidated, and has been recently 
questioned (Bergman et al., 2007).  A large, long-term follow-up study of 20 293 subjects 
showed that MS and DM were more important prognostic indicators of CVD risk, than 
abdominal obesity (Wildman et al., 2011). This was not the case in our study, which 
showed that although 45% of subjects with MS did not have DM (55% of subjects with 
MS were diabetic) and 25% of these were prediabetic (Table 3-12), abdominal obesity 




was present in all subjects (Table 3-11) irrespective of the criteria that were applied 
(NCEP, IDF and Harmonizing).  
The notion that the increased waist circumference measurement, being an obligatory 
inclusion for the definition of MS using the IDF criteria could somewhat water-down the 
effects of the other cardio-metabolic risk factors of the MS (Kalke & Joffe, 2008) did not 
appear to weaken the definition, since the IDF identified the highest number of subjects 
with MS in our sample. This may be explained by the propensity of Asian Indians to gain 
fat in the abdominal area, as opposed to the hip, buttock, and limb areas, and hence 
develop central, rather than generalised obesity (Misra et al., 2004). In addition, Das 
(2003) suggested that higher levels of TNF-α and IL-6 in Asian Indians may trigger 
increased expression of 11ß-HSD-1, which promotes the development of abdominal 
obesity, and may possibly explain why Asian Indians are more prone to develop 
abdominal, rather than general obesity. This was also shown in our study, by the strong, 
positive correlations between abdominal obesity and HOMA-IR, and abdominal obesity 
and MS (Table 3-8), confirming the close relationship between increased waist 
circumference, MS and insulin resistance. Additionally, the differing trends in obesity 
prevalence with respect to Asian Indians in the diaspora may once again be attributed to 
the potential contribution of environmental and lifestyle factors. 
 
In terms of the frequency of the other components of MS observed in our study: there 
was a high prevalence of elevated triglyceride levels, followed by decreased HDL and 
then hypertension and DM consecutively, in descending order of prevalence (Table 3-




11). Ntyintyane et al. (2007) also found hypertriglyceridemia a common abnormality in 
their cohort of MS subjects; the difference being that while hypertriglyceridemia was the 
most common component in Black subjects with MS, the increased waist circumference 
was the most common in ours. The increased presence of raised triglycerides, 
particularly when using the IDF criteria, may be explained by the mechanisms proposed 
by Stannard & Johnson (2004). They reported that intramyocellular triglyceride content 
was inversely associated with whole-body insulin sensitivity, independent of general 
obesity.  
The combination of abdominal obesity, elevated triglyceride levels and low HDL levels 
(Table 3-11) differs slightly to what has been reported in other studies, where 
hypertension (Hsieh et al., 2008) and impaired fasting glucose predominated (Dhanaraj 
et al., 2009).  A possible explanation for this trend in our study may lie in the 
pathophysiology of MS, which has been related to systemic inflammation (Das, 2002; 
Rutter et al., 2004). Healthy Asian Indians have been documented as having raised CRP 
and hence higher levels of TNF-α and IL-6 (through the feedback mechanism) as 
compared to Caucasians (Das, 2001). But hypertriglyceridemia, and glucose intolerance 
have also been associated with elevated TNF-α levels (Jovinge et al., 1998), which 








4.2.3 The agreement between the IDF, NCEP ATP III and Harmonizing 
definitions of MS 
The Harmonizing criteria, which includes raised ethnic-specific waist circumference 
measurement as one of the features of MS, was proposed to address the previous 
limitations of the IDF criteria and MS as a whole. Its merit lies in the removal of the 
obligatory waist circumference measurement, but includes it as part of the five criteria 
for the diagnosis of MS, to ensure that the effects of the remaining cardio-metabolic risk 
factors are not diluted. In keeping with studies done in the Brazilian population (Dutra et 
al., 2012), our study reflects the effects of using the  Harmonized criteria, which yielded 
a prevalence of  41%; a value that lies between the NCEP criteria (38%), and the IDF 
(46%) criteria (Table 3-9). We found that there was a strong agreement between the 
Harmonized and the IDF criteria when diagnosing MS (Kappa = 0.883), The Kappa 
statistic was slightly lower, when ascertaining the level of agreement between the NCEP 
ATP III definitions and the Harmonized criteria (0.812), although both levels of 
agreements are classified in the “almost perfect agreement” category (Landis & Koch, 
1997).   
 
4.3 The Echocardiographic analysis of this sample  
The use of echocardiography for the evaluation of the left ventricular (LV) function and 
structure is regarded as one of the significant developments of modern medicine, 
especially in the area of risk stratification. Its value is especially relevant in the face of 




the global epidemic of CVD and the concern with CV risk factors and MS appearing in 
younger individuals. There is evidence that indicates that, prior to the emergence of risk 
factors; vascular disease would have already developed in 30–50% of patients (Yusuf et 
al., 2001). This supports the view that it may be possible to detect subtle, preclinical 
changes before overt structural and functional alterations of the heart occurs. This is the 
first population-based study that shows alterations in cardiac structure in the presence 
of CV risk factors, in Asian Indians in South Africa. It is also the first study to derive 
reference ranges for echocardiography parameters from a sample of apparently normal 
individuals for this population group in South Africa. 
 
Although the baseline parameters were within the normal ranges (Lang et al., 2006), we 
found that the median value of the left atrium (LA) dimension was much higher as 
compared to values published by Lang et al. (2006). This feature was also described by 
Cuspidi et al. (2005), where the increase in the LA dimension was a reflection of the 
increased LV mass associated with hypertension. Increases in the LV mass in our subjects 
(Table 3-13) was also a prominent feature, with increased wall thickness, and altered 
Doppler parameters also observed in females with CV risk factors (Table 3-14). These 
findings were similar to those reported by Rutter et al. (2003) where these structural 
changes were attributed to the effects of insulin resistance. This theory may well be 
applicable to our cohort since we documented a high prevalence of insulin resistance 
and DM. Non-enzymatic glycation of vascular and membrane proteins, increased cellular 
fatty acid uptake, and hyperglycemia-induced oxidative stress (Dhalla et al., 1998) are 




known sub-cellular changes that occur in response to DM, which promote these 
structural alterations in the heart. 
 
4.3.1 Diastolic abnormalities and dysfunction 
Our study confirms the association reported between age and diastolic dysfunction, as 
the median (IQR) age of subjects with diastolic dysfunction was higher than in those 
without diastolic abnormalities (Table 3-16). The increases in left ventricular mass index 
(LVMI) and the attenuation of transmitral indices with age were similar to those found in 
other community-based studies (Fischer et al., 2003; Redfield et al., 2003; Abhayrathna 
et al., 2006). Recent studies have focused on the prognosis associated with 
asymptomatic early LV dysfunction (Kuznetsova et al., 2010) and on the relatively high 
prevalence of heart failure with preserved LV ejection fraction (LVEF) (Redfield et al., 
2003; Abhayaratna et al., 2006) in community-based settings. In keeping with these 
findings we have shown an elevation in the TDI diastolic filling ratio (Table 3-16), 
consistent with increased LV filling pressures in those subjects with diastolic 
abnormalities. This was evident in the almost one third of our cohort (31%) who 
manifested with diastolic abnormalities (Table 3-16). We also showed a greater 
prevalence of DM in subjects with diastolic abnormalities (32%) as compared to those 
subjects with normal diastolic profile (22%) in keeping with a recent study (Kim et al., 
2011) which reported a significant worsening of diastolic parameters as the duration of 
DM increased in a cohort of 547 patients. In contrast to the limited number of 
community-based studies (Fischer et al., 2002; Redfield et al., 2003;  Abhayrathna et al., 




2006), we found that there was a very low prevalence (<0.5%) of diastolic dysfunction 
per se in this community, when using the European Study Group on Diastolic Heart 
Failure (1998) guidelines. 
Univariate associations revealed that an increasing age, BMI, left atrial volume index 
(LAVI) and the LVMI were independent predictors of diastolic abnormities (Table 3-17). 
Using multivariate step-wise regression, and after adjusting for age, female gender, 
hypertension, DM, LAVI and LVMI, we found that subjects were more likely to present 
with diastolic abnormalities if they were older (OR=0.986), female (OR =0.658) or 
hypertensive (OR= 0.73) (Table 3-17). The only independent echocardiographic predictor 
of diastolic abnormalities was an increase in the LAVI (0.882), in contrast to the TDI ratio, 
which is supposed to reflect LV filling pressure, independent of loading conditions.  This 
may be explained by the fact that the TDI diastolic filling ratio (Em/Ea) represents a one-
off evaluation of the LV filling pressure, while an increased LAVI provides physiological 
and morphological evidence of the chronic elevation in the LVEDP.   
 
This study shows that the prevalence of diastolic dysfunction in this community is low. 
However, the changes to LV dimensions, as well as the increased LVM and LVMI, in the 
absence of diastolic dysfunction may well be due to the pathophysiological 
consequences of hypertension and obesity (Alpert, 2001). Cardiac remodeling in obese 
subjects is characterised by increased LV mass and end-diastolic dimensions (Powell et 
al., 2006) and is not without risk (Levy et al., 1990) since an increased LV mass is an 
independent predictor for cardiovascular morbidity and mortality in individuals 




previously free of clinical CVD.  
 
4.3.2 Echocardiographic changes in the presence of MS  
In this study we have demonstrated that significant differences exist between subjects 
with and without the MS for chamber dimensions, wall thickness, transmitral flow 
velocities and TDI diastolic filling ratio (Em/Ea) (Table 3-18).  There are many causative 
factors that may result in the alteration of LV structure and function in subjects with MS, 
namely obesity, hypertension, endothelial dysfunction, CAD, autonomic dysfunction and 
metabolic abnormalities (Farkouh et al., 2008). In fact, the MS was found to be one of 
the main determinants of increased LA dimension (Cuspidi et al., 2005). Considering that 
almost half our sample was diagnosed with the MS, with significant changes already 
apparent in the LA dimension in subjects with MS (Table 3-18), further complications 
related to this adverse remodeling are almost inevitable.  Therefore, the major finding in 
our study is that changes in cardiac structure are present in the preclinical phase, when 
there is already interplay of the components constituting the syndrome (MS). Our study 
therefore supports the evidence that abnormal LV geometry and function, related to the 
MS (Chinali et al., 2006; Schillaci et al., 2006) are present in subjects who may not be 
diabetic or hypertensive. 
Our study has also documented changes in diastolic filling parameters,  with attenuation 
of the early mitral (E-wave) filling velocity and the transmitral filling ratio (Em/Am), as 
well as an increase in the Tissue Doppler (Em/Ea) ratio in subjects with MS (Table 3-18). 




These changes could all be secondary to the increase in the LVM and left ventricular 
mass index (LVMI). The effect of MS on LV diastolic function has previously been 
reported (Chinali et al., 2006) in the Strong Heart study, which showed that MS was 
associated with a higher prevalence of abnormal early left ventricular relaxation. 
However, we found a low prevalence of impaired diastolic function in this sample, with 
the alteration to diastolic parameters more likely being attributed to the very high 
prevalence of obesity and hypertension in this sample. A possible mechanism may be 
that the high prevalence of hypertension in this group contributed to ventricular 
remodeling; hence the resultant increases in LVM and LVMI. This was supported by a 
good correlation between blood pressure and the LVM and LVMI (rs =0.337) (Table 3-
19). Interestingly, these significant changes in LVM between subjects with and without 
MS persisted after controlling for hypertension (Table 3-18), suggesting that there may 
be other pathophysiological mechanisms driving cardiac remodeling, aside from 
hypertension. Although data regarding the relationships of diabetes and insulin 
resistance are conflicting, Sundström et al. (2006) reported that insulin resistance is a 
mitogenic stimulus for cardiac hypertrophy, with consequent increases in the LV mass, 
ventricular wall thickness and LA dimension. This underlying mechanism is plausible 
considering the high prevalence of insulin resistance (in 58% of subjects) in this sample 
(Table 3-7a). 
The present study was one of the first to measure sub-epicardial fat tissue (SEAT) 
thickness echocardiographically, and showed a significantly increased thickness of sub-
epicardial fat (Table 3-18) in subjects with MS as compared to those without (p < 0.005). 




SEAT thickness has been recently validated as a measure of visceral adiposity (Iacobellis 
et al., 2005), which is accompanied by an increase in adipocyte size and subsequent 
adipose tissue dysfunction.  The resultant production of inflammatory cytokines by 
adipose tissue macrophages (Baker et al., 2006) has been shown to contribute to the 
formation of an intimal atherosclerotic lesion (Miyata et al., 2000; Verhagen & Visseren, 
2011), explaining the increased risk for coronary artery disease in subjects with MS.  
The measurement of SEAT thickness has been shown to provide a more accurate 
assessment of metabolic risk, which could not be accounted for by anthropometric 
indexes and intra-abdominal visceral fat (Wang et al., 2009). The present study showed 
that SEAT was moderately correlated with fasting blood glucose, blood pressure and the 
presence of MS (Table 3-19). SEAT thickness was significantly increased in subjects with 
DM, hypertension, abdominal and general obesity (Table 3-20). Bivariate correlations 
(Table 3-20) indicated that correlations were strongest between SEAT and BMI (rs= 
0.416) as well as the waist circumference (rs = 0.415) measurement. There was a weaker 
correlation with DM (rs = 0.249). Linear regression showed that a 1mm in SEAT thickness 
was associated with a 3 times likelihood of being diagnosed with MS. (Table 3-21).  This 
association may be related to the inflammatory milieu that underpins the 
pathophysiology of both conditions (Das, 2002; Mazurek et al., 2003; Baker et al., 2006, 
Samaras et al., 2011; Ahn et al., 2007).  
The measurement of SEAT thickness routinely in the echocardiography laboratory is 
feasible, as well as reliable in trained hands. Previous studies indicate that there is good 




reproducibility in SEAT measurements, if adherence to standardised guidelines as 
proposed by Iacobellis et al. (2003) is complied with, and would minimise the inter-
observer variability in a unit with many echocardiographers. Future studies in this aspect 
are promising, as the measurement of sub-epicardial fat has been used to evaluate 
therapeutic targets that modulate adipose tissue. Epicardial fat loss has been 
documented to be much faster than other indices of body fat (Iacobellis et al., 2008), 
and has been found in subjects undergoing weight loss interventions (Iacobellis et al., 
2005).  
 
4.4 The receiver operator curve and discriminating capacity to 
determine the presence of MS   
A receiver operator curve (Figure 3.7) was constructed to assess discriminating capacity 
of individual MS components, anthropometry, and biochemical and echocardiography 
parameters to identify the MS diagnosis (IDF criteria). The highest AUC was yielded by 
the fasting blood glucose levels (AUC = 0.822), followed by HOMA-IR values (AUC = 
0.816). The waist circumference had an AUC = 0.807, followed by the triglyceride levels 
(AUC = 0.806), while the mean LA dimension had the highest echocardiographic 
measure of AUC = 0.745 (Table 3-21). Categorising blood pressure (>or <130/85) using 
the IDF criteria, yielded the highest AUC was for this parameter. (AUC= 0.792).   
In spite of the current controversies surrounding the MS, and its relevance as a 
syndromic entity, we share the views expressed by Reaven (2007) in that to date, there 




is no alternative hypothesis to understanding of the clustering of these components in 
an individual and how each component correlates strongly with the “same defect-insulin 
resistance and compensatory hyperinsulinemia”. The present study shows that MS is 
clearly related to an adverse cardiac phenotype, in the presence of even subtle CV risk 
factors.   
 
4.5 Normal echocardiography reference ranges for this sample 
One of the strengths of the present study was the opportunity to derive normal 
echocardiography ranges from this sample that is specific for the inhabitants of the 
Phoenix community. Initial studies looking at the effect of ethnicity on cardiac geometry 
recommended the development of ethnic-specific reference ranges (Chahal et al., 2010). 
Currently, there are very few data available on the echocardiography reference ranges in 
Asian Indians (Chahal et al., 2010) to reliably detect early cardiac structural and 
functional changes, since most studies have been mainly conducted between African-
Caribbean and  Caucasian populations. It is possible that these measurements, which 
form the basis of recent guidelines regarding the echocardiographic quantification and 
diagnosis of diastolic heart failure, may not be wholly applicable to this population 
group. 
 
The present study examined the echocardiography variables of 1428 subjects: there 
were 38 subjects who were found to have structural and functional abnormalities, a 




further 667 subjects who were diagnosed with MS (IDF criteria), and an additional 377 
subjects with isolated and clustered risk factors who did not meet the criteria for the 
diagnosis of MS, and were subsequently excluded. Therefore, the measurements from 
384 subjects (89 males and 257 females) who were free of cardiac structural and 
functional abnormalities, as detected by echocardiography, and without documented CV 
risk factors, were analysed (results are presented in Tables 3-23 and 3-24). The influence 
of the results by subjects who were replaced by substitutes could not be directly 
determined in this study. However, since the substitutes were recruited from the same 
geographical area, and were of similar socio-economic statues, we assume that the bias 
on selection was minimal.  
 
The chamber dimensions, wall thickness and LV mass were significantly higher in males 
(Table 3-24). These differences in gender, which have been described previously by 
other researchers, were not unexpected, and may be attributed to the strong 
correlation that exists between linear measurements of LV dimensions and body habitus 
(Salton et al., 2002), since males were generally taller, and weighed more than females 
(Table 3-24).  
But considering that the prevalence of over-weight and obesity in this sample was very 
high, the effects of obesity on LV geometry (Gottdiener et al., 1994, Salton et al., 2002) 
may be confounding, especially when assessing these variables to ascertain pathology.  
But, since height is strongly associated with lean body mass (Devereux et al., 1986), it is 
considered to be the best indication of the metabolic demands on the heart, negating 




the effects of weight (or excess weight in our case). Indexing echocardiographic 
dimensions to height revealed a significantly larger LA dimension in females, but a 
higher LVMI and thicker SEAT in males (Table 3-25). 
 
The analysis of the raw data (Table 3-24) showed that there was an increase in the LA 
dimension in our population, as compared to those proposed by Lang et al. (2005), as 
the 95th percentile values were in excess of the upper range for men (44mm cf  40mm) 
and women (44mm cf 38mm). However, a smaller LAVI was calculated in the present 
study, when compared to the reference values from Lang et al. (Appendix 4). The 
differences in the ranges may be explained by the fact that these values were calculated 
from subjects that  are of Asian Indian ethnicity, while Lang et al. used subjects of 
Caucasian descent. These differences may therefore reflect the variances that exist in 
anthropometry (as shown by the lower 95th percentile value in the LVEDD measurement 
in Table 3-24).  So, the smaller LAVI seen in this population may well be due to the 
relatively smaller heart sizes of the subjects in our cohort, rather than a mere reflection 
of lower filling LV pressures.  
What appears to be apparent are the effects of obesity on cardiac remodeling (in the LA) 
in this sample, since this group of subjects was not diagnosed with hypertension, 
glycaemic or lipid abnormalities. The MONICA/KORA study also shown a similar trend 
(Stritzke et al., 2009); where the effect of obesity was reported as being almost twice 
the effect of hypertension on increased LA size. These authors suggested that a possible 
mechanism for LA dilation was the hemodynamic alterations due to increased 




intravascular volume and increased cardiac output associated with an obese state. 
Worryingly, an increase in the LA dimension, associated with obesity, has also been 
reported to confer increased risk for the development of atrial fibrillation (Wang et al., 
2004), with its accompanying risk of stroke and heart failure in the general population. 
With regards to the median LAVI values obtained in this study (13.9): this value was 
almost identical to that reported by Chahal et al. (2010) in a group of normal migrant 
Asian Indians residing in West London (14.2±4).  However, there were differences in the 
other echocardiography parameters, as the ejection fraction that we recorded was 
higher, with the LVM and the LVM indexed to BSA, being smaller than the West London 
cohort. In spite of the similarity in Asian Indians, the LVMI may not be valid for 
comparison between different ethnic groups (Chahal et al., 2010), as was shown in our 
study, with the mean and 95th percentile values for the LVMI in our sample being higher 
than published ranges (Lang et al., 2006).  
The benefit of indexing echocardiographic parameters to the body surface area is that 
the BSA makes provisions for obesity (as weight is used in conjunction with height to 
determine BSA). When echocardiographic variables were indexed to BSA, the significant 
differences between males and females in the LVM and LA dimension, as well as SEAT 
thickness persisted, but with females having larger LA dimensions and higher SEAT 
measurements (Table 25). 
 
The echocardiography findings on normal subjects show that there are definite 
variations in terms of the prescribed normal reference ranges. Other studies which have 




found discrepant reference values to published guidelines (Vasan et al., 2000) attribute 
them to the differences in sampling techniques, and different models of equipment used 
to acquire the images and the software for calculation: this may also be the case in our 
study. Furthermore, the variations in ethnicity are a very likely cause for the differences 
in parameters that we have shown. The new reference ranges that we have proposed 
will be valuable in clinical practice where CV risk stratification is required in this 
population.   
 
4.6 Genetic patterns in the Metabolic Syndrome 
In recent times, there has been an escalation in interest in the field of genetics, with the 
focus in cardiovascular medicine being the contribution of genetic variation to CVD risk 
(Gohlke et al., 2009). Although the benefits of association studies have been recognised, 
its weakness lies in the heterogeneous nature of CVD, which would account for the 
different sets of genetic factors which predispose to CVD in different populations. 
Furthermore, atherosclerosis is known to be a multifactorial disease, without a single 
pathophysiological pathway. In this context, this means that some polymorphisms may 
be strongly associated with the disease in one population, but weak in others due to the 
presence of genetic factors. This therefore underscores the importance of population-
based studies.  
 
The Asian Indian population is known to demonstrate the triad of high triglyceride levels, 
with high LDL and low HDL levels, as described by Ravi et al. (2004), and hence, an 




increased predisposition for CVD. The increasing rate of MS in this population also 
remains a concern. We therefore determined the genetic patterns associated with 
conventional CV risk factors and the metabolic syndrome, and the allele frequencies 
associated with particular CV risk factors, as well as risk factor clustering.   
 
4.6.1 Lipoprotein Lipase polymorphisms  
Lipoprotein Lipase has a direct role in pathophysiology of atherogenesis (Malloy, 2001). 
Lipid abnormalities are modulated by multiple gene-gene and gene-environmental 
interactions (Corella et al., 2002; Lee et al., 2004), and are hence subject to 
environmental and genetic variations. Since plasma fatty acid composition has been 
reported as a strong determinant in the development of MS (Garcia-Rios et al., 2011), 
polymorphisms which are of major importance to lipid metabolism were studied to 
determine their possible role in relation to MS and specific phenotypes.  
 
4.6.1.1 FREQUENCY OF THE S447X POLYMORPHISM 
The distribution of this genotype was almost equally distributed amongst males and 
females, with a much higher prevalence of the heterozygous variants of the S447X 
polymorphism than the homozygous wild-type (Table 3-26). There were no 
polymorphisms detected for the S291N variant, although Spence et al. (2003) also 
reported a 0.9% frequency for the S291N mutation in a sample of 452 subjects, while 
the EARS study (Gerdes et al., 1997) reported an allelic frequency of 3.1%.    
 




There have been inconsistent observations made with regards to the allelic frequencies 
of the S447X polymorphism. Corella et al. (2002) reported a frequency of 0.14 in the 
Mediterranean population, while Spence et al. (2003) reported an allelic frequency of 
4.4% for the S447X. The HuGe Association review and meta-analysis (Sagoo et al., 2008) 
reported a frequency of 9.9% in the X allele and overall, with this mutation being more 
common in East Asians (12.2%) than Caucasians (10.3%). Our study reports a 
comparatively high allelic frequency of the 447X in our sample (0.38), as compared to 
the frequency of (0.08) as reported by Bhanushali & Das (2010) in Asian Indians.   
 
4.6.1.2 GENOTYPIC-PHENOTYPIC ASSOCIATIONS OF THE LPL POLYMORPHISMS 
The lipoprotein lipase (LPL) gene is considered as a strong candidate gene for 
atherogenic lipid profiles and CAD. In particular, the S447X polymorphism has been 
reported as a putative gain-of-function mutation, with substantial debate as to whether 
it demonstrates increased lipolytic activity (Ross et al., 2005). Previous studies, including 
a meta-analysis on Caucasians by Whittrup et al. (1999) reported that the X447 allele 
was significantly associated with decreased triglyceride and increased HDL levels. This 
allele has therefore been associated with a reduced risk of CV disease, including 
myocardial infarction (Samani et al., 2007). This polymorphism is consequently regarded 
as conferring a cardio-protective effect, although this has been an inconsistent finding in 
some studies of Asian Indians (Lee et al., 2004; McGladdery et al., 2000). Our results did 
not suggest this protective effect, and indeed, were in contrast to what was found in a 
local study, which examined this polymorphism in subjects with MI (Ranjith et al., 2009). 




These authors found a significant relationship between the X allele of S447X 
polymorphism and the presence of MS (NCEP criteria) with this particular polymorphism 
being associated with a favourable lipid profile. Since we found no significant 
relationships between this SNP and favourable or adverse lipid levels, it may be that the 
S447X SNP may not be the major causal SNP within LPL that influences lipid levels in this 
community-based population. In the same vein, we did not find any associations 
between this polymorphism and the presence of MS (Table 3-27) or with its components 
(Table 3-28). 
Kern et al. (1990) reported that the relationship between LPL and BMI may alter clinical 
phenotypes, as LPL activity is up-regulated in response to caloric restriction. In spite of 
the high prevalence of this mutation in this sample, our study did not find any significant 
relationships between the S447X polymorphism and BMI. 
 
The N291S variant has been reported to be associated with dyslipidemia, DM and CAD, 
and more especially with ageing and obesity (Yaomin et al., 2006). The underlying 
mechanisms relate to the increased rate of dissociation of LPL dimerisation, and hence, 
alteration of LPL enzymatic activity (Razzaghi et al., 2001). This mutation was not 
observed in our study, similar to the findings reported by Bhanushali & Das (2010), who, 
in their study of South Indian Asians, suggested that this mutation may be extremely 
rare or absent in the Indian population. This highlights the importance of population-
based studies as disparities with other studies may be explained by the fact that 
particular associations found in one population may not necessarily be extrapolated to 




others. In addition, inter-sample variations are likely to occur because of the linkage 
disequilibrium between a measured marker and an unmeasured functional allele at or 
near the LPL locus (Spence et al., 2003).  
 
 
4.6.2 Polymorphisms of the Human Paraoxonase gene 
The contribution of oxidation on the pathogenesis of atherosclerosis has been well-
established, as oxidized low-density lipoproteins (LDL) are thought to promote 
endothelial injury and foam cell formation (Lusis, 2001). There has therefore been great 
clinical interest in polymorphisms conferring risk or protection from the effects of 
systemic oxidation. Previous studies (Getz et al., 2004) found a strong association 
between PON-1 polymorphisms and systemic measures of oxidative stress, which, in 
turn has been linked to the development of CVD (Stocker & Keany, 2004). PON-1 has 
also been reported to possess significant anti-atherogenic properties (Shih et al., 1998) 
and hence, has been suggested to lower susceptibility to CAD, although the effects of 
PON-1 polymorphisms to systemic atherogenesis in Asian Indians have been inconsistent 
(Sanghera et al., 1998). PON-1 has been reported to be associated with the oxidative 
modification of HDL and LDL, as well as in preventing the induction of monocyte-
endothelial interactions on the arterial wall (Watson et al., 1995). PON-1 is also 
predictive of CVD risk (Jarvik et al., 2003; Mackness et al., 2003), and since MS has been 
reported to alter oxidative stress and contribute to atherosclerosis-related conditions 
(Tabur et al., 2010; Lavi et al., 2008), we examined the association of these common 




polymorphisms with MS and its components.  
 
4.6.2.1  FREQUENCY OF THE PON-1 POLYMORPHISMS 
The frequency of both polymorphisms (Q192R and L55M) were similarly distributed in 
males and females with no significance detected (Table 3-26). 
The frequency of the PON-1 polymorphisms has been comprehensively described by 
Ginsberg et al. (2009). The 192R allele has been documented in 20–30% of Caucasian 
subjects, with similar percentages observed in Turkish (28%) and Asian Indian (31%) 
populations. This mutation appeared to be the dominant allele in certain populations, 
where the frequency was significantly increased: in African Americans (64%), Japanese 
(66%) and the Chinese (57%).  
The frequency of the 192R-alelle in our sample was similar to those reported by 
Ginsberg et al. (2009), and was detected in 33% of subjects. 
 
The frequency of the 55M allele is documented as being lower than the 192R allele, with 
estimates ranging from 26-38% in Caucasians, 18% in Afro-Americans and 21% in Asian 
Indians (Ginsberg et al., 2009). We found a frequency of 34% for the distribution of the 
55M allele in the present study.  
 
4.6.2.2  GENOTYPIC-PHENOTYPIC ASSOCIATIONS OF THE PON 1 POLYMORPHISMS 
PON-1 polymorphisms have been somewhat inconsistently linked to the risk of coronary 
artery disease in population studies. For example, a meta-analysis by Wheeler et al. 




(2004) reported that there was a weak association with CAD with the Q192R mutation, 
whereas, in contrast, Bhattacharya et al. (2008) reported an increased risk of all-cause 
mortality in subjects with the QQ192 genotype, the increased risk being ascribed to low 
PON-1 activity.  
Insulin resistance and adiposity, which are considered to be the key components of MS, 
have also been associated with altered oxidative stress, which increases with increasing 
BMI. There are few available association studies with MS, with the focus being on PON-1 
activity. Senti et al. (2003) reported lower PON-1 activity in subjects with MS compared 
to controls, due to the influence of oxidative stress, whereas Tabur et al. (2010) 
reported low or unchanged PON-1 activity, in the presence of oxidative stress. In terms 
of the polymorphisms, Martinelli et al. (2005) found that carriers of the 55Leu and 
192Arg allele were at an increased risk of CAD in subjects with MS, although the 
genotypes were equally distributed between subjects with and without MS. 
Since we did not measure PON-1 activity in our study, we were not able to make these 
comparisons. Furthermore, we did not find significant associations between MS and 
PON-1 polymorphisms (Table 3-27), as there were similar distributions in subjects with 
and without MS, the same trend that was noted with Senti et al. (2003).   
In terms of the association with MS components: there was only one significant 
association detected in terms of the association between MS components, that being 
with HDL levels. Carriers of the 192R allele, which is known to reduce protection against 
lipid peroxidation, were inclined to have lower HDL levels (Table 3-28). This is plausible 
since 192R-allele has a lower activity for hydrolyzing lipid peroxide (Aviram et al., 1999, 




2000), hence resulting in lower anti-atherogenic properties, with subjects manifesting 
with lower HDL levels as an adverse phenotype. 
Similarly, we found a significant interaction between the Q192R variant and obese 
females, where this polymorphism appeared to confer a predisposition for the 
development of obesity (Table 3-29), using the Asian cut-off for obesity (>25 kg/m2). 
Although these findings were similar to those found in Portuguese women (Veiga et al., 
2011), where the R-allele was found to be a risk factor for obesity, significant 
associations between the homozygous L (LL) variant and obesity has also been found in 
recent studies in the Mexican (Martínez-Salazar et al., 2011) population.   
Vincent & Taylor (2006) reported that obesity was linked to increased oxidative stress 
and decreased concentrations of plasma antioxidants, hence, a higher susceptibility to 
lipid peroxidation. Therefore the relationship between obesity and the R-allele is not 
difficult to understand, as the R-allele has been reported as being less effective in 
protection from the effects of oxidative stress (Aubo et al., 2000; Levy, 2003).  Another 
mechanism that has recently been suggested is that oxidized LDLs may encourage the 
development of obesity when endocytosed by adipocytes (Marsella et al., 2006). 
Adipocyte proliferation and differentiation is then stimulated, which consequently 
contributes to the increase in adipose tissue mass (Martínez-Salazar et al., 2011). 
However, recent research by Galinier et al. (2006) reported that the adipose tissue of 
obese rats showed lesser indications of lipid peroxidation than that of lean rats, 
suggesting that obesity may not be associated with an inflammatory state since it is 




related to a reduced redox state. Therefore, larger studies are necessary to confirm 
whether PON-1 polymorphisms indeed confer greater risk for obesity.  
 
4.6.3 The Hardy-Weinberg equilibrium 
We did not document Hardy Weinberg equilibrium (HWE) for any of the polymorphisms 
that we studied. The lack of HWE in population-based studies may be due to many 
reasons: existence of migration, selection, mutation and absence of random mating 
(Wittke-Thompson et al., 2005). The fact that these Asian Indian community members 
display significant heterogeneity in terms of their place of origin in India, their marriage 
and customs, their dietary and cultural habits (Seedat et al., 2005) may have contributed 
to this finding. Subjects with differences between groups of ethnic origin or differences 
between groups of similar ethnic origin but with limited admixture are known to 
contribute to lack of HWE (Radha et al., 2010) may have been included in this sample.  
HWE violation may also be due to an excess of homozygotes or heterozygotes detected 
in the sample (Sen  & Burmeister, 2008): our population reflects the latter. This pattern 
is probably indicative of over dominant selection or of outbreeding. Interestingly, 
several large studies have failed to show Hardy-Weinberg equilibrium (Zhong et al., 
2013; Tan et al., 2010). Finally, it may also be possible that our study was underpowered 
to detect HWE deviation, as has been the case in many published studies (Salanti et al., 
2005).  
 




4.7 Conclusion and recommendations  
The interdependent relationship between lifestyle “risk factors” and CVD appear to be 
strongly influenced by lifestyle patterns (dietary habits, physical inactivity, adiposity and 
harmful behavioural traits) via the effects on endothelial function, 
inflammation/oxidative stress, thrombosis/coagulation, arrhythmia, and other pathways 
(Mozaffarian et al., 2008), which are all modifiable to some degree. However, certain 
ethnic groups have a higher propensity to develop clustering of risk factors, leading to a 
heightened predisposition to CV disease (Chaturvedi, 2003). In particular, Asian Indians 
are at a particularly higher risk of developing non-communicable diseases (Misra & 
Khurana, 2011; Yusuf et al., 2001) related to obesity, and have a higher incidence and 
mortality rate from CVD than other population groups, with a plethora of research 
conducted to explain possible mechanisms for this excess in risk. Notwithstanding the 
accelerative effects of urbanisation and westernisation on CVD, Asian Indians have an 
additional increased susceptibility arising from altered biochemistry (dyslipidaemia, 
hyperinsulinaemia, and hyperglycaemia) (McKeige et al., 1991), anthropometry (“thin-
fat” phenotype) (Misra, 2003), perinatal conditioning (Yajnik et al., 2002), a pro-coagulant 
state (Anand et al., 2000), as well as genetic factors (Yusuf et al., 2001). Furthermore, the 
prevalence of CV risk factors and risk factor clustering has been documented to be higher 
in Indians than the native populations of the diaspora. Epidemiologists have been 
sounding warning bells on the rising burden of cardiovascular disease (CVD) which has 
now exploded into epidemic proportions, including subjects from the Phoenix 
community.  




The data from this study adds to the evidence that cardiovascular diseases now 
contribute, and continue contributing towards an ever-increasing proportion of non-
communicable diseases in developing countries (WHO, 2002), promoted by the increase 
in life expectancy, together with the increasing global prevalence of CV risk factors like 
hypertension, obesity and DM.  More importantly, for us, this study has drawn attention 
to the evolving epidemic of CV risk in the young in this population, particularly in the 
form of a high prevalence (~ 50%) of insulin resistance, hypercholesterolemia, increased 
BMI and waist circumference (Table 3-7a; 3-7b). These subjects are now manifesting with 
changes to their cardiac structure, fuelled by the high prevalence of CV risk factors, 
particularly, insulin resistance and obesity. These observations suggest a greater burden 
of CV disease in the near future, as these individuals reach adulthood, with these 
estimates projected to increase substantially in keeping with data extrapolated from 
other developing countries (Kruger et al., 2002). 
 
The clustering of risk factors into the metabolic syndrome (MS) is believed to account for 
approximately half of CVD risk for the development of atherosclerosis (Grundy, 2008), 
with the risk conferred deemed to be much higher than currently estimated. The main 
role of MS (Kahn et al., 2005), therefore, seems to be its potential for identifying risk 
factors that are likely to occur concurrently. It is believed that the key to delaying the 
onset of a higher CV risk profile is early detection and intervention, particularly from 
childhood, considering the premature, malignant nature of CAD amongst Asian Indians 




(Thankappen et al., 2006). This will permit early detection and treatment of multiple risk 
factors, and the implementation of lifestyle modification, if necessary.  
Our study has shown that there is a 46% prevalence of MS in a sample of the Phoenix 
community, driven largely by the presence of obesity and insulin resistance and is 
associated with significant alterations in cardiac structure.  In our sample, the extremely 
high prevalence of MS in this community is a call to alert Health authorities to realise the 
long-term effects, and to expect a greater lifetime burden of CV disease, if interventions, 
specific to this population, are not implemented. 
Since the high prevalence of MS in this community appears to be driven by central and 
abdominal obesity and insulin resistance, an emphasis on the developed risk factors like 
hypertension, dyslipidemia, and DM does not address the root causes of adiposity or its 
full cardiovascular consequences, since adiposity develops as a result of inadequate 
physical activity and poor dietary (high-caloric) habits, One of the key suggestions from 
the INTERHEART study was that common strategies be adopted for MI prevention for 
individuals from all backgrounds, age-groups and ethnicities, as well as both genders with 
these risk factors (Yusuf et al., 2004). Changes in lifestyle (Ratner et al., 2005) may be the 
most important factor for primary prevention, where subjects increase their physical 
activity and change their diet to one richer in fresh vegetables and fruit. This approach 
has been shown to produce great benefits with regards to other established CV risk 
factors related to inactivity, adiposity, and poor dietary habits at a community level. 
 




These interventions must start as part of the public health strategy, particularly targeted 
at population and individuals who are prone to develop chronic diseases of lifestyle. 
Changes in legislation to incorporate physical education programmes at schools must be 
made, to reduce the burden of childhood obesity, which is already rife in South Africa. 
The population at large should be actively engaged and educated on the prevention and 
treatment of chronic diseases of lifestyle, and on how to take responsibility for their own 
health. This should be driven primarily by local, provincial and central government, 
together with the food industry, non-governmental agencies, and the media. These 
strategies, in addition to increasing awareness and possibly curtailing the burden of CVD 
on many levels, are also critical in order to prevent premature cardiovascular remodeling, 
considering that cardiac remodeling is already manifesting as a consequence of the 
obesity epidemic in this population, even in subjects free of CV risk factors. This study 
therefore strongly advocates echocardiographic evaluations on high-risk subjects. In so 
doing, structural changes may be identified early in the course of the “obesity 
cardiomyopathy”, considering the high prevalence of CV and metabolic risk factors in this 
community, along with the absence of guidelines and detection strategies for control of 
CVD in our population.   
 
Recent population-based investigations (Mollentze et al., 1995; Kruger et al., 2003; 
Tibazarwa et al., 2009) consistently recommend strategic and systematic surveillance of 
CV risk factors, particularly in communities undergoing epidemiological transition, like the 
Phoenix community. Therefore, longitudinal studies in this particular population should 




be supported and implemented in order to determine the epidemiology patterns of CV 
risk factor development. This is critical since it is now established that clinical DM and 
coronary artery disease, which are the more common non-communicable diseases in 
developing countries, are preceded by risk factor clustering. If not, the current situation 
augurs a pandemic of CVD in this population in the near future, which is further 
intensified by the high CV risk profile of its younger members. Screening and intervention 
should therefore be focused in school-going individuals, when CV risk factors are already 
manifesting in this population. 
 A clearer understanding of many modern health conditions will emerge as one considers 
that most of human evolution took place when our ancestors were hunter-gatherers 
(Trevathan et al., 1999). This study therefore recommends that immediate strategies be 
developed and implemented to curtail the epidemic of cardiovascular disease, in keeping 
with the recent call from the World Heart Federation, Geneva, Switzerland (Ralston, 
2012). In doing so modern man may regain the ‘normal’ physiology of our hunter–
gatherer ancestors and thereby express the phenotype as it has evolved to be.  




4.8 Limitations of the study  
We have identified several limitations in our study, and they are discussed briefly below: 
1. The design of this study was cross-sectional in nature:  we could not observe and 
were therefore not able to report on trends that could have developed over time. 
We were therefore unable to ascertain risk associated with CV events, which 
could have been better addressed with a longitudinal study.  
2. There was a predominance of females in our sample. This was attributed to the 
nature of randomly sampling subjects for this project. In hindsight, a stratified 
sample would have yielded a higher number of male participants. However, in 
terms of the comparability of our demographics with other population studies, it 
appears that the predominance of females appears to be a common trend in 
South African population studies (Erasmus et al., 2012). This high female to male 
participation ratios (2:1) have been observed in other community-based studies, 
looking at cardiovascular risk profiles and/or the metabolic syndrome (Omar et al, 
1988; Tibazarwa et al.,2008, Motala et al. 2011 ) in South Africa, with the male 
component at times being as low as 19% (Erasmus et al. 2012).   
 
3. It is established that the presence of MS does not predict absolute risk for CVD, as 
a significant portion of the pathogenesis of CV risk factors may be related to other 
factors such as gender, age and smoking, which are not included in the MS 
criteria, but included in other risk factor scores (like the Framingham criteria). 




However, substantial data indicate that there is an increased CV risk associated 
with the presence of MS (Grundy, 2008).  The Framingham criteria does not 
include features like abdominal obesity, increased fasting glucose and 
hypertriglyceridemia in its risk score, but uses age, gender and smoking status as 
well as cholesterol to predict CV risk (D’Augustino et al, 2001). The diagnosis of 
MS could therefore be used to refine CV risk in subjects with risk factors, and 
thereby extend the concept of cardiovascular risk (Opie, 2007).  
 
4. In the present study, measurement of inflammatory markers (like CRP) was not 
done. CRP levels correlate strongly with the number of metabolic disorders 
(dyslipidemia, upper body adiposity, insulin resistance, and hypertension) that 
together constitute the MS. Since the metabolic syndrome has been associated 
with an inflammatory state (Fester et al., 2000), CRP might have served as a 
composite marker of risk and inflammation. In its absence, it would not be 
possible to assess the effect of these parameters on the presence of MS.  
 
5. An important and recent enhancement of the assessment of regional LV function 
has been the calculation of the myocardial velocity gradient or strain rate imaging 
(SRI). Therefore future studies in this field will pursue an evaluation of systolic and 
diastolic ventricular function using global strain rate, strain, and regional systolic 
velocity and diastolic velocity, as was undertaken by Wong et al. (2005), to further 
evaluate the role of echocardiography as a screening tool for the early detection 




of CV risk factors and MS.   
 
6. The current study did not measure PON-1 serum concentrations or enzymatic 
activity, which would have been useful to correlate with such CV risk factors as 
prediabetes, hypertriglyceridemia and smoking. However, in retrospect, 
measurement of PON-1 activity and concentration would have been made from 
blood drawn possibly after the development or CV risk factors or a cardiovascular 
event. It would then not be possible to know whether the reflected PON-1 
activity/concentration was due to the consequence of the event or the cause of 
the event, apart from the fact that wide variability exists, in terms of the 
enzymatic activity of PON-1 in humans (Balcerzyk et al., 2007). The challenges of 
deeming causality based on genetic association were also highlighted in this 
study, as shown by the lack of significant relationships between LPL SNPs and 
biochemical and anthropometric parameters. These associations have been 
reported elsewhere in other population groups, but were not found in this 
population. 
 
7. The present project looked at four SNPs from two genes. Given the complexity of 
lipid and insulin regulation, as well as the multifactorial pathophysiology that is 
characteristic of the metabolic syndrome, it is reasonable that many genes may be 
responsible for these functions. Future studies in this population should look at 
genome-wide association scans (Zabaneh & Balding, 2010), which may yield more 




information about the genetic pathways contributing to the common 
pathogenesis of the metabolic syndrome. 
 
 





1. Adkins, S.S., Gan, K.N. Mody, M. La Du, B.N. (1993) ‘Molecular basis for the 
polymorphic forms of human serum paraoxonase/arylesteras: glutamine or argentine 
at position 191 for respective A or B allozymes.’ Am J Hum Genet, 52:598-608 
2. Abhayaratna, W.P. Marwick, T.H. Smith, W.T. Becker, N.G. (2006) ‘Characteristics of 
left ventricular diastolic dysfunction in the community: an echocardiographic survey.’ 
Heart, 92(9):1259-1264 
3. Aguilera, C.M. Gil-Campos, M. Canete, R. Gil, A. (2008) ‘Alterations in plasma and 
tissue lipids associated with obesity and the metabolic syndrome.’ Clin Sci, 114:183-
193 
4. Ahn, S.G. and Lim, S. (2008) ‘Relationship of epicardial adipose tissue by 
echocardiography to coronary artery disease.’ Heart, 94(3): e7 
5. Aijaz, B.K. Ammar, A. Lopez-Jimenez, F. Redfield, M.M, Jacobsen, S.J. Rodeheffer, R.J. 
(2008) ‘Abnormal cardiac structure and function in the metabolic syndrome: a 
population-based study.’ Mayo Clin Proc, 83(12);1350-7 
6. Al-Shaer, M.H. (2005) ‘The impact of ethnicity on the lifetime risk of metabolic 
syndrome and diabetes mellitus.’ The American Journal of Cardiolog, 95(6):819-820 
7. Alam, M. Wardell, J. Andersson, E. Samad, B.A. Nordlander, R. (1999) ‘Characteristics 
of mitral and tricuspid annular velocities determined by pulsed wave Doppler tissue 
imaging in healthy subjects.’ J Am Soc Echocardiogr, 12:618–628 
8. Alberti, K.G. Eckel, R.H.  Grundy, S.M., et al (2009) ‘Harmonizing the metabolic 
syndrome: a joint interim statement of the International Diabetes Federation Task 




Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; 
American Heart Association; World Heart Federation; International Atherosclerosis 
Society; and International Association for the Study of Obesity.’ Circulation,120:1640–
1645 
9. Alberti, K.G. Zimmet, P. and Shaw, J. (2005) ‘The metabolic syndrome—a new 
worldwide definition.’ Lancet, 366:1059–1062 
10. Alberti, G. Zimmet, P. Shaw, J. Grundy, S.M. The IDF consensus worldwide definition of 
the metabolic syndrome.  available at: 
http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf (accessed on 13/10/2010) 
11. Alexander, C.M. Landsman, P.B. Teutsch, S.M. Haffner, S.M. (2003) ‘NCEP-defined 
metabolic syndrome, diabetes, and prevalence of coronary heart disease among 
NHANES III participants age 50 years and older.’ Diabetes, 52:1210-14 
12. Alpert, M.A. (2001) ‘Obesity cardiomyopathy pathophysiology and evolution of the 
clinical syndrome.’ Am J Med Sci,321:225–236 
13. American Diabetes Association. (2012) ‘Standards of medical care in diabetes—2012.’ 
Diabetes Care, 35 (Suppl 1):S11-63 
14. American Diabetes Association. (2006) ‘Diagnosis and classification of diabetes 
mellitus.’ Diabetes Care, 29 (Suppl 1):S43-8 
15. Anand, S.A. Enas, A.E. Pogue, J. Haffner, S. Pearson, T. Yusuf, S. (1998)’Elevated 
Lipoprotein (a) levels in South Asians in North America.’ Metabolism, 47(2): 182-184 




16. Ascaso, J.F. Pardo, S. Real, .JT. Lorente, R.I. Priego, A., et al. (2003) ‘Diagnosing Insulin 
Resistance by Simple Quantitative Methods in Subjects With Normal Glucose 
Metabolism.’ Diabetes Care, 26: 3320–3325 
17. Aubo, C. Senti M. Marrugat, J. Tomas, M. Vila, J. Sala, J. Masia, R. (2000) ‘Risk of 
myocardial infarction associated with Gln/Arg 192 polymorphism in the human 
paraoxonase gene and diabetes mellitus. The REGICOR investigators.’ Eur Heart 
J,21:33-38 
18. Aviram, M. Hardak, E. Vaya, J. Mahmood, S. Milo, S., et al. (2000) ‘Human serum 
paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary 
and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities.’ 
Circulation, 101: 2510-2517 
19. Aviram, M. Rosenblat, M. Billecke, S. et al. (1999) ‘Human serum paraoxonase (PON1) 
is inactivated by oxidised low density lipoprotein and preserved by antioxidants.’ Free 
Radic Biol Med, 26:892-904 
20. Baik, S.H. Ahn, S.G. Choi, J.H. Koh, B.R. Yoo, J.H. Kang, S.J. Choi, B.J. Choi, S.Y. Yoon, 
M.H. Tahk, S.J. Shin, J.H. (2007) ‘The relationship of epicardial adipose tissue to 
metabolic syndrome and cardiovascular risk factors.’ Korean J Med, 72:290-297 
21. Baker, A.R. Silva, N.F. Quinn, D.W. Harte, A.L. Pagano, D. Bonser, R.S., et al. (2006) 
‘Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in 
patients with cardiovascular disease.’ Cardiovasc Diabetol, 5:1 
22. Balarajan R. (1991). ‘Ethnic differences in mortality from ischaemic heart disease and 
cerebrovascular disease in England and Wales.’ BMJ, 302:560–564 




23. Balcerzyk, A. Zak, I. and Krauze, J. (2007) ‘Synergistic effects between Q192R 
polymorphism of paraoxonase 1 gene and some conventional risk factors in 
premature coronary artery disease.’ Arch Med Res, 38:545–550 
24. Balkau, B. and Charles, M.A. (1999) ‘Comment on the provisional report from the 
WHO consultation. European Group for the Study of Insulin Resistance (EGIR).’ Diabet 
Med, 16:442–443 
25. Banerjee, I. (2010) ‘Relationship between Paraoxonase 1 (PON1) gene polymorphisms 
and susceptibility of stroke: a meta-analysis.’ Eur J Epidemiol.,25(7):449-589 
26. Barbieri, M. Bonafe, M. Marfella, R. Ragno, E. Guigliano, D. Franceschi, C., et al. (2002) 
‘LL_paraoxonase genotype is associated with a more severe degree of homeostasis 
model assessment of IR in healthy subjects.’ J Clin Endocrinol Metab, 87:2225 
27. Bayturan, O. Tuzcu, E.M. Lavoie, A., et al. (2010) ‘The metabolic syndrome, its 
component risk factors and progression of coronary atherosclerosis.’ Arch Intern Med, 
170:478 
28. Beaglehole R & Bonita R. (2008) ‘Global public health: a scorecard.’ Lancet  372: 1988–
1996 
29. Bergman, R.N. Kim, S.P. Hsu, I.R. Catalano, K.J. Chiu, J.D. Kabir, M. Richey, J.M. Ader, 
M. (2007) ‘Abdominal obesity: role in the patho- physiology of metabolic disease and 
cardiovascular risk.’ Am J Med,  120:S3–S8 
30. Bhattacharyya, T.  Nicholls, S.J. Topol, E.J. Zhang, R. Yang, X. Schmidtt, D., et al. (2008) 
‘Relationship of Paraoxonase 1 (PON1) Gene Polymorphisms and Functional Activity 
With Systemic Oxidative Stress and Cardiovascular Risk.’ JAMA,  299 (11): 1265-1276 




31. Bhanushali, A.A. Das, B.R. (2010) ‘Genetic variants at the APOE, lipoprotein lipase 
(LpL), cholesteryl ester transfer protein (CETP), and endothelial nitric oxide (eNOS) 
genes and coronary artery disease (CAD): CETP Taq1 B2B2 associates with lower risk 
of CAD in Asian Indians.’ J Community Genet, 1:55–62 
32. Blatter-Garin, M.C. James, R.W. Messmer, S. Barja, F. Pometta, D. (1994) 
‘Quantification of human serum paraoxonase by enzyme linked immunoassay: 
population differences in protein concentrations.’ Biochem, 304:549-554 
33. Borch-Johnsen, K. and Wareham, N. (2010) ‘The rise and fall of the Metabolic 
Syndrome.’ Diabetologia. Available from: http://dx.doi.org/10.1007/s00125-009-
1620-4 [accessed 15 February 2012] 
34. Bosello, O. and Zamboni, M. (2000) ‘Visceral obesity and metabolic syndrome.’ Obes 
Rev, 1:47–56. 
35. Bradshaw, D. Nannan, N. Laubscher, R., et al. (2007) ‘South African national burden of 
disease study 2000. Estimates of provincial mortality.’ Cape Town: Medical Research 
Council. Available at http://www.mrc.ac.za/bod/estimate.pdf (Accessed on 21 April 
2010) 
36. Buysschaert, M. and Bergman, M. (2011) ‘Definition of Prediabetes.’ Med Clin N Am, 
95: 289–297 
37. Cabré, J.J. Martín, F. Costa, B. Piñol, J.L. Llor, J.L. Ortega, Y. Basora, J. Baldrich, M. Solà, 
R. Daniel, J. Hernández, J.M. Saumell, J., et al. (2008) ‘Metabolic syndrome as a 
cardiovascular disease risk factor: patients evaluated in primary care.’ BMC Public 
Health,  8:251 




38. Cappuccio, C.P. (1997) ‘Ethnicity and cardiovascular risk: variations in people of 
African ancestry and South Asian origin.’ Journal of Human Hypertension, 11: 571–576 
39. Ceriello, A. and Motz, E. (2004) ‘Is oxidative stress the pathogenic mechanism 
underlying insulin resistance, diabetes and cardiovascular disease? The common soil 
hypothesis revisited.’ Aterioscler Thromb Vasc Biol, 24:816-823 
40.  Chahal, N.S. Lim, T.K. Jain, P. Chambers, J.C. Kooner, J.S. Senior, R. (2010) ‘Ethnicity-
related differences in left ventricular function, structure and geometry: a population 
study of UK Indian Asian and European white subjects.’ Heart, 96:466-471  
41. Chaowalit, N. Somers, V.K. Pellikka, P.A. Rihal, C.S. Lopez-Jimenez, F. (2006) 
‘Subepicardial adipose tissue and the presence and severity of coronary artery 
disease.’ Atherosclerosis, 18:6354–6359 
42. Chaturvedi, N. (2003) ‘Ethnic differences in cardiovascular disease.’ Heart, 89(6): 681–
686 
43. Cheal, K.L. Abbasi, F. Lamendola, C. McLaughlin, T. Reaven, G.M. Ford, E.S. (2004) 
‘Relationship to insulin resistance of the Adult Treatment Panel III diagnostic criteria 
for identification of the metabolic syndrome.’ Diabetes, 53:1195-1200 
44. Cheatham, B. Vlahos, C.J. Cheatham, L. Wang, L. Blenis, J. Kahn, C.R. (1994) 
‘Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 S6 
kinase, DNA synthesis and glucose transporter translocation.’ Mol Cell Biol, 14:4902–
4911 




45. Chinali, M. de Simone, G. Roman, M.J., et al. (2006) ‘Impact of obesity on cardiac 
geometry and function in a population of adolescents: the Strong Heart study.’ J Am 
Coll Cardiol, 47:2267–2273 
46. Chobanian, A.V. Bakris, G.L. Black, H.R. Cushman, W.C. Green, L.A. Izzo, J.L Jr. Jones, 
D.W. Materson, B.J. Oparil, S. Wright, J.T Jr. Roccella, E.J. (2003) ‘Seventh report of the 
Joint National Committee on prevention, detection, evaluation, and treatment of high 
blood pressure.’ Hypertension, 42: 1206–1252 
47. Chow, C.K. Naidu, S. Raju, K., et al. (2008) ‘Significant lipid, adiposity and metabolic 
abnormalities amongst 4535 Indians from a developing region of rural Andhra 
Pradesh.’ Atherosclerosis, 196(2): 943–952 
48. Christiansen, L. Bathum, L. Frederiksen, H. Chrisitiansen, K. (2004) ‘Paraoxonase 1 
polymorphisms and survival.’ Eur J Hum Genet, 12:843-847 
49. Clendenning, J.B. Humbert, R. Green, E.D. Wood, C. Traver, D. Furlong, C.E. (1996) 
‘Structural organization of the human PON1 gene.’ Genomics, 35: 586–589 
50. Conus, F. Allison, D.B. Rabasa-Lhoret, R., et al. (2004) ‘Metabolic and behavioral 
characteristics of metabolically obese but normal-weight women.’ J Clin Endocrinol 
Metab,  89:5013 
51. Corella, D. Guillen, M. Saiz, C., et al. (2002) ‘Associations of LPL and APOC3 gene 
polymorphisms on plasma lipids in a Mediterranean population: interaction with 
tobacco smoking and the APOE locus.’ J Lipid Res, 43:416-427 
52. Cornier, M. Dabelea, D. Hernandez, T.L. Lindstrom, R.C. Steig, A.J. (2008) ‘The 
Metabolic syndrome.’ Endocrine Reviews, 29(7):777–822 




53. Cosson, S. and Kevorkian, J.P. (2003) ‘Left ventricular diastolic dysfunction: an early 
sign of diabetic cardiomyopathy?’ Diabetes Metab, 29:455-466 
54. Cusi, K. Maezono, K. Osman, A. Pendergrass, M. Patti, M.E. Pratipanawatr, T. 
DeFronzo, R.A. Kahn, C.R. Mandarino, L.J. (2000) ‘Insulin resistance differentially 
affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle.’ J Clin 
Invest, 105:311-320 
55. Cuspidi, C. Meani, S. Valerio, C. Fusi, V. Sala, C. Zanchetti, A. (2005) ‘Prevalence and 
correlates of left atrial enlargement in essential hypertension: role of ventricular 
geometry and the metabolic syndrome: The Evaluation of Target Organ Damage in 
Hypertension study.’ J Hypertens, 23(4):875-822 
56. D’Agostino, R.B Sr. Grundy, S. Sullivan, L.M. Wilson, P.  (2001) ‘Validation of the 
Framingham coronary heart disease prediction scores: results of a multiple ethnic 
groups investigation.’ JAMA,  286(2):180-187 
57. Dahabreh, I.J. Kitsios, G.D. Kent, D.M. Trikalinos, T.A. (2010) ‘Paraoxonase 1 
polymorphisms and ischemic stroke risk: A systematic review and meta-analysis.’ 
Genet Med., 12(10):606-15 
58. Damani, S.B. (2011) ‘Emerging Genomic Applications in Coronary Artery Disease.’ J Am 
Coll Cardiol Intv., 4(5):473-482 
59. Das, U.N. (2002) ‘Is metabolic syndrome X an inflammatory condition?’ Exp Biol Med, 
227:989 




60. De las Fuentes, L. Brown, A. and Mathews, S. (2007) ‘Metabolic syndrome is 
associated with abnormal left ventricular diastolic function independent of left 
ventricular mass.’ European Heart Journal, 28; 553–559 
61. De Marco, M. De Simone, D. Roman, M.J. Chinali, M. Lee, E.T. Calhoun, D. Howard, 
B.V. Devereux, R.B. (2012) ‘Cardiac Geometry and Function in Diabetic or Prediabetic 
Adolescents and Young Adults. The Strong Heart Study.’ Diabetes Care, 34(10): 2300-
2305 
62. Deepa, M. Farooq, S. Datta, M. Deepa, R, Mohan, V. (2007) ‘Prevalence of metabolic 
syndrome using WHO, ATPIII and IDF definitions in Asian Indians: the Chennai Urban 
Rural Epidemiology Study (CURES-34).’ Diabetes Metab Res Rev, 23:127–134 
63. Dekker, J.M. Girman, C. Rhodes, T. Nijpels, G. Stehouwer, C.D. Bouter, L.M. (2005) 
‘Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn study.’ 
Circulation, 112:666-673 
64. Devereux, R.B. Lutas, E.M. Casale, P.N., et al. (1984) ‘Standardization of M-mode 
echocardiographic left ventricular anatomic measurements.’ Am Coll Cardiol, 4:1222–
1230 
65. Devereux, R.B. Alonso, D.R. Lutas, E.M. Gottlieb, G.J. Campo, E. Sachs, I. Reichek, N. 
(1986) ‘Echocardiographic assessment of left ventricular hypertrophy: comparison to 
necropsy findings.’ Am J Cardiol, 57:450–458 
66. Devereux, R.B. Roman, M.J. Paranicas, M. O’Grady, M.J. Lee, E.T. Welty, T.K. Fabsitz, 
R.R. Robbins, D. Rhoades, E.R. Howard, B.V. (2000) ‘Impact of Diabetes on Cardiac 
Structure and Function. The Strong Heart Study.’ Circulation, 101:2271-2276 




67. Dhalla, N.S. Liu, X. Panagia, V., et al. (1998) ‘Subcellular remodeling and heart 
dysfunction in chronic diabetes.’ Cardiovasc Res, 40: 239–247 
68. Dhanaraj, E. Bhanshali, A Jaggi, S. Dutta, P. Jain, S. et al. (2009)’ Predictors of 
metabolic syndrome in Asian north Indians with newly detected type 2 diabetes.’ 
Indian J Med Res, 129:506-514 
69. Dhawan, S. (1995) ‘Birth weights of infants of first generation Asian women in Britain 
compared with second generation Asian women.’ BMJ, 311:86 
70. Didenko, V.V. (2001) ‘DNA probes using fluorescence resonance energy transfer 
(FRET): designs and applications.’ Biotechniques, 31:1106-1116 
71. Ding, J. Hsu, F.C. Harris, T.B. Liu, Y. Kritchevsky, S.B. Szklo, M. Ouyang, P. Espeland, 
M.A. Lohman, K.K. Criqui, M.H. Allison, M. Bluemke, D.A. Carr, J.J. (2009) ‘The 
association of pericardial fat with incident coronary heart disease: the Multi-Ethnic 
Study of Atherosclerosis (MESA).’  Am J Clin Nutr, 90(3):499-504 
72. Dowse, G.K. Gareeboo, H. Alberti, K.G. Zimmet, P. Tuomilehto, J. Purran, A. Fareed, D. 
Chitson, P. Collins, V.R. (1995) ‘Changes in population cholesterol concentrations and 
other cardiovascular risk factor levels after five years of the non-communicable 
disease intervention programme in Mauritius. Mauritius Non-communicable Disease 
Study Group.’ BMJ, 311(7015): 1255–1259 
73. Drukteinis, J.S. Roman, M.J. Fabsitz, R.R., et al. (2007) ‘Cardiac and systemic 
hemodynamic characteristics of hypertension and prehypertension in adolescents and 
young adults. The Strong Heart Study.’ Circulation; DOI: 
10.1161/CIRCULATIONAHA.106.668921 




74. Dumesnil, J.G. Paulin, C. Pibarot, P. Coulombe, D. Arsenault, M. (2002) ‘Mitral annulus 
velocities by Doppler tissue imaging: Practical implications with regard to preload 
alterations, sample position, and normal values.’ J Am Soc Echocardiogr, 15:1226–
1231. 
75. Durrington, P.N. Mackness, B. and Mackness, M.I. (2001) ‘Paraoxonase and 
atherosclerosis.’ Arterioscler Thromb Vasc Biol, 4(Apr 21):473–480 
76. Dutra, E.S. Baiocchi de Carvalho, K.M. Miyazaki, E., et al. (2012) ‘Metabolic syndrome 
in central Brazil: prevalence and correlates in the adult population.’ Diabetology & 
Metabolic Syndrome, 4:20 
77. Eapen, D. Kalra, G.L. Merchant, N. Arora, A. Khan, B.V. (2009) ‘Metabolic syndrome 
and cardiovascular disease in South Asians.’ Vascular Health and Risk Management, 5: 
731–743 
78. Eckel, R.H. Grundy, S.M. Zimmet, P.Z. (2005) ‘The metabolic syndrome.’ Lancet, 
365:1415 
79. Enas, E.A. Chacko, V. Pazhoor, S.G. Chennikkara, H. Devarapalli, H.P. (2007) 
‘Dyslipidemia in South Asian patients. Current Atherosclerosis Report, 9 (5):367–374 
80. Enas, E.A. Singh, V. Gupta, R. Patel, R., et al. (2009) ‘Recommendations of the Second 
Indo-US Health Summit for the prevention and control of cardiovascular disease 
among Asian Indians.’ Indian heart journal, 61:265-274 
81. Eroglu, S. Sade, L.E. Yildirir, A. Bal, U. Ozgul, A.S. et al. ( 2009) ‘Epicardial adipose 
tissue thickness by echocardiography is a marker for the presence and severity of 




coronary artery disease.’ Nutrition, Metabolism and Cardiovascular 
diseases,19(3):211-217 
82. European Study Group on Diastolic Heart Failure. (1998) ‘How to diagnose diastolic 
heart failure.’ Eur Heart J, 19:990–1003 
83. Executive Summary of The Third Report of the National Cholesterol Education 
Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults (Adult Treatment Panel III) final report. (2002) Circulation, 
106:3143–421. 
84. Farkouh, M.E. Rayfield, E. and Fuster, W. (2008) ‘Diabetes and cardiovascular disease.’ 
In: Fuster, W.. O'Rourke, R.A Poole-Wilson, P. (Eds.), Hurst's The Heart (12th ed.), 
McGraw-Hill Company: pp. 2077–2081 
85. Festa, A. D’Agostino, R.J. Howard G., et al. (2000) ‘Chronic subclinical inflammation as 
part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study 
(IRAS).’ Circulation, 102: 42–47 
86. Fischer, M. Baessler, A. Hense, H.W. Hengstenberg, C., et al. (2003) ‘Prevalence of left 
ventricular diastolic dysfunction in the community. Results from a Doppler 
echocardiographic-based survey of a population sample.’ European Heart Journal, 24: 
320–328 
87. Flekac, M. Skrha, J. Zı´dkova´, K. Lacinova´, Z. Hilgertova´, J. (2008) ‘Paraoxonase 1 
gene polymorphisms and enzyme activities in diabetes mellitus.’ Physiological 
Research, 57: 717–726 




88. Florentin, M, Liberopoulos, E.N. Wierzbicki, A.S. Mikhailidis, D.P. (2008) ‘Multiple 
actions of high-density lipoprotein.’ Curr. Opin. Cardiol, 23: 370–378 
89. Ford, E.S. Giles, W.H. and Dietz, W.H. (2002) ‘Prevalence of metabolic syndrome 
among US adults: findings from the Third National Health and Nutrition Examination 
Survey.’ JAMA, 287:356– 359 
90. Ford, E.S. and Giles, W.H. (2003) ‘A comparison of the prevalence of the metabolic 
syndrome using two proposed definitions.’ Diabetes Care, 26:575–581 
91. Ford, E.S. (2005) ‘Risks for all-cause mortality, cardiovascular disease, and diabetes 
associated with the metabolic syndrome: a summary of the evidence.’ Diabetes Care, 
28:1769 
92. Fox, E.R. Alnabhan, N. Penman, A.D. Butler, K.R. Taylor, H.A Jr. Skelton, T.N., et al. 
(2007) ‘Echocardiographic left ventricular mass index predicts incident stroke in 
African Americans: Atherosclerosis Risk in Communities (ARIC) Study.’ Stroke, 38: 
2686-2691 
93. Fraser, A.G. (2009) ‘Echocardiographic epidemiology—an emerging tool for early 
diagnosis, studying pathophysiology, predicting prognosis, and testing treatments.’ 
European Heart Journal, 30: 642–644  
94. Fujihara, F. Yasuda, T. Kawai, Y. Morikawa, N. Arakawa, K. Koda, Y. Soejima, M. 
Kimura-Kataoka, K. Takeshita, H. (2011) ‘First survey of the three gene polymorphisms 
(PON1 Q192R, eNOS E298D and eNOS C-786T) potentially associated with coronary 
artery spasm in African populations and comparison with worldwide data.’ Cell 
Biochemistry and Function, 29 (2):156–163 




95. Fuster, V. Kelly, B.B., editors. (2010) ‘Promoting Cardiovascular Health in the 
Developing World: A Critical Challenge to Achieve Global Health. Institute of Medicine 
(US) Committee on Preventing the Global Epidemic of Cardiovascular Disease: 
Meeting the Challenges in Developing Countries.’ National Academies Press (US); 
Washington DC 
96. Gaidukov, L. Rosenblat, M. Aviram, M. Tawfik, D.S. (2006) ‘The 192R/Q polymorphs of 
serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and 
cholesterol efflux.’ J Lipid Res,  47(11):2492–2502 
97. Galassi, A. Reynolds, K. and He, J. (2006) ‘Metabolic syndrome and risk of 
cardiovascular disease: a meta-analysis.’ Am J Med, 119:812 
98. Galinier, A. Carrière, A. Fernandez, Y. Carpéné, C. André, M. Caspar-Bauguil, S., et al.  
(2006) ‘Adipose tissue proadipogenic redox changes in obesity.’ Journal of Biological 
Chemistry, 281:12682–12687 
99. Gami, A.S. Witt, B.J. Howard, D.E. Erwin, P.J., et al. (2007) ‘Metabolic Syndrome and 
Risk of Incident Cardiovascular Events and Death A Systematic Review and Meta-
Analysis of Longitudinal Studies.’ JACC, 49(4): 403-414 
100. Garcia-Rios, A. Delgado-Lista, J. Perez-Martinez, P. Phillips, C.M. Ferguson, J.F. 
Gjelstad, I.M. (2011) ‘Genetic variations at the lipoprotein lipase gene influence 
plasma lipid concentrations and interact with plasma n-6 polyunsaturated fatty acids 
to modulate lipid metabolism.’ Atherosclerosis,  218(2):416-422 




101. Garrido, R.A. Semeraro, M.B. Temesgen, S.M. Simi, M.R. (2009) ‘Metabolic 
syndrome and obesity among workers at Kanye Seventh-day Adventist Hospital, 
Botswana.’ SAMJ, 99(5): 331-334 
102. Gazino, J.M. (2005) ‘Global burden of cardio vascular disease.’ In: Braunwald 
Eugene, ed. Heart disease a text book of cardiovascular medicine. USA. 7th edition. 
WB Saunders Company. Philadelphia, Pensylvania 
103. Genuth, S. Alberti, K.G. Bennett, P. Buse, J. Defronzo, R. Kahn, R. Kitzmiller, J. 
Knowler, W.C. Lebovitz, H. Lernmark, A. Nathan, D. Palmer, J., et al (2003) ‘Follow-up 
report on the diagnosis of diabetes mellitus.’ Diabetes Care, 26: 3160–3167 
104. Getz, G.S. and Reardon, C.A. (2004) ‘Paraoxonase: a cardioprotective enzyme: 
continuing issues.’ Curr Opin Lipidiol, 15:261-267 
105. Ghanim, H. Aljada, A. Hofmeyer, D, Syed, T. Mohanty, P. Dandona, P. (2004) 
‘Circulating mononuclear cells in the obese are in a proinflammatory state.’ 
Circulation, 110:1564-1571 
106. Ginsberg, H.N. Zhang, Y.L. and Hernandez-Ono, A. (2005) ‘Regulation of plasma 
triglycerides in insulin resistance and diabetes.’ Arch Med Res,  36:232–240 
107. Goedecke, J.H. Jennings, C.L. and Lambert, E.V. (2005) ‘Obesity in South Africa. 
Chronic Diseases of Lifestyle in South Africa since 1995 – 2005.’ Available on: 
http://www.mrc.ac.za/chronic/cdl1995-2005.htm. Accessed on 19 August 2010 
108. Gohlke, J.M. Thomas, R. Zhang, Y. Rosenstein, M.C. Davis, A.P. Murphy, C. (2009) 
‘Genetic and environmental pathways to complex diseases.’ BMC Syst Biol , 3: 46 




109. Goodarzi, M.O. Guo, X. Taylor, K.D. Quinones, M.J. Saad, M.F. Yang, H. Hsueh, W.A. 
Rotter, J.I. (2004) ‘Lipoprotein lipase is a gene for insulin resistance in Mexican 
Americans.’ Diabetes,  53:214–220 
110. Goodarzi, M.O. Guo, X. Taylor, K.D. Quiñones, M.J. Samayoa, C. Yang, H. Saad, M.F. 
Palotie, A. Krauss, R.M. Hsueh, W.A. Rotter, J.I. (2004) ‘Determination and use of 
haplotypes: ethnic comparison and association of the lipoprotein lipase gene and 
coronary artery disease in Mexican-Americans.’ Genet Med , 5:322–327 
111. Goodarzi, M.O. Taylor, K.D. Guo, X. Hokanson, J.E. Haffner, S.M. Cui, J. Chen, Y.D. 
Wagenknecht, L.E. Bergman, R.N. Rotter, J.I. (2007) ‘Haplotypes in the lipoprotein 
lipase gene influence fasting insulin and discovery of a new risk haplotype.’ J Clin 
Endocrinol Metab, 92:293–296 
112. Gordon, G.W. Berry, G. Liang, X.H. Levine, B. Herman, B. (1998) ‘Quantitative 
fluorescence resonance energy transfer measurements using fluorescence 
microscopy.’ Biophys J., 74(5):2702-2713 
113. Gottdiener, J.S. Reda, D.J. Materson, B.J., et al. (1994) ‘Importance of obesity, race 
and age to the cardiac structural and functional effects of hypertension.’ J Am Coll 
Cardiol, 24:1492–1498 
114. Greenlund, K.J. Croft, J.B. and Mensah, G.A. (2004) ‘Prevalence of heart disease and 
stroke risk factors in persons with prehypertension in the United States, 1999–2000.’ 
Arch Intern Med, 164:2113–2118 
115. Groop, L. and Orho-Melander, M. (2001). ‘The dyssmetabolic syndrome.’ J Intern 
Med,  250:105-120 




116. Grundy, S.M. (1997) ‘Small LDL, atherogenic dyslipidemia, and the metabolic 
syndrome.’ Circulation, 95:1–4 
117. Grundy, S.M. Brewer, H.B Jr. Cleeman, J.I. Smith, S.C Jr. Lenfant, C. American Heart 
Association; National Heart, Lung, and Blood Institute. (2001) ‘Executive summary of 
the third report of the National Cholesterol Education Program (NCEP) Expert Panel 
on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult 
Treatment Panel III).’ JAMA, 285(19): 2486–2497 
118. Grundy, S.M. Cleeman, J.I. Daniels, S.R. Donato, K.A. Eckel, R.H. Franklin, B.A. 
Gordon, D.J. Krauss, R.M. Savage, P.J. Smith Jr, S.C. Spertus, J.A. Costa, F. (2005) 
‘Diagnosis and management of the metabolic syndrome. An American Heart 
Association/ National Heart, Lung, and Blood Institute Scientific Statement.’ 
Circulation,  112:2735–2752 
119. Grundy, S.M. (2007) ‘Metabolic syndrome: a multiplex cardiovascular factor.’ 
Journal of Clinical Endocrinology and Metabolism, 92( 2):399–404 
120. Grundy, S.M. (2008) ‘Metabolic syndrome pandemic.’ Arterioscler Thromb Vasc Biol, 
28:629–636  
121. Gulliford, M.C. Mahabir, D. Rocke, B. Chinn, S. Rona, R. (2001) ‘Overweight, obesity 
and skinfold thicknesses of children of African or Indian descent in Trinidad and 
Tobago.’ Int J Epidemiol, 30(5):989-998 
122. Gupta, R. Deedwania, P.C. Gupta, A. Rastogi, S. Panwar, R.B. Kothari, K. (2004) 
‘Prevalence of the metabolic syndrome in an Indian urban population.’ International 
Journal of Cardiology,  97: 257– 261 




123. Gupta, R. Rastogi, P. Sarna, M. Gupta, V.P. Sharma, S.K. Kothari, K. (2007) ‘Body-
mass index, waist-size, waist-hip ratio and cardiovascular risk factors in urban 
subjects.’ J Assoc Physicians India,  55: 621-627 
124. Gupta, N. Singh, S. Maturu, V.N. Sharma, Y.P. Gill, K.D. (2011) ‘Paraoxonase 1 (PON1) 
polymorphisms, haplotypes and activity in predicting cad risk in North-West Indian 
Punjabis.’ PLos One  6(5):e17805. Epub 2011 May 24. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/21629682. (Accessed on 24 June 2012) 
125. Hales, N.P. and Barker, D.J.P. (2001) ‘The Thrifty phenotype hypothesis: Type 2 
Diabetes.’ Br Med Bull, 60 (1): 5-20 
126. Hansel, B. Giral, P. Nobecourt, E. Chantepie, S. Bruckert, E. Chapman, M.J. Kontush, 
A. (2004) ‘Metabolic Syndrome Is Associated with Elevated Oxidative Stress and 
Dysfunctional Dense High-Density Lipoprotein Particles Displaying Impaired 
Antioxidative Activity.’  Journal of Clinical Endocrinology & Metabolism, 89(10): 4963-
4971 
127. Haring, H.U. (1991) ‘The insulin receptor: signally mechanism and contribution to 
the pathogenesis of insulin resistance.’ Diabetologica, 34:848-861 
128. Harding, S. (2003) ‘Mortality of migrants from the Indian subcontinent to England 
and Wales: effect of duration of residence.’ Epidemiology, 14:287–292 
129. Hayden, M.R. Ma, Y. Brunzell, J. Henderson, H.E. (1991) ‘Genetic variants affecting 
human lipoprotein and hepatic lipases.’ Curr Opin Lipidol,  2:104–109 
130. Heller, G.V. (2005) ‘Evaluation of the patient with diabetes mellitus and suspected 
coronary artery disease.’ Am J Med, 118(Suppl 2):9S-14S 




131. Hsieh, C.H. Pei, D. Hung, Y.J. Kuo, S.W. He, C.T. Lee, C.H., et al. (2008) ‘Identifying 
subjects with insulin resistance by using the modified criteria of metabolic syndrome.’ 
J Korean Med Sci, 23: 465-9. Published online 2008 June 20. doi:  
10.3346/jkms.2008.23.3.465 (accessed on 10 September 2010) 
132. Himsworth, H. (1936) ‘Diabetes mellitus: a differentiation into insulin-sensitive and 
insulin-insensitive types.’ Lancet i:127–130 
133. Hokanson, J.E. and Austin, M.A. (1996) ‘Plasma triglyceride level is a risk factor for 
cardiovascular disease independent of high-density lipoprotein cholesterol levels: a 
meta-analysis of population-based prospective studies.’ J Cardiovasc Risk, 3 (2):213-
219 
134. Hokanson, J.E. (1999) ‘Functional variants in the lipoprotein gene and cardiovascular 
disease.’ Curr Opin Lipidol, 10(5):393-399 
135. Hoogeveen, R.C. Gambhir, J.K. Gambhir, D.S. Kimball, K.T. Ghazzaly, K. Gaubatz, J.W. 
Vaduganathan, M. Rao, R.S. Koschinsky, M. Morrisett, J.D. (2001) ‘Evaluation of Lp(a) 
and other independent risk factors for CHD in Asian Indians and their USA 
counterparts.’ J Lipid Res., 42:631– 638 
136. Hu, G. Qiao, Q. Tuomilehto, J. Balkau, B. Borch-Johnsen, K. Pyorala, K. (2004) 
‘Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular 
mortality in nondiabetic European men and women.’ Arch Intern Med, 164:1066-1076 
137. Huang, P.L. (2009) ‘A comprehensive definition for metabolic syndrome.’ Dis Model 
Mech; 2(5-6): 231-237 




138. Huang AQ, Hu YH, Zhan SY, Xu B, Pang ZC, Cao WH, Lu J,Qin Y, Lee LM (2006) 
Lipoprotein lipase gene S447X polymorphism modulates the relation between central 
obesity and serum lipids, a twin study. Int J Obes (Lond) 30:1693–1701 
139. Huddle, K.R.L. and Kalk, W.J. (1994) ‘Practical Diabetes Management’, 3rd edition 
Johannesburg: Wits Diabetes Group 
140. Humphries, S.E. Nicaud, V. Margalef, J. Tiret, L. Talmud, P.J. (1998) ‘Lipoprotein 
lipase gene variation is associated with a paternal history of premature coronary 
artery disease and fasting and and postprandial plasma trigylcerides: the European 
Atherosclerosis Research Study (EARS).’ Atheroscler Thromb Vasc Biol, 18:526-534  
141. Iacobellis, G. Ribaudo, M.C. Assael, F. Vecci, E. Tiberti, C.  Zappaterreno, A. Di 
Mario, U. Leonetti, F. (2003) ‘Echocardiographic epicardial adipose tissue is related to 
anthropometric and clinical parameters of metabolic syndrome: a new indicator of 
cardiovascular risk.’ J Clin Endocrinol Metab, 88: 5163–5168  
142. Iacobellis, G. Assael, F. Ribaudo, M.C. Zappaterreno, A. Alessi, G. Di Mario, U. 
Leonetti, F. (2003) ‘Epicardial fat from echocardiography: a new method for visceral 
adipose tissue prediction.’ Obes Res., 11(2):304-310 
143. Iacobellis, G. and Leonetti, F. (2005) ‘Epicardial adipose tissue and insulin 
resistance in obese subjects.’ J Clin Endocrinol Metab, 90:6300–6302 
144. Imai, Y. Morita, H. Kurhara, H. Sugiyama, T. Kato, N. Ebihara, A. Hamada, C., et al. 
(2000) ‘Evidence for association between paraoxonase gene polymorphisms and 
atherosclerotic diseases.’ Atherosclerosis, 149:435-442 




145. International Diabetes Federation. (2005) ‘The IDF consensus worldwide definition 
of the metabolic syndrome.’ Available  from 
http://www.idf.org/webdata/docs/Metabolic_syndrome_definition. (Accessed 24 
February 2009) 
146. Jarvik, G.P. Hatsukami, T.S. Carlson, C., et al. (2003) ‘Paraoxonase activity, but not 
haplotype utilizing the linkage disequilibrium structure, predicts vascular disease.’ 
Arterioscler Thromb Vasc Biol, 231:1465-1471 
147. Jarvik, G.P. Rozek, L.S. Brophy, V.H., et al. (2000) ‘Paraoxonase (PON1) phenotype is 
a better predictor of vascular disease than is PON1192 or PON155 genotype.’ 
Arterioscler Thromb Vasc Bio,  20:2441-2447 
148. Jennings, C.L. Lambert, E.V. Collins, M. Levitt, N.S. Goedecke, J.H. (2009) ‘The 
atypical presentation of the metabolic syndrome components in black African women: 
the relationship with insulin resistance and the influence of regional adipose tissue 
distribution.’ Metabolism, 58(2):149-157 
149. Jensen, M.K. Rimm, E.B. Rader, D. Schmidt, E.B. et al. (2009) ‘S447X variant of the 
lipoprotein lipase gene, lipids, and  risk of coronary heart disease in 3 prospective 
cohort studies.’ Am Heart J, 157:384-390 
150. Jiang, Z.Y. Lin, Y.W. Clemont, A. Feener, E.P. Hein, K.D. Igarashi, M. Yamauchi, T. 
White, M.F. King, G.L. (1999) ‘Characterization of selective resistance to insulin 
signaling in the vasculature of obese Zuker ( fa / fa ) rats.’ J Clin Invest, 104:447-457 
151. JiangPing, L. Xiaobin, W. Yong, H. TianHua, N. ChangZhong, C. GuoYing, Z., et al.  
(2005) ‘PON-1 polymorphism, diabetes, obesity and risk of myocardial infarction: 




modifying effects of diabetes mellitus and myocardial infarction.’ Genet Med, 7(1):58-
63  
152. Jonas, M.A. Oates, J.A. Ockene, J.K. Hennekens, C.H. (1992) ‘Statement on smoking 
and cardiovascular disease for healthcare professionals: American Heart Association.’ 
Circulation, 86:1664-1669 
153. Joy, T. Lahiry, P. Pollex, R.L. Hegele, R.A. (2008) ‘Genetics of the metabolic 
syndrome.’ Current Diabetes Reports, 8: 141–148 
154. Jovinge, S. Hamsten, A. Tomvall, P., et al. (1998) ‘Evidence for the role of tumor 
necrosis factor alpha in disturbances of triglycerides and glucose metabolism 
predisposing to coronary heart disease). Metabolism, 47:113 
155. Juhan-Vague, I. Alessi, M.C. Mavri, A. Morange, P.E. (2003) ‘Plasminogen activator 
inhibitor-1, inflammation, obesity, insulin resistance and vascular risk.’ J Thromb 
Haemost, 1:1575–1579 
156. Kaan, O. Balcioglu, A.S. Tavil, Y., et al. (2008) ‘A relationship between 
echocardiographic subepicardial adipose tissue and metabolic syndrome.’ Int J 
Cardiovasc Imaging, 24:577–583 
157. Kahn, R. Buse, J. Ferrannini, E. Stern, M. (2005). ‘The metabolic syndrome: time for a 
critical appraisal: joint statement from the American Diabetes Association and the 
European Association for the Study of Diabetes.’ Diabetes Care,  28:2289 –2304 
158. Kain, K. Catto, A.J. and Grant, P.J. (2003) ‘Associations between insulin resistance 
and thrombotic risk factors in high-risk south Asian subjects.’ Diabet Med, 20:651-655 




159. Kalk, W. and Joffe, B. (2007) ‘Differences in coronary heart disease prevalence and 
risk factors in African and White patients with type 2 diabetes.’ Diabetes Res Clin 
Pract,  77(1):107-112 
160. Kalk, W. and Joffe, B. (2008) ‘The metabolic syndrome, insulin resistance and its 
surrogates in African and White subjects with type 2 diabetes in South Africa.’ Metab 
Syndr Relat Disord, 6:247– 255 
161. Kassi, E. Pervanidou, P. Kaltsas, G. Chrousos, G. (2011) ‘Metabolic Syndrome: 
definitions and controversies.’ BMC Medicine, 9:48 
162. Kastelein, J.J. Ordovas, J.M. Wittekoek, M.E. Pimstone, S.N. Wilson, W.F. Gagne, S.E. 
Larson, M.G. Schaefer, E.F. Boer, J.M. Gerdes, C. Hayden, M.R. (1999) ‘Two common 
mutations (D9N, N291S) in lipoprotein lipase: a cumulative analysis of their influence 
on plasma lipids and lipoproteins in men and women.’ Clin Genet, 56:297–305 
163. Kastelein, J.J. Jukema, J.W. Zwinderman, A.H. Clee, S.M. van Boven, A.J. Jansen, H. 
Rabelink, T.J. Peters, R.J. Lie, K.I. Liu, G. Bruschke, A.V. Hayden, M.R. for the REGRESS 
Study Group. (2000) ‘Lipoprotein lipase activity is associated with severity of angina 
pectoris.’ Circulation, 102:1629–1633 
164. Kathiresan, S. Melander, O. Guiducci, C., et al. (2008) ‘Six new loci associated with 
blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or 
triglycerides in humans.’ Nat Genet., 40:189–197 
165. Kedia, G. Habibzadeh, M.R. Kudithipudi, V., et al. (2008) ‘Using traditional 
measurements of the left atrial diameter to predict the left atrial volume index.’ 
Echocardiography, 25(1):36-39 




166. Ker, J.A. Rheeder, P. and Van Tonder, R. (2007) ‘Frequency of the metabolic 
syndrome in screened South African corporate executives.’ CVJSA, 8( 1 ): 30-31 
167. Kern, P.A. Ong, J.M. Saffari, B. Carty, J. (1990) ‘The effects of weight loss on the 
activity and expression of adipose-tissue lipoprotein lipase in very obese humans.’ N 
Engl J Med., 322:1053–1059 
168. Kerkeni, M. Addad, F. Chauffert, M. Chuniaud, L. Miled, A. Trivin, F. Maaroufi, K. 
(2006) ‘Hyperhomocysteinemia, paraoxonase activity and risk of coronary artery 
disease.’ Clinical Biochemistry, 39 821–825 
169. Kershaw, E.E. Flier, J.S. (2004) ‘Adipose tissue as an endocrine organ.’ J Clin 
Endocrinol Metab., 89(6):2548-2556 
170. Kim, C.H. and Younossi, Z.M. (2008) ‘Non-alcoholic fatty liver disease: a 
manifestation of the metabolic syndrome.’ Cleveland Clinic Journal of Medicine,  75: 
721–728 
171. Kim, N.S.  Kang, K. Cha, M.H. Kang,  B. Moon, J. Kang, B.  Yu, B. Kim, Y. Choi, S.M.  
Bang, O. (2007) ‘Decreased paraoxonase-1 activity is a risk factor for ischemic stroke 
in Koreans.’ Biochemical and Biophysical Research Communications, 364:157–162 
172. Kim, Y. Shin, M. Kim, Y. Kang, W.C. Kim, B.R. Moon, J. Chung, W. Ahn, T.H. Shin, 
E.K. (2011) ‘The impact of diabetes duration on left ventricular diastolic function and 
cardiovascular disease.’ Postgrad Med J, 10:1136  
173. Koh, K.K. Han, S.H. and Quon, M.J. (2005) ‘Inflammatory markers and the 
metabolic syndrome: insights from therapeutic interventions.’ J Am Coll Cardiol, 
46:1978 




174. Komurcu-Bayrak, E. Onat, E. Poda, M. Humphries, S.E., et al. (2007) ‘The S447X 
variant of lipoprotein lipase gene is associated with metabolic syndrome and lipid 
levels among Turks.’ Clinica Chimica Acta, 383 :110–115 
175. Krishnaveni, G.V. Hill, J.C. Veena, S.R. Leary, S.D. Saperia, J. Chachyamma, K.J. Karat, 
S.C. Fall, C.H. (2005) ‘Truncal adiposity is present at birth and in early childhood in 
South Indian children.’  Indian Pediatr, 42:527–538 
176. Kruger, H.S. Venter, C.S. Vorster, H.H. (2003) ‘Physical inactivity as a risk factor for 
cardiovascular disease in communities undergoing rural to urban transition: the 
THUSA study.’ Cardiovasc J S Afr, 14:16–23 
177. Kusminski, C.M., Shetty, S., Orci, L.,Unger,R.H., Scherer,P.E. (2009)‘Diabetes and 
apoptosis:Lipotoxicity.’Apoptosis, 14:1484-1495 
178. Kuznetsova, T. Herbots, L. Jin, Y. Stolarz-Skrzypek, K. Staessen, J.A. (2010) ‘Systolic 
and diastolic left ventricular dysfunction: from risk factors to overt heart failure.’  
Expert Review of Cardiovascular Therapy, 8 (2):251-258 
179. Kwok, P.Y. and Chen, X. (2003) ‘Detection of single nucleotide polymorphisms.’ 
Curr Issues Mol Biol, 5(2):43-60 
180. Kylin, E. (1923) ‘Studien ueber das Hypertonie-hyperglykamie-
Hyperurikamiesyndrom.’ Zentralblatt fuer Innere Medizin, 44:105-127 Available on: 
http://www.medscape.org/viewarticle/458372. (Accessed on 17 September 2009) 
181. Lakka, H.M. Laaksonen, D.E. Lakka, T.A. Niskanen, L.K. Kumpusalo, E. Tuomilehto, J. 
Salonen, J.T. (2002) ‘The metabolic syndrome and total cardiovascular disease 
mortality in middle-aged men.’ JAMA, 288:2709–2716 




182. Landis, J.R. and Koch, G.G. (1977) ‘The measurement of observer agreement for 
categorical data.’ Biometrics, 33:159-174 
183. Lang, R.M. Bierig, M. Devereux, R.B., et al. (2006) ‘Recommendations for chamber 
quantification.’ Eur J Echocardiogr, 7(2):79-108 
184. Larsson, B. (1991) ‘Obesity, fat distribution and cardiovascular disease.’ Int J 
Obesity, 15:53–57  
185. Lavi, S. McConnell, J.P. Lavi, R. Barsness, G.W. Rihal, C.S. Novak, G.D., et al.  (2008) 
‘Association between the Paraoxonase-1 192Q>R Alleleic Variant and Coronary 
Endothelial Dysfunction in Patients with Early Coronary Artery Disease.’ Mayo Clin 
Proc., 83(2):158-164 
186. Lee, J. Tan, C.S. Chia, K.S., et al. (2004) ‘The lipoprotein lipase S447X polymorphism 
and plasma lipids: interactions with APOE polymorphisms, smoking and alcohol 
consumption.’ J Lipid Res, 45:1132-1139 
187. Leeder, S. Raymond, S. Greenberg, H. (2004) ‘Race against time: The challenge of 
cardiovascular disease in developing economies.’ New York: Columbia University  
188. Leviev, I. Kalix, B. Brulhart, M. James, R.W. (2001) ‘The paraoxonase PON 1 promoter 
polymorphism is associated with increased serum glucose concentrations in non-
diabetic patients.’ Diabetologia, 44:1177-1183 
189. Levy, A.P. (2003) ‘Genetics of cardiovascular disease: identification of a major 
susceptibility gene.’ Acta Diabetol, 40:S330–S333 




190. Levy, D, Garrison, R.J. Savage, D.D. Kannel, W.B. Castelli, W.P. (1990) ‘Prognostic 
implications of echocardiographically determined left ventricular mass in the 
Framingham Heart Study.’ N Engl J Med, 322: 1561-1566 
191. Libby, P. (2002) ‘Inflammation in atherosclerosis.’ Nature, 420(6917):868-874 
192. Li, H. Liu, D. and Liang, C. (2003) ‘Paraoxonase gene polymorphisms, oxidative 
stress, and diseases.’ J Mol Med, 81:766-779 
193. Lim, W.Y.A. Chia, Y.Y. Liong, S.Y. Ton, S.H. Kadir, K.A. Husain, S.N.  (2009) 
‘Lipoprotein lipase expression, serum lipid and tissue lipid deposition in orally-
administered glycyrrhizic acid-treated rats.’ Lipids in Health and Disease, 8:31 
194. Lin, S.X. Pi, L. and Sunyer, E.X. (2007) ‘Prevalence of the metabolic syndrome among 
US middle-aged and older adults with and without diabetes-a preliminary analysis of 
the NHANES 1999-2002 data.’ Ethn Dis, 17:35-39 
195. Lindsay, R.S. and Howard, B.V. (2004) ‘Cardiovascular risk associated with the 
metabolic syndrome.’ Curr Diab Rep, 4:63 
196. Liu, J.E. Palmieri, V. Roman, M.J. Bella, J.N. Fabsitz, R. Howard, B.V. Welty, T.K. Lee, 
E.T. Devereux, R.B. (2001) ‘The impact of diabetes on left ventricular filling pattern in 
normotensive and hypertensive adults: The Strong Heart Study.’ J Am Coll Cardiol, 
37:1943–1949 
197. López-Ruiz, A. Jarabo, M.M. Martínez-Triguero, M.L. Morales-Suárez-Varela, M. Solá, 
E. Bañuls, C. (2009) ‘Small and dense LDL in familial combined hyperlipidemia and 
N291S polymorphism of the lipoprotein lipase gene.’ Lipids in Health and Disease, 
8:12 




198. Low, S. Chin, M.C. Ma, S. Heng, D. Deurenberg-Yap, M. (2009) ‘Rationale for 
Redefining Obesity in Asians.’ Ann Acad Med Singapore, 38:66-74 
199. Lusis, A.J. Fogelman, A.M. and Fonarow, G.C. (2001) ‘Genetic basis of 
atherosclerosis: part I: new genes and pathways.’ Circulation, 110:1868–1873 
200. Lusis, A.J. Mar, R. and Pajukanta, P. (2004) ‘Genetics of atherosclerosis.’ Annu Rev 
Genomics Hum Genet,  5:189–218 
201. Mackness, M.I. Arrol, S. Abbot, C. Durrinton, P.N. (1993) ‘Protection of low-density 
lipoprotein against oxidative modification by high-density lipoprotein associated 
paraoxonase.’ Atherosclerosis ,104:129-135 
202. Mackness, B. Davies, G.K. Turkie, W., et al. (2001) ‘Paraoxonase status in coronary 
heart disease: are activity and concentration more important than genotype?’ 
Arterioscler Thromb Vasc Biol, 21:1451-1457 
203. Mackness, B. Durrington, P. McElduff, P., et al. (2003) ‘Low paraoxonase activity 
predicts coronary events in the Caerphilly Prospective Study.’ Circulation, 107:2775-
2779 
204. Maddux, B.A. See, W. Lawrence, J.C. Goldfine, A.L. et al. (2001) ‘Protection Against 
Oxidative Stress–Induced Insulin Resistance in Rat L6 Muscle Cells by Micromolar 
Concentrations of α-Lipoic Acid.’ Diabetes, 50:404–410 
205. Mahabadi, A.A. Massaro, J.M. Rositi, G.A. Levy, D. et al. (2009) ‘Association of 
pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular 
disease burden: the Framingham Heart Study.’ European Heart Journal, 30: 850–856 




206. Malloy, M.J. and Kane, J.P. (2001) ‘A risk factor for atherosclerosis: triglyceride-rich 
lipoproteins.’ Adv Intern Med, 47:111-136 
207. Marchington, J.M. Mattacks, C.A. and Pond, C.M. (1989) ‘Adipose tissue in the 
mammalian heart and pericardium: structure, foetal development and biochemical 
properties.’ Comp Biochem Physiol B, 94: 225–232 
208. Märin, P. Andersson, B. Ottosson, M. Olbe, L. Chowdhury, B. Kvist, H. Holm, G. 
Sjöström, L. Björntorp, P. (1992) ‘The morphology and metabolism of intra-abdominal 
adipose tissue in men.’ Metabolism,  41:1242–1248 
209. Maritim, A.C. Sanders, R.A. and Watkins, J.B. (2003) ‘Diabetes, oxidative stress and 
antioxidants: a review.’ J Biochem Mol Toxicol,  17:24-38 
210. Marmot, M. (2000) ‘Multilevel approaches to understanding social determinants.’ 
In: Berkman LF, Kawachi I, editor. Social epidemiology. Oxford. Oxford University 
Press; pp. 349–367 
211. Marsella, R. Vari, R. D`Archivio, M., et al. (2006) ‘Oxidised LDL modulate 
adipogenesis in 3T-L1 preadipocytes by affecting the balance between cell 
proliferation and differentiation.’ FEBS Lett., 580:2421–2429 
212. Martinelli, N. Girelli, D. Olivieri, O.,et al. (2005) ‘Interaction between metabolic 
syndrome and PON1 polymorphisms as a determinant of the risk of coronary artery 
disease.’ Clin Exp Med, 5:20–30 
213. Martínez-Salazar, M.F. Almenares-López, D. García-Jiménez, S. Sánchez-Alemán, 
M.A. Juantorena-Ugás, A. Ríos, C. Monroy-Noyola, A. (2011) ‘Relationship between 




the paraoxonase (PON1) L55M and Q192R polymorphisms and obesity in a Mexican 
population: a pilot study.’ Genes Nutr., 6(4):361-368 
214. Matthews, D.R. Hosker, J.P. Rudenski, A.S. Naylor, B.A. Treacher, D.F. Turner, R.C. 
(1985) ‘Homeostasis model assessment: insulin resistance and beta-cell function from 
fasting plasma glucose and insulin concentrations in man.’ Diabetologia, 28 (7): 412–
419  
215. Mayosi, B.M. Flisher, A.J. Lalloo, U.G. Sitas, F. Tollman, S.M. Bradshaw, D. (2009) 
‘The burden of non-communicable diseases in South Africa.’ Lancet, 374:934–947  
216. Mazurek, T. Zhang, L. Zalewski, A. Mannion, J.D. Diehl, J.T. Arafat, H., et al. (2003) 
‘Human epicardial adipose tissue is a source of inflammatory mediators.’ Circulation,  
108: 2460–2466 
217. Mbanya, J.C. Motala, A.A. Sobngwi, E. Assah, F.K. Enoru, S.T. (2010) ‘Diabetes in sub-
Saharan Africa.’ Lancet , 375:2254–2266 
218. McGladdery, S.H. Pimstone, S.N. Clee, S.M. Bowden, J.F. Hayden, M.R. Frohlich, J.J. 
(2001) ‘Common mutations in the lipoprotein lipase gene (LPL): effects on HDL-
cholesterol levels in a Chinese Canadian population.’ Atherosclerosis, 156(2):401-407 
219. McKeigue, P.M. Shah, B. and Marmot, M.G. (1991) ‘Relation of central obesity and 
insulin resistance with high diabetes prevalence and cardiovascular risk in south 
Asians.’ Lancet, 337:382-386 
220. McNeill, A.M. Rosamond, W.D. Girman, C.J., et al. (2005) ‘The metabolic syndrome 
and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in 
Communities study.’ Diabetes Care, 28(2):385-390 




221. McPhee, S.J. and Hammer, G.D. (2010) ‘Cardiovascular diseases”. In: 
Pathophysiology of Disease: An Introduction to Clinical Medicine. 6th Edition. McGraw-
Hill Medical  
222. Mead, J.R. and Ramji, D.P. (2005) ‘The pivotal role of lipoprotein lipase in 
atherosclerosis.’ Cardiovasc Res, 55:261–269 
223. Mehan, M.B. Srivastava, N. and Pandya, H. (2006) ‘Profile of NCD risk factors in an 
Industrial setting.’ J Postgrad Med,  52 : 167-173 
224. Meigs, J.B. Wilson, P.W. Nathan, D.M., et al. (2003) ‘Prevalence and characteristics 
of the metabolic syndrome in the San Antonio Heart and Framingham Offspring 
studies.’ Diabetes, 52:2160-2167 
225. Mente, A. Yusuf, S. Islam, S. McQueen, M.J. Tanomsup, S. Onen, C.L. Rangarajan, S. 
Gerstein, H.C. Anand, S.S. INTERHEART Investigators. (2010) ‘Metabolic syndrome and 
risk of acute myocardial infarction a case-control study of 26,903 subjects from 52 
countries.’ J Am Coll Cardiol, 55:2390-2398. 
226. Misra, A. (2003) ‘Body composition and the metabolic syndrome in Asian Indians: a 
saga of multiple adversities.’ Natl Med J India, 16 : 3-7  
227. Misra, A. Vikram, N.K. Arya, S. Pandey, R.M. Dhingra, V. Chatterjee, A., et al. (2004) 
‘High prevalence of insulin resistance in postpubertal Asian Indian children is 
associated with adverse truncal body fat patterning, abdominal adiposity and excess 
body fat.’ Int J Obes Relat Metab Disord, 28 : 1217-1226 
228. Misra, A. and Khurana, L. (2011) ‘Obesity-related non-communicable diseases: South 
Asians vs White Caucasians.’ Int J Obes (London), 35(2):167-87.  




229. Misra, K.B. Endemann, S.W. and Ayer, M. (2005) ‘Leisure time physical activity and 
metabolic syndrome in Asian Indian immigrants residing in northern California.’ Ethn 
Dis, 15 : 627-634 
230. Misra, R. Patel, T. Kotha, P. Raji, A. Ganda, O. Banerji, M., et al. (2010) ‘Prevalence of 
diabetes, metabolic syndrome and cardiovascular risk factors in US Asian Indians: 
results from a national study.’ Journal of Diabetes and its complications, 24:145-153 
231. Miyata, K. Shimokawa, H. Kandabashi, T. Higo, T. Morishige, K. Eto, Y., et al. (2000) 
‘Rho-kinase is involved in macrophage-mediated formation of coronary vascular 
lesions in pigs in vivo.’ Arterioscler Thromb Vasc Biol, 20: 2351–2358 
232. Modan, M. Halkin, H. Almog, S., et al. (1985) ‘Hyperinsulinemia: a link between 
hypertension obesity and glucose intolerance.’ J Clin Invest., 75: 809–811 
233. Mogelvang, R. Sogaard, P. Pedersen, S.A. Olsen, N.T. Schnohr, P. Jensen, J.S. (2009)  
‘Tissue Doppler echocardiography in persons with hypertension, diabetes, or 
ischaemic heart disease: the Copenhagen City Heart Study.’ Eur Heart J, 30:731–739. 
234. Mohamed, R.H. Karam, R.A. and Abd El-Aziz, T.A. (2010) ‘The relationship between 
paraoxonase1-192 polymorphism and activity with coronary artery disease.’ Clin 
Biochem,  43(6):553-558 
235. Mollentze, W.F. Moore, A.J. Weigh, D.J., et al. (1995) ‘Coronary heart disease risk 
factors in a rural and urban Orange Free State black population.’ S Afr Med J 85(2):90-
96  
236. Mouhamed, D.H.  Ezzaher, A. Mechri, A.  Neffati, F. Omezzine, A.  Bouslama, A.  
Gaha, L.  Douki, W. Najjar, M.F. (2011) ‘Effect of cigarette smoking on paraoxonase 1 




activity according to PON1 L55M and PON1 Q192R gene polymorphisms.’ Environ 
Health Prev Med, Dec 29. [Epub ahead of print] 
237. Mohan, V. Shanthirani, C.S. and Deepa, R. (2003) ‘Glucose intolerance (diabetes 
and IGT) in a selected south Indian population with special reference to family history, 
obesity and lifestyle factors: the Chennai Urban Population Study (CUPS 14).’ J Assoc 
Physicians India, 51 : 771-777 
238. Morcos, M. Humpert, P. Bierhaus, A. Nawroth, P. (2009) ‘The unsolved problem of   
diabetes mellitus type 2 and associated complications.’ Chirurg, 80 (5): 400-404 
239. Motala, A.A. Omar, M.A. and Gouws, E. (1993) ‘High Risk of Progression to NIDDM 
in South - African Indians with Impaired Glucose Tolerance.’ Diabetes, 42, 556-563 
240. Motala, A. Esterhuizen, T. Piries, F.J. Omar, M.A.K. (2011) ‘The Prevalence of 
Metabolic Syndrome and Determination of the Optimal Waist Circumference Cutoff 
Points in a Rural South African Community.’  Diabetes Care,  February 17 
241. Motulsky, A.G. and Brunzell, J.D. (2002) ‘Genetics of coronary atherosclerosis.’ In: 
The genetic basis of Common Diseases. 2nd ed. King RA, Rotter JI, Motulsky AG, Eds. 
New York, Oxford University Press 
242. Mozaffarian, D. Wilson, P.W.F. Kannel, W.B. (2008) ‘Beyond Established and Novel 
Risk Factors. Lifestyle Risk Factors for Cardiovascular Disease.’ Circulation, 117: 3031-
3038 
243. Mukhopadhyay, B. Sattar, N. and Fisher, M. (2005) ‘Diabetes and Cardiac Disease in 
South Asians.’ British Journal of Diabetes and Vascular Disease, 5(5):253-259 




244. Murray, C.J.L. and Lopez, A.D. (1994) ‘Global comparative assessments in the health 
sector.’ Geneva, Switzerland: World Health Organization 
245. Murthy, V. Julien, P. and Gagne, C. (1996) ‘Molecular pathobiology of the human 
lipoprotein lipase gene.’ Pharmacol Ther,  70: 101–135 
246. Nagueh, S.F. Appleton, C.P. Gilleber, T.C., et al. (2009) ‘Recommendations for the 
evaluation of left ventricular diastolic function by echocardiography.’ J Am Soc 
Echocardiogr, 22:107 
247. Nagueh, S.F. Sun, H. Kopelen, H.A. Middleton, K.J. Khoury, D.S. (2001) 
‘Hemodynamic determinants of the mitral annulus diastolic velocities by tissue 
Doppler.’ J Am Coll Cardiol, 37:278-285  
248. Nagueh, S.F. Middleton, K.J. Kopelen, H.A. Zoghbi, W.A. Quinones, M.A. (1997) 
‘Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular 
relaxation and estimation of filling pressures.’ J Am Coll Cardiol., 30: 1527–1533 
249. National Cholesterol Education Program (NCEP) Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel 
III). (2001) ‘Third report of the National Cholesterol Education Program (NCEP).’ JAMA, 
285:2486-2497 
250. National Institutes of Health. (1998) ‘Clinical guidelines on the identification, 
evaluation, and treatment of overweight and obesity in adults: executive summary. 
Expert Panel on the Identification, Evaluation, and Treatment of Overweight in 
Adults.’ Am J Clin Nutr ,68(4):899–917 




251. Nauck, M. Wieland, H. and Ma¨rz, W. (1999) ‘Rapid, Homogeneous Genotyping of 
the 4G/5G Polymorphism in the Promoter Region of the PAI1 Gene by Fluorescence 
Resonance Energy Transfer and Probe Melting Curves.’ Clinical Chemistry, 45(8): 
1141–1147  
252. Neel, J.V. (1962) ‘Diabetes Mellitus: a ‘thrifty’ genotype rendered detrimental by 
‘progress’?’ Am J Hum Genet,  14: 353-362 
253. Ntyintyane, L.M. Panz, V.R. Raal, V.R. Gill, G.V. (2007) ‘Postprandial lipaemia, 
metabolic syndrome and LDL particle size in urbanised South African blacks with and 
without coronary artery disease.’ International Journal of Medicine, 101 (2): 111-119 
254. Nugent, A.P. (2004) ‘The metabolic syndrome.’ Nutrition Bulletin, 29 (1): 36-43 
255. Ockene, I.S. and Miller, N.H. (1997) ‘Cigarette Smoking, Cardiovascular Disease, and 
Stroke. A Statement for Healthcare Professionals from the American Heart 
Association.’ Circulation,  96: 3243-3247 
256. Ogah, O.S. Adebanjo, A>T. Adedeji, S.O. Tarwanger, J.J. (2006) ‘Echocardiography in 
Nigeria: use, problems, reproducibility and potentials.’ Cardiovascular Ultrasound,  
4:13 
257. Oh, J.K Hatle, L. Tajik, J. Little, W.C. (2006) ‘Diastolic Heart Failure Can Be Diagnosed 
by Comprehensive Two-Dimensional and Doppler Echocardiography.’ J Am Coll 
Cardiol., 47(3):500-506 




258. Oka, K. Tkalcevic, G.T. Nakano, T. Tucker, H. Ishimura-Oka, K. Brown, W.V. (1990) 
‘Structure and polymorphic map of human lipoprotein lipase gene.’ Biochim. Biophys. 
Acta, 1049:21-26 
259. Olivera, S.A. Mansur, A.P. Ribiero, C.C. Ramires, J.A. Annichino-Bizzacchi, J.M. (2004) 
‘PON1 M/L 55 mutation protects high-risk patients against coronary heart disease.’ Int 
J Cardiol., 94:73-77 
260. Omar, M.A. Seedat, M.A. Dyer, R.B. Motala, A.A. (1988) ‘Diabetes and hypertension 
in South African Indians. A community study.’ S. Afr. Med. J.,  73:635-637 
261. Omar, M.A. Seedat, M.A. Motala, A.A. Dyer, R.B. Becker, P. (1993) ‘The prevalence 
of diabetes mellitus and impaired glucose tolerance in a group of urban South African 
blacks.’ S. Afr. Med. J., 83:641-643  
262. Omar, M.A. Seedat, M.A Dyer, R.B. Motala, A.A. Knight, L.T. Becker, P.J. (1994) 
‘South African Indians show a high prevalence of NIDDM and bimodality in plasma 
glucose distribution patterns.’ Diabetes Care, 17:70-73 
263. Ommen, S.R. Nishimura, R.A. Appleton, C.P. Miller, F.A. Oh, J.K. Redfield, M.M. Tajik, 
A.J. (2000) ‘Clinical utility of Doppler echocardiography and tissue Doppler imaging in 
the estimation of left ventricular filling pressures: a comparative simultaneous 
Doppler-catheterization study.’ Circulation, 102:1788 –1794 
264. Onat, A. Ozhan, H. Erbilen, E. Albayrak, S. Küçükdurmaz, Z. Can, G. Keleş, I. 
Hergenç, G. (2009) ‘Independent prediction of metabolic syndrome by plasma 
fibrinogen in men, and predictors of elevated levels.’ Int J Cardiol, 135:211-217 




265. Ong, K.K and Loos, R.J.F. (2007) ‘Rapid infancy weight gain and subsequent 
obesity: Systematic reviews and hopeful suggestions.’ 29 MAR 2007 
DOI: 10.1080/08035250600719754. (Accessed on 06/02/2012) 
266. Opie, L.H. (2007) ‘Metabolic syndrome.’ Circulation, 115: e32-e35 
267. Opie, L.H and Mayosi, B. (2005) ‘Cardiovascular disease in sub-Saharan Africa.’ 
Circulation, 112:3536-3540 
268. Owan, T.E. Hodge, D.O. Herges, R.M. Jacobsen, S.J. Roger, V.L. Redfield, M.M. (2006) 
‘Trends in prevalance and outcome of heart failure with preserved ejection fraction.’ 
N Engl J Med, 355:251–259. 
269. PAHO/WHO. (1999).a. Trinidad and Tobago: Basic Country Health Profiles, 
Summaries. PAHO/WHO Web page. Country Health Profiles Available on 
(http://www.paho.org) (Accessed 31 March 2012) 
270. Park, J.H. Park, Y.S. Kim, Y.J. Lee, I.S. Kim, J.H. Lee, J.H. Choi, S.W. Jeong, J.O. Seong, 
I.W. (2010) ‘Effects of statins on the epicardial fat thickness in patients with coronary 
artery stenosis underwent percutaneous coronary intervention: comparison of 
atorvastatin with simvastatin/ezetimibe.’ J Cardiovasc Ultrasound, 18(4):121-126 
271.  Pan, C.Y. So, W.Y. Khalid, B.A.K., et al., on behalf of the ASDIAB Study Group. (2004) 
‘Metabolic, immunological and clinical characteristics in newly diagnosed Asian 
diabetes patients aged 12-40 years.’ Diabet Med, 21:1007- 1013 
272. Patel, J.V. Vyas, A. Cruickshank, J.K. Prabhakaran, D. Hughes, E. Reddy, K.S. 
Mackness, M.I. Bhatnagar, D. Durrington, P.N. (2006) ‘Impact of migration on 




coronary heart disease risk factors: comparison of Gujaratis in Britain and their 
contemporaries in villages of origin in India.’ Atherosclerosis, 185:297–306 
273. Pati, N. and Pati, U. (1998) ‘Paraoxonase gene polymorphism and coronary artery 
disease in Indian subjects.’ International Journal of Cardiology, 66:165-168 
274. Paulus, W.J. Tsch¨ope,C. Sanderson, J.E., et al. (2007) ‘How to diagnose diastolic 
heart failure: a consensus statement on the diagnosis of heart failure with normal left 
ventricular ejection fraction by the Heart Failure and Echocardiography Associations 
of the European Society of Cardiology.’ Eur Heart J, 28:2539-2550 
275. Pearson, T.A. Bazzarre, T.L. Daniels, S.R. Fair, J.M. Fortmann, S.P. Franklin, B.A., et al. 
(2003) ‘American Heart Association guide for improving cardiovascular health at the 
community level: a statement for public health practitioners, healthcare providers, 
and health policy makers from the American Heart Association Expert Panel on 
Population and Prevention Science.’ Circulation, 107; 645-651  
276. Peterson, L.R. Waggoner, A.D. Schechtman, K.B. Meyer, T. Gropler, R.J. Barzilai, B. 
Davila-Roman, V.G. (2004) ‘Alterations in left ventricular structure and function in 
young healthy obese women: Assessment by echocardiographyand tissue Doppler 
imaging.’ J Am Coll Cardiol, 43:1399–1404 
277. Phillips, C.M. Tierney, A.C. and Roche, H.M. (2008) ‘Gene-Nutrients in the Metabolic 
Syndrome.’ J Nutrignet Nutrigenomics, 1: 135-151 
278. Pietropaolo, M. and Le Roith, D.  (2001) ‘Pathogenesis of diabetes: our current 
understanding.’  Clin Cornerstone, 4:1–16 




279. Pillarisetti, S, and Saxena, U. (2003) ‘Lipoprotein lipase as a therapeutic target for 
dyslipidemia.’ Front Biosci,  8:d238-241 
280. Poirer, P. Bogaty, P. Garneau, C Marois, L. Dumesnil, L.G. (2001) ‘Diastolic 
dysfunction in normotensive men with well-controlled type 2 diabetes: importance of 
maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy.’ 
Diabetes Care, 24 (1): 5–10 
281.  Pollare, T. Lithell, H. and Vessby, B. (1991) ‘Lipoprotein lipase activity in the skeletal 
muscle is related to insulin sensitivity.’ Atheroscler Throm Vasc Biol, 11:1192-1203 
282. Pont-Kingdon, G, and Lyon, E. (2005) ‘Direct molecular haplotying by melting curve 
analysis of hybridization probes: beta 2-adrenergic receptor haplotypes as an 
example.’ Nucleic Acids  Research, 10 (33):e89 
283. Poole-Wilson, P.  (2005) ‘The prevention of cardiovascular disease worldwide: 
Whose task and WHO’s task?’ Clinical Medicine, 5: 379–384  
284. Powell, B.D. Redfield, M.M. Bybee, K.A. Freeman, W.K.  Rihal, C.S. (2006) 
‘Association of Obesity with Left Ventricular Remodeling and Diastolic Dysfunction in 
Patients without Coronary Artery Disease.’ Am J Cardiol, 98(1):116-120  
285. Preiss-Landi, K. Zimmermann, R. Hammerle, G. Zechner, R. (2002) ‘Lipoprotein 
lipase: the regulation of tissue specific expression and its role in lipid and energy 
metabolism.’ Curr Opin Lipidol, 13(5):471-481 
286. Primo-Parmo, S.L. Sorenson, R.C Teiber, J. LaDu, B.N. (1996) ‘The human serum 
paraoxonase/arylesterase gene (PON1) is one member of a multigene family.’ 
Genomics, 1;33(3):498-507 




287.  Pritchett, A.M. Jacobsen, S.J. Mahoney, D.W. Rodeheffer, R.J. Bailey, K.R. Redfield, 
M.M. (2003) ‘Left atrial volume as an index of left atrial size: a population-based 
study.’ J Am Coll Cardiol, 41:1036–1043 
288. Puoane, T. Steyn, K. Bradshaw, D., et al. (2002) ‘Obesity in South Africa: the South 
African demographic and health survey.’ Obes Res,;10:1038–1048 
289. Quinones, M.A. Otto, C.M. Stoddard, M. Waggoner, A. Zoghbi, W.A. (2002) 
‘Recommendations for quantification of Doppler echocardiography: A report from the 
Doppler quantification task force of the nomenclature and standards committee of 
the American Society of Echocardiography.’ J Am Soc Echocardiogr, 15:167–184 
290. Radha, V. Vimaleswaran, K.S. Ayyappa, K.A. Mohan, V. (2007) ‘Association of 
lipoprotein lipase gene polymorphisms with obesity and type 2 diabetes in an Asian 
Indian population.’ Int J Obes (Lond),  31:913–918 
291. Ralston, J. (2012) ‘New global target on non-communicable diseases: a call to action 
for the global cardiovascular disease community.’ CVJA, 23(5):241-242 
292. Ramachandran, A. Ching Wan, Ma. Snehalatha, R. (2010) ‘Diabetes in Asia.’ Lancet, 
375(9712):408 – 418 
293. Ranjith, N. Pegeraro, R. Naidoo, D.P. Shanmugam, R. Rom, L. (2008) ‘Genetic 
variants associated with Insulin Resistance and Metabolic syndrome in Young Asian 
Indians with Myocardial Infarction.’ Metabolic Syndrome and Related disorders,  6(3): 
209-214 
294. Ranjith, N. Verho, N.K. Verho, M.  Winkelmann, B.R. (2002) ‘Acute Myocardial 
Infarction in a Young South African Indian-Based Population: Patient Characteristics 




on Admission and Gender-Specific Risk Factor Prevalence.’ Curr Med Res Opin, 18, 
242-248 
295. Ratner, R. Goldberg, R. Haffner, S. Marcovina, S. Orchard, T. Fowler, S. Temprosa, 
M. (2005) ‘Impact of intensive lifestyle and metformin therapy on cardiovascular 
disease risk factors in the diabetes prevention program.’ Diabetes Care, 28: 888–894 
296. Ravi, G.R. Pradeepa, R. and Mohan, V. (2004) ‘Hypertriglyceridemia and coronary 
artery disease-an update.’ Indian Heart J, 56:21–26 
297. Razzaghi, H.B. Day, W. McClure, R.J. Kamboh, M.I. (2001) ‘Structure-function 
analysis of D9N and N291S mutations in human lipoprotein lipase using molecular 
modeling.’ J. Mol. Graph. Model.,  19: 487–490 
298. Reaven, G.M. (1988) ‘Role of insulin resistance in human disease.’ Diabetes, 
37:1595-1607 
299. Reaven, G.M. (2007) ‘The Individual Components of the Metabolic Syndrome: Is 
There a Raison d'Etre?’ J Am Coll Nutr, 26( 3): 191-195 
300. Redfield, M.M. Jacobsen, S.J. Burnett, J.C Jr. Mahoney, D.W. Bailey, K.R. Rodeheffer, 
R.J. (2003) ‘Burden of systolic and diastolic ventricular dysfunction in the community: 
appreciating the scope of the heart failure epidemic.’ JAMA, 289(2):194-202 
301. Rheeder, P. (2006) ‘Type 2 diabetes: the emerging epidemic.’ SA Fam Pract, 48(10): 
20 
302. Rip, M. Nierman, C. Ross, C.J., et al. (2006) ‘Lipoprotein lipase S447X: a naturally 
occurring gain-of-function mutation.’ Arterioscler Thromb Vasc Biol., 26:1236–1245 




303. Ririe, K.M. Rasmussen, R.P. and Wittwer, C.T. (1997) ‘Product differentiation by 
analysis of DNA melting curves during the polymerase chain reaction.’ Anal Biochem, 
245: 154-160  
304. Ristow, B. Ali, S. Whooley, M.A. Schiller, N.B. (2008) ‘Usefulness of Left Atrial 
Volume Index to Predict Heart Failure Hospitalization and Mortality in Ambulatory 
Patients With Coronary Heart Disease and Comparison to Left Ventricular Ejection 
Fraction (from the Heart and Soul Study).’ Am J Cardiol, 102:70 –76 
305. Roche, H.M. (2005) ‘Fatty acids and the metabolic syndrome.’ Proc Nutr Soc, 64:23-
29 
306. Roger V.L., Go A.S., Lloyd-Jones D.M., et al. (2011) ‘Heart Disease and Stroke 
Statisitics - 2011 Update: A Report From the American Heart Association. Circulation, 
123:e18-e209 
307. Rosenzweig, J.L. Ferrannini, E. Grundy, S.M., et al. (2008) ‘Primary prevention of 
cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine 
society clinical practice guideline.’ J Clin Endocrinol Metab, 93:3671 
308. Ross, C.J.  Liu, G. Kuivenhoven, J.A., et al. (2005) ‘Complete rescue of lipoprotein 
lipase–deficient mice by somatic gene transfer of the naturally occurring LPLS447X 
beneficial mutation.’  Arterioscler Thromb Vasc Biol., 25: 2143–2150 
309. Rudich, A. Kozlovsky, N. Potashnik, R. Bashan, N. (1997) ‘Oxidant stress reduces 
insulin responsiveness in 3T3-L1 adipocytes.’ Am J Physiol, 272:E935-940 
310. Ruderman, N. Chisholm, D. Pi-Sunyer, X.,et al. (1998) ‘The metabolically obese, 
normal-weight individual revisited.’ Diabetes, 47: 699–713 




311. Rutter, M.K. Parise, H. Benjamin, E.J., et al. (2003) ‘Impact of Glucose Intolerance 
and Insulin Resistance on Cardiac Structure and Function: Sex-Related Differences in 
the Framingham Heart Study.’ Circulation, 107: 448-454 
312. Rutter, M.K. Meigs, J.B. Sullivan, L.M., et al. (2004) ‘C-reactive protein, the 
metabolic syndrome, and prediction of cardiovascular events in the Framingham 
Offspring Study.’ Circulation,  110:380 
313. Sagoo, G.S. Tatt, I. Salanti, G. Butterworth, A.S. Sarwar, N. Van Maarle, M., et al. 
(2008) ‘LPL polymorphisms, lipid fractions and coronary disease: a HUGE association, 
review and meta-analysis.’ Am J Epidemiol, 168:1233-1246 
314. Salanti, G. Amountza, G. Ntanzi, E.E. Ionnidid, J.P. (2005) ‘Hardy-Weinberg 
equilibrium in genetic association studies: an empirical evaluation of reporting, 
deviations, and power.’ Eur J Hum Genet.,13(7):840-848 
315. Salton, C.J. Chuang, M.L. o’Donnell, C.J. Kupka, M.J. et al(2002) ‘Gender Differences 
and Normal Left Ventricular Anatomy in an Adult Population Free of Hypertension.’ J 
Am Coll Cardiol, 39:1055–1060 
316. Samani, N.J. Erdmann, J. Hall, A.S. Hengstenberg, C. Mangino, M., et al. (2007) 
‘Genomewide association analysis of coronary artery disease.’ N Engl J Med.  
357:443–453.  
317. Samaras K. Botelho, N.K. Chisholm, D.J. Lord, R.V. (2010) ‘Subcutaneous and 
visceral adipose tissue gene expression of serum adipokines that predict type 2 
diabetes.’ Obesity,  18(5):884-889 




318. Sandeep, S. Gokulakrishnan, K. Deepa, M. Mohun, V. (2011) ‘Insulin resistance is 
associated with increased cardiovascular risk in Asian Indians with normal glucose 
tolerance--the Chennai Urban Rural Epidemiology Study (CURES-66).’ J Assoc 
Physicians India, 59:480-484 
319. Sanghera, D.K. Saha, N. and Kamboh, M.I. (1998) ‘The codon 55 polymorphism in the 
paraoxonase 1 gene is not associated with the risk of coronary heart disease in Asian 
Indians and Chinese.’ Atherosclerosis, 136:217–223 
320. Sattar, N. McConnachie, A. Shaper, A.G., et al. (2008) ‘Can metabolic syndrome 
usefully predict cardiovascular disease and diabetes? Outcome data from two 
prospective studies.’ Lancet, 371:1927–1935 
321. Schejba, l.V. (1989) ‘Epicardial fatty tissue of the right ventricle morphology, 
morphometry and functional significance.’ Pneumologie, 43: 490–499 
322. Schillaci, G. Pirro, M. Pucci, G., et al. (2006) ‘Different impact of the metabolic 
syndrome on left ventricular structure and function in hypertensive men and women.’ 
Hypertension, 47 : 881–886 
323. Schiller, N.B. Shah, P.M. Crawford, M. De Maria, A. Devereux, R. Feigenbaum, H. 
Gutgesell, H. Reichek, N. Sahn, D. Schnittger, I. (1989) ‘Recommendations for 
quantitation of the left ventricle by two-dimensional echocardiography. American 
Society of Echocardiography committee on standards, subcommittee on quantitation 
of two-dimensional echocardiograms.’ J Am Soc Echocardiogr,  2:358–367 
324. Schinner, S. Scherbaum, W.A. Bornstein, W.A. Barthel, A. (2005) ‘Molecular 
mechanisms of insulin resistance.’ Diabet Med, 22:674-682  




325. Scholl, J. (2012) ‘Traditional Dietary Recommendations for the Prevention of 
Cardiovascular Disease: Do They Meet the Needs of Our Patients?’ Cholesterol, 2012, 
Article ID 367898, 9 pages. Available on 
http://www.hindawi.com/journals/chol/2012/367898/ (accessed on 5 August 2012) 
326. Seedat, Y. K. Seedat, M.A. and Reddy, K. (1978) ‘The prevalence of hypertension in 
the Indian population of Durban.’ S. Afr. Med. J., 54:10-15  
327. Seedat, Y.K. Mayet, F.G. Khan, S. Somers, S.R. Joubert, G. (1990) ‘Risk factors for 
coronary heart disease in the Indians of Durban.’ S. Afr. Med. J., 78: 447-454  
328. Seedat, Y. Mayet, F.G. and Gouws, E. (1994) ‘Risk factors for coronary heart disease 
in the white community of Durban.’ S. Afr. Med. J., 84: 257-262  
329. Seedat, Y.K. (2005) ‘Review: Diabetes mellitus in South African Indians’ British 
Journal of Diabetes & Vascular Disease, 5 (5): 249-251 
330. Seidell, J.C. Kahn, H.S. Williamson, D.F. Lissner, L. Valdez, R. (2001) ‘Report from a 
Centers for Disease Control and Prevention Workshop on use of adult anthropometry 
for public health and primary health care.’ Am J Clin Nutr,73(1):123–126 
331. Sen, S. and Burmeister, M. (2008) ‘Hardy-Weinberg analysis of a large set of 
published association studies reveals genotyping error and a deficit of heterozygotes 
across multiple loci.’ Hum Genomics, 3(1):36-52 
332. Senti, M. Tomas, M. Fito, M. Weinbrenner, T. et al. (2003) ‘Antioxidant Paraoxonase 
1 Activity in the Metabolic Syndrome.’ J Clin Endocrinol Metab 88: 5422–5426 
333. Sewdarsen, M. Vythilingum, S. Jialal, I., et al. (1987) ‘Risk factors in young Indian 
males with myocardial infarction.’ S Afr Med J.,71: 261–262  




334. Shapiro, L.M. Howat, A.P. and Calter, M.M. (1981) ‘Left ventricular function in 
diabetes mellitus. I. Methodology, and prevalence and spectrum of abnormalities.’ Br 
Heart J,  45: 122-128 
335. Shih, D.M. Gu, L. Xia, Y.R. Navab, M. Li, W.F. Hama, S. Castellani, L.W. Furlong, C.E. 
Costa, L.G. Fogelman, A.M.  Lusis, A.J. (1998) ‘Mice lacking serum paraoxonase are 
susceptible to organophosphate toxicity and atherosclerosis.’ Nature, 394:284–287 
336. Simmons, R.K. Alberti, K.G.M.M., Gale, E.A.M., et al. (2010) ‘The metabolic 
syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation.’ 
Diabetologia, 53 (4):600-605 
337. Skoumas, J. Papadimitriou, L. Pitsavos, C. Masoura, C., et al. (2007) ‘Metabolic 
syndrome: prevalence and characteristics in Greek adults with familial combined 
hypertension.’ Metabolis, 56:135-141 
338. Snehalatha, C. Viswanathan, V. Ramachandran, A. (2003) ‘Cutoff Values for Normal 
Anthropometric Variables in Asian Indian Adults.’ Diabetes Care, 26(5): 1380-1384 
339. Sniderman, A.D. and Faraj, M. (2007) ‘Apolipoprotein B, apolipoprotein A-I, insulin 
resistance and the metabolic syndrome.’ Curr Opin Lipidol, 18:633–637 
340. Souverein, O.W. Jukema, J.W. Boekholdt, S.M. Zwinderman, A.H. Tanck, M.W. 
(2005) ‘Polymorphisms in APOA1 and LPL genes are statistically independently 
associated with fasting TG in men with CAD.’ Eur. J. Hum. Genet., 13: 445–451 
341. Spence, J.D. Ban, M.R. and Hegele, R.A. (2003) ‘Lipoprotein Lipase (LPL) Gene 
Variation and Progression of Carotid Artery Plaque.’ Stroke,  34:1176-1180 




342. Stannard, S.R. and Johnson, N.A. (2004) ‘Insulin resistance and elevated 
triglyceride in muscle: more important for survival than "thrifty" genes?’ Physiol, 1; 
(554):595-607 
343. Statistics South Africa. (2011), 27 July p. 3. (Accessed on 13/08/2011) 
http://www.statssa.gov.za/publications/P0302/P03022011.pdf 
344. Stein, Y. and Stein, O. (2003) ‘Lipoprotein lipase and atherosclerosis.’ 
Atherosclerosis, 170:181-189 
345. Stern, M.P. Williams, K. González-Villalpando, C. Hunt, K.J. Haffner, S.M. (2004) 
‘Does the metabolic syndrome improve identification of individuals at risk of type 2 
diabetes and/or cardiovascular disease?’ Diabetes Care, 27:2676–2681 
346. Steyn, K. Levitt, N.S. Hoffman, M. Marais, A.D. Fourie, J.M., et al. (2004) ‘The global 
cardiovascular diseases risk pattern in a peri-urban working class community in South 
Africa.’ Ethn Dis.,  14(2):233-242 
347. Stewart, S. Carrington, M. Pretoriuous, S. Methusi, P. Sliwa, K. (2011) ‘Standing at 
the crossroads between new and historically prevalent heart disease: effects of 
migration and socio-economic factors in the Heart of Soweto cohort study.’ Eur Heart 
J, 32 (4): 492-499 
348. St-Onge, M.P. Janssen, I. Heymsfield, S.B. (2004) ‘Metabolic syndrome in normal-
weight Americans: new definition of the metabolically obese, normal-weight 
individual.’ Diabetes Care, 27:2222 
349. Stocker, R. and Keaney, J.F. (2004) ‘Role of oxidative modifications in 
atherosclerosis.’ Physiol Rev, 84:1381–1388 




350. Stritzke, J. Markus, R.P. Duderstadt, S. Lieb, W. Luchner, A. Döring, A., et al. (2009) 
‘The Aging Process of the Heart: Obesity Is the Main Risk Factor for Left Atrial 
Enlargement During Aging. The MONICA/KORA (Monitoring of Trends and 
Determinations in Cardiovascular Disease/Cooperative Research in the Region of 
Augsburg) Study.’ J Am Coll Cardiol., 54(21):1982-1989  
351. Sundström, J. Vallhagen, E. Risérus, U., et al. (2006) ‘Risk associated with the 
metabolic syndrome versus the sum of its individual components.’ Diabetes Care, 
29:1673 
352. Syvanen, A. (2001) ‘Accessing genetic variation: genotyping single nucleotide 
polymorphisms.’ Nature, 2: 930 – 942 
353. Tabur, S. Torun, A.N. Sabuncu, T. Turan, M.N. Celik, H. Ocak, A.R. Aksoy, N. (2010) 
‘Non-diabetic metabolic syndrome and obesity do not affect serum paraoxonase and 
arylesterase activities but do affect oxidative stress and inflammation.’ Eur J 
Endocrinol., 162: 535-541 
354. Taegtmeyer, H. McNulty, P. and Young, M.E. (2002) ‘Adaptation and 
maladaptation of the heart in diabetes: Part I: general concepts.’ Circulation, 
105:1727–1733 
355. Talmund, P.J. Flavell, D.M. Alfakih, K. Cooper, J.A. Balmford, A.J. Sivananthan, M., et 
al. (2007) ‘The lipoprotein lipase gene serine 447 stop variant influences 
hypertension-induced left ventricular hypertrophy and risk of coronary heart disease.’ 
Clin Sci (London), 112(12): 617-624 




356. Tan, J.T.  Ng, D.P.K. Nurbaya, S. Ye, S. Lim, X.L.  Leong, H., et al. ‘Polymorphisms 
Identified through Genome-Wide Association Studies and Their Associations with 
Type 2 Diabetes in Chinese, Malays, and Asian-Indians in Singapore. ‘The Journal of 
Clinical Endocrinology & Metabolism 2010; 95(1): 390-397 
357. Tarek, A.  Abd, E.  Rasha, H.M. Reem, M.H. (2011) ‘Association of lipoprotein lipase 
and apolipoprotein C-III genes polymorphism with acute myocardial infarction in 
diabetic patients.’ Mol Cell Biochem,  354:141–150 
358. Taşkiran, P. Cam, S.F. Sekuri, C. Tüzün, N. Alioğlu, E. Altintaş, N. Berdeli, A. (2009) 
‘The relationship between paraoxanase gene Leu-Met (55) and Gln-Arg (192) 
polymorphisms and coronary artery disease.’ Turk Kardiyol Dern Ars., 37(7):473-478 
359. Thankappan, K.R. Sivasankaran, S. Khader, S.A. Padmanabhan, P.G. Sarma, P.S. Mini, 
G.K., et al. (2006) ‘Prevalence, correlates, awareness, treatment, and control of 
hypertension in Kumarakom, Kerala: Baseline results of a community-based 
intervention program.’ Indian Heart J, 58 : 28-33 
360. The International Expert Committee. (2009) ‘International Expert Committee Report 
on the role of the A1C assay in the diagnosis of diabetes.’ Diabetes Care,  32:1327–
1334 
361. Tibazarwa, K.  Ntyintyane, L.  Sliwa, K. Gerntholtz, T. Carrington, M. Wilkinson, D. 
Stewart, S. (2009) ‘A time bomb of cardiovascular risk factors in South Africa: Results 
from the Heart of Soweto Study “Heart Awareness Days”.’ International Journal of 
Cardiology, 132: 233–239 




362. Tobacco Products Control Act. (1993) Downloaded from: 
www.acts.co.za/tobacco_products_control_act_1993.htm. Accessed 10 August 2012 
363. Took, J.E. (2000) ‘Possible pathophysiological mechanisms for diabetic angiopathy in 
Type-2 diabetes.’ J Diabetes Complications,  14:197-200 
364. Tremblay, M. Gaudet, D. and Brisson, D. (2011) ‘Metabolic Syndrome and Oral 
Markers of Cardio metabolic Risk.’ J Can Dent Assoc,;77:b125 
365. Trevathan, W.R. Smith, E.O. and McKenna, J.J. (1999) ‘Introduction.’ In: 
Evolutionary Medicine, Trevathan WR, Smith EO, and McKenna JJ (eds). New York: 
Oxford Univ. Press pp. 3-6 
366. Tsang, T.S. Barnes, M.E. Gersh, B.J. Bailey, K.R. Seward, J.B. (2002) ‘Left atrial 
volume as a morphophysiologic expression of left ventricular diastolic dysfunction and 
relation to cardiovascular risk burden.’ Am J Cardiol, 90:1284 –1289 
367. Tward, A. Xia, Y.R. Wang, X.P. Shi, Y.S. Pak, C. Castellani, L.W. Lusis, A.J. Shih, D.M. 
(2002) ‘Decreased atherosclerotic lesion formation in human serum paraoxonase 
transgenic mice.’ Circulation, 106:484-940 
368. UK Prospective Diabetes Study Group. (1998) ‘The incidence of myocardial infarction 
in White, south Asian and Afro-Caribbean patients with type diabetes (UKPDS).’ 
Diabetes Care, 21:1271-1277 
369. Vague, J. (1947) ‘La differénciation sexuelle, facteur determinant des formes de 
l’obésité.’ Presse méd,  55:339–340 




370. Van Bockxmeer, F.M. Liub, Q. Mamotteb, C. Burked, V. Taylor, R. (2001) ‘Lipoprotein 
lipase D9N, N291S and S447X polymorphisms: their influence on premature coronary 
heart disease and plasma lipids.’ Atherosclerosis, 157 (1): 123-129 
371. Van de Weijer, T. Schrauwen-Hinderling, V.B. and Schrauwen P. (2011) ‘Lipotoxicity 
in type 2 diabetic cardiomyopathy.’ Cardiovascular Research,  92: 10–18 
372. Vasan, R.S. Levy, D. Larson, M. Benjamin, E. (2000) ‘Interpretation of 
Echocardiographic measurements: a call for standardization.’ Am Heart J, 139(3):412-
422 
373. Vasan, R.S. Larson, M.G. Leip, E.P. Kannel, W.B. Levy, D. (2001) ‘Assessment of 
frequency of progression to hypertension in non-hypertensive participants in the 
Framingham Heart Study: a cohort study.’ Lancet, 358: 1682–1686 
374. Victora, C. Adair, G. Hallal, L.  Martorell, P.C. Richter, R. Singh, L. Sachdev, H., for the 
Maternal and Child Undernutrition Study Group. (2008) ‘Maternal and child under 
nutrition: consequences for adult health and human capital.’ Lancet,  371(9609): 340–
357 
375. Veiga, L. Silva-Nunes, J. Mela, A. Oliveira, A. Duarte, L. Brito, M. (2011) ‘Q192R 
polymorphism of the paraoxonase-1 gene as a risk factor for obesity in Portuguese 
women.’ European journal of Cardiology, 164(2):213-218 
376. Verhagen, S.N. and Visseren F.L.J. (2011) ‘Perivascular adipose tissue as a cause of 
atherosclerosis.’  Atherosclerosis, 214:3–10 




377. Vincent, H.K. and Taylor, A.G. (2006) ‘Biomarkers and potential mechanisms of 
obesity-induced oxidant stress in humans.’ International Journal of Obesity, 30: 400–
418 
378. Virmani, R. Burke, A.P. Farb, A. Kolodgie, F.D. (2006) ‘Pathology of the vulnerable 
plaque.’ J Am Coll Cardiol,  47:C13-18 
379. Wallace, C. Newhouse, S.J. Braund, P. Zhang, F. Tobin, M. Falchi, M. Ahmadi, K. 
Dobson, R.J. Marcano, A.C. Hajat, C., et al. (2008) ‘Genome-wide association study 
identifies genes for biomarkers of cardiovascular disease: serum urate and 
dyslipidemia.’ Am. J. Hum. Genet., 82:139-149. 
380. Wang, T.D Lee, W. Shih, F. Huang, C.Chang, Y. et al. (2009). ‘Relations of Epicardial 
Adipose Tissue Measured by Multidetector Computed Tomography to Components of 
the Metabolic Syndrome Are Region-Specific and Independent of Anthropometric 
Indexes and Intra-abdominal Visceral Fat’. The Journal of Clinical Endocrinology & 
Metabolism, 94 (2): 662-669 
381. Wang, T.J. Parise, H. Levy, D., et al.  (2004) ‘Obesity and the risk of new-onset atrial 
fibrillation.’ JAMA,  292: 2471-2477 
382. Wang, C.C.L. Goalstone, M.L. and Draznin, B. (2004) ‘Molecular Mechanisms of 
Insulin Resistance That Impact Cardiovascular Biology.’ Diabetes,  53(11): 2735-2740 
383. Wang, H. and Eckel, R.H. (2009) ‘Lipoprotein lipase: from gene to obesity.’ Am J 
Physiol Endocrinol Metab,  297:E271-288 
384. Wajchenberg, B.L. (2000) ‘Subcutaneous and Visceral Adipose Tissue: Their 
Relation to the Metabolic Syndrome.’ Endocrine Reviews,  21 (6): 697-738 




385. Wasir, J.S. Misra, A. Vikram, N.K. Pandey, R.M. Gupta, R. (2008) ‘Comparison of 
definitions of the metabolic syndrome in adult Asian Indians.’ J Assoc Physicians India, 
56 :158-164 
386. Watson, A.D. Berliner, J.A. Hama, S.Y. La Du, B.N. Faull, K.F. Fogelman, A.M. Navab, 
M. (1995) ‘Protective effect of high density lipoprotein associated paraoxonase. 
Inhibition of the biological activity of minimally oxidized low density lipoprotein.’ J. 
Clin. Invest., 96: 2882–2891 
387. Watzinger, N. Schmidt, H. Schumacher, M. Schmidt, R. Eber, B. Feuhwald, F.M., et al. 
(2002) ‘Human Paraoxonase 1 gene polymorphisms and the risk of coronary heart 
disease: a community based study.’ Cardiology, 98:116-122 
388. Tang, W. Apostol, G. Schreiner P.J. Jacobs Jr, D.R, et al. (2010) ‘Associations of 
Lipoprotein Lipase Gene Polymorphisms with Longitudinal Plasma Lipid Trends in 
Young Adults: the CARDIA Study.’ Circ Cardiovasc Genet., 3(2): 179–186. 
389. Weissglas-Volkov, D. and Pajukanta, P. (2010) ‘Genetic causes of high and low serum 
HDL-cholesterol.’ Journal of Lipid Research, 51:2032-2057 
390. Wellen, K.E. and Hotamisligil, G.S. (2003) ‘Obesity-induced inflammatory changes in 
adipose tissue.’ J Clin Invest, 112:1785–1788 
391. Whaley-Connell, A, McCullough, P.A. and Sowers, J.R. (2011) ‘The role of oxidative 
stress in the metabolic syndrome.’ Reviews in Cardiovascular Medicine, 12 :21–29 
392. Wheeler, J.G. Keavney, B.D. Watkins, H., et al. (2004) ‘Four paraoxonase gene 
polymorphisms in 11 212 cases of coronary heart disease and 12 786 controls: meta-
analysis of 43 studies.’ Lancet, 363(9410): 689–695 




393. Whincup, P.H. Gilg, J.A. Papacosta, O. Seymour, C. Miller, G.J. Alberti, K.G. Cook, 
D.G. (2002) ‘Early evidence of ethnic differences in cardiovascular risk: cross sectional 
comparison of British South Asian and white children.’ BMJ, 324(7338): 635 
394. WHO Expert Consultation. (2004) ‘Appropriate body-mass index for Asian 
populations and its implications for policy and intervention strategies.’ Lancet,  
363:157–163  
395. World Health Organization. Definition, diagnosis and classification of diabetes 
mellitus and its complications. Report of a WHO consultation 1999. 
396. Wildman, R.P. McGinn, A.P. Lin, J. Wang, D.  Muntner, P., et al. (2011) 
‘Cardiovascular Disease Risk of Abdominal Obesity vs. Metabolic Abnormalities.’ 
Obesity, 19: 853-860  
397. Wittke-Thompson, Pluzhnikov, A. Cox, N.J. (2005) ‘Rational inferences about 
departures from Hardy-Weinberg equilibrium.’ Am J Hum Genet.,76(6):967-986 
398. Wittrup, H.H. Tybjaerg-Hansen, A. and Nordestgaard, B.G. (1999) ‘Lipoprotein lipase 
mutations, plasma lipids and lipoproteins, and the risk of ischemic heart disease: a 
metal-analysis.’ Circulation, 99:2901-2907 
399. Wong, C.Y. O'Moore-Sullivan, T. Fang, Z.Y. Haluska, B. Leano, R. Marwick, T.H. (2005)  
‘Myocardial and vascular dysfunction and exercise capacity in the metabolic 
syndrome.’ Am J Cardiol,  96:1686–1691 
400. Wu, Z. and Schimmele, M.A. (2011) ‘Racial/Ethnic Variation in Functional and Self-
Reported Health. Am J Public Health, 95(4): 710–716 




401. Wung, S.  Kulkarni, M.V. Pullinger, C.R. Malloy, M.J. Kane, J.P. Aouizerat, B.E. (2006) 
‘The lipoprotein lipase gene in combined hyperlipidemia: evidence of protective allele 
depletion.’ Lipids in Health and Disease,  5:19 
402. Yajnik, C.S. Lubree, H.G. Rege, S.S., et al. (2002) ‘Adiposity and hyperinsulinaemia in 
Indians are present at birth.’ J Clin Endocrinol Metab, 87:5575-5580 
403. Yaomin, H. Wei, L. Rong, H. Xiaoying, Z. (2006) ‘A systematic review and meta-
analysis of the relationship between lipoprotein lipase Asn291Ser variant and 
diseases.’ J. Lipid Res., 47: 1908–1914 
404. Young, M.E. McNulty, P. and Taegtmeyer, H. (2002) ‘Adaptation and 
maladaptation of the heart in diabetes: Part II: potential mechanisms.’ Circulation,  
105:1861–1870 
405. Yusuf, S. Reddy, S. Oˆ unpuu, S. Anand, S. (2001) ‘Global Burden of Cardiovascular 
diseases Part II: variations in cardiovascular disease by specific ethnic groups and 
geographic regions and prevention strategies.’ Circulation, 104: 2855–2864 
406. Yusuf, S. Hawken, S. Ounpuu, S. Dans, T. Avezum, A. Lanas, F. McQueen, M. Budaj, 
A. Pais, P. Varigos, J. Lisheng, L. INTERHEART Study Investigators. (2004) ‘Effect of 
potentially modifiable risk factors associated with myocardial infarction in 52 
countries (the INTERHEART study): case-control study.’ Lancet,  364: 937–952 
407. Zabaneh, D. and Balding, D.J. (2010) ‘A Genome-Wide Association Study of the 
Metabolic Syndrome in Indian Asian Men.’ PLoS ONE,  5(8): e11961 




408. Zabaneh, D. Chambers, J.C. Elliott, P. Scott, J. Balding, D.J., et al. (2009) ‘Heritability 
and genetic correlations of insulin resistance and component phenotypes in Asian 
Indian families using a multivariate analysis.’ Diabetologia,  52 (12): 2582–2589 
409. Zechner, R. (1997) ‘Tissue-specific expression of lipoprotein lipase: implications for 
energy and lipoprotein metabolism.’ Curr Opin lipidol, 8:77-88 
410. Zhang, H. Henderson, H. Gagne, S.E. Clee, S.M. Miao, L. Liu, G. Hayden, M.R. (1996) 
‘Common sequence variants of lipoprotein lipase: standardized studies of in viro 
expression and catalytic expression.’ Biochimica et Acta., 1302: 159-166 
411. Zhong ,J.H. Rodríguez, A.C. Yang, N.N. Li, L.Q. ‘Methylenetetrahydrofolate 
Reductase Gene Polymorphism and Risk of Type 2 Diabetes Mellitus’. PLoS ONE 2013; 
8(9): e74521. doi:10.1371/journal.pone.007452 
412. Zile, M.R. Baicu, C.F. and Gaasch, W.H. (2004) ‘Diastolic heart failure—abnormalities 
in active relaxation and passive stiffness of the left ventricle.’ N Engl J Med, 350:1953–
1959 
413. Zimmet, P. Alberti, K.G. and Shaw, J. (2001) ‘Global and societal implications of the 
diabetes epidemic.’ Nature, 414: 782–787 




APPENDIX 1:  INSTRUCTIONS FOR RECRUITER 
 
1. RECRUITING  INSTRUCTIONS         
 
The sample for the study has already been selected.  There are 1200 people in the 
sample. 
 
The sample has been selected to ensure that participants are spread out evenly over the 
township. 
 
The sample has also been chosen to ensure that a specific number of men and women in 
different age categories are included in the study. 
The sampling has been designed in theory, but the YOU THE RECRUITER must make sure 
that it is carried out in practice.  The methods and rules have been worked out to help 
you in the selection of the participants.  Following these methods and rules may at times 
seem difficult and unnecessary, but the success of the study depends on it. 
 
Methods for recruiting 
 
Sampling will include the following:       
 
(1) Finding a selected household in Phoenix.          
 
(2) Selecting participants out of the chosen household. 
 
1 Finding a selected household in Phoenix 





For the aim of this study, Phoenix has been divided into different areas.  In each of these 
areas, households that have been selected for the study have been marked.  We will 
provide each field-worker with a list that contains the addresses of household listed by 
household study number (i.e. 1 to nth) household.  If nobody is home, try to visit the 
household on different times of the day, for instance, once in the morning and once in the 
evening or during the weekends. If you are unable to find anybody at a particular 
household on several attempts the write down the number of visits you have made to the 
household as well as the reasons why you were not successful in the relevant section in 
the STEPS questionnaire.  
 
Each recruiter will commence with house number 1 on their list 
 
2. Selecting participants from the household  
 
2.1 Introduce yourself to the household and hand them the information page for the 
Phoenix study and explain the reason for your visit. 
 
.At house #1: 
2.2 write down the names, ages and relation of all persons 15 years and older who 
stay at this address in Form A (appendix 1) and record date of birth, relation to 
householder. 
i) To select a person for the study ask who has had a birthday most recently, and 
select that person.  If birth dates are unknown then select the oldest person in the 
household. 
ii) Next, you will record this household study number in the table below in a cell that 
best describes the person who was selected.  For example, if the person selected is a 38-
year old male enter household 1 in grid marked 5 address in the table (see record in 
yellow highlight). 
 




  Male Female 
Age (yrs) 15-24 1 Address 2 Address 
 25-34 3 Address 4 Address 
 35-44 5 Address 6 Address 
 45-54 7 Address 8 Address 
 55-64 9 Address 10 Address 
 ≥65 11 Address 12 Address 
 
iii) Next you will go to household number 2 on your list. Try to find someone in this 
household who will fit the next cell (6 Address) moving from right to left and top to 
bottom on your list. So, the next cell will be for a female aged 35-44 years (6 Address). 
Select that person from this household and record household study number in this cell. 
Now you will have: 
 
  Male Female 
Age (yrs) 15-24 1 Address 2 Address 
 25-34 3 Address 4 Address 
 35-44 Household 1 Household 2 
 45-54 7 Address 8 Address 
 55-64 9 Address 10 Address 
 ≥65 11 Address 12 Address 
 
iv) Next you will go to household number 3 on your list. Try to find someone in this 
household who will fit the next cell moving from right to left and top to bottom on your 
table. So, the next cell will be for a male aged 45-54 years. 
 




v) Continue this process until you get to the bottom of the list and then move to the 
first cell which should be a male aged 15-24 years. Continue downward until all cells are 
complete. 
 
vi) If you visit a household where there is no person that can fill the description of 
your cell then move on to the next cell. For example, if at household number 2 there was 
no female aged 35-44 years then try to select someone for the next cell which requires a 
male aged 45-54 years, and so on, until you have selected someone from the household. 
At your next household, household number 3, you will once again try to select someone 
to fill the cell that was not successful at the previous home.  
 
This is done so that we do not have more than one subject from each home and so that 
the selection is random and represents all ages. Remember to obtain written consent for 
participation into the programme and also remember that in certain age categories 
people are more likely to be at school, college or work when you visit; so always enquire 
about all members and include them in your list for selection. This may mean re-visiting 
the home to contact them and obtain consent.  
 
We will give you lists with additional homes in the event that there are refusals to 
participate or no-one at home on at least 3 occasions. To ensure an unbiased sample we 
need to keep careful records of reasons for not including a person in the study. You will 
be required to keep a log of each home approached, date and time, outcome and reason. 
The possible outcomes are consented to participation/refused/not present at 1st visit/ 
not present at 2nd visit/ not present at 3rd visit. For everything except consented to 
participation, you need to ascertain and record a reason and the gender and age of the 
person who refused or was not present on all occasions in the relevant section in the 
STEPS Questionnaire. 
 
Remember:  Pregnant women and handicapped people (bedridden and in a wheelchair) 
are not selected for the study. 
 




(3) Hand the consent form to participant who has been selected for the study and 
who has accepted to participate.  Participant must sign this form and hand it back to you. 
 
(4) Make an appointment with the participant to meet with the research assistant to 
administer the STEPS QUESTIONNAIRE Write the date and time of the appointment on 





















APPENDIX 2: INFORMATION AND CONSENT DOCUMENT FOR 
PARTICIPANTS 
 
Dear Member of the Phoenix community, 
 
Greetings to You, 
 
I, Professor DP Naidoo, together with other members of my team from the University of 
KwaZulu-Natal, am carrying out a research study on residents in the Phoenix.  You may 
have read of this research in pamphlets circulated to residents and in advertisements in 
the local newspapers. In this study we want to learn about the health, lifestyle (physical 
activity, dietary patterns, smoking and drinking of alcohol habits), psychological well-
being, diseases of lifestyle and sleeping disorders of the residents. 
 
You, perhaps, may know that heart attack, stroke, kidney failure and complications of 
diabetes (high blood sugar levels) – gangrene, problems with the eyes and kidneys are 
becoming a big problem amongst the South African Indian population. The main reason 
for this study is to try to reduce the factors which cause these cardiovascular problems in 
our community.   
 
We are inviting you to participate in this research study. 
 
During this study, a brief detail about yourself and your family will be taken by one of our 
researchers and a questionnaire regarding your lifestyle, diet, physical activity, smoking 
habits, psychological well-being, cardiovascular problems, sleep and family history of 
cardiovascular problems and diabetes will be filled by the researcher. This should take 
about 30-45 minutes to complete and this interview will be held at your residence at a 
time convenient to you. In addition your blood pressure will also be measured by the 
trained researcher. 
 




Following the above an appointment will be then made for you to meet, at a day and time 
convenient to you, at a local doctor’s rooms (at the Sunford Medical Centre) the address 
will be given to you by our researcher. The night before the scheduled appointment you 
will be required to fast for about 10 hours prior to this date. You will be transported from 
the Medical Centre to the Albert Luthuli Central Hospital in Cato Manor.  At this venue a 
qualified person (either a nurse or a medical doctor) will measure your blood pressure 
and take an ultrasound picture and ECG recording of your heart. Fasting blood and urine 
samples (to measure blood glucose, insulin and cholesterol and urine protein levels) will 
be done. If you agree, you will then be given 75 grams of glucose to drink over a two-
minute period and after 2 hours another sample of blood will be taken (to measure blood 
sugar and insulin levels). In addition, weight and height will be measured and 
measurements of the circumference of the waist, arm, and neck and skinfold thickness 
will be made by the researcher before taking blood samples.  In total the time required 
for these procedures will be over two and half hours.   
 
Should you be employed, or should you be attending a school/college a leave form for 
being absent will be given which has to be handed to the employer or school teacher 
before the scheduled visit. 
 
You will also be required to participate in a programme designed to reduce the risk of 
developing cardiovascular disease.  Our research assistant will give you the details of the 
programme.  This programme will go on for one year. During this one year you will be 
visited by our researcher at the end of six months and again at the end of the one year 
during which the questionnaire will again be filled and all the measurements will again be 
made and your blood and urine samples  will also be taken in the same way as the initial 
time.  We will then compare the results to see whether this intervention programme has 
benefited you. You will be regularly informed of your progress 
  
 
Individuals in the age range 15-64 years, both males and females will be selected.  In all 
2500 people will be randomly selected from the Phoenix community.  The person 
selected must not be pregnant or confined to a wheel chair or bed or have any 
neurological problems e.g., stroke. 




There will be no risks to you if you participate in this research programme.  Only slight 
discomfort will be experienced during withdrawal of blood. You are free to withdraw from 
the programme at any time should you so desire. However, if you are identified as having 
disorders such as hypertension and diabetes for the first time you will be referred to your 
family doctor or a clinic or a hospital for appropriate treatment: 
 
In order to benefit optimally from the programme it will be advisable for you to adhere to 
the prescribed physical activity, the dietary and psychological prescriptions given by one 
of our researchers for the one year period.  You will also be expected to reliably answer 
questions posed to you by our interviewer and agree to taking of blood samples and spot 
urine samples 
 
You will be informed of all the results regarding yourself, including the effects of the 
intervention programme.  Besides yourself nobody else will have access to your 
information and results other than your family doctor. 
 
You are assured of confidentially of your details and the data of the results.  Your name 
will not appear on the questionnaire, forms and containers for blood & urine samples.  
You will be assigned an identity number by the leader of the research team.  This identity 
number will appear on the questionnaire, forms, and blood and urine sample containers.  
Your information will be securely kept.  Should any research publications or reports be 
compiled your identity will not be disclosed.  Your anonymity and right to privacy will be 
retained at all times.  However, absolute confidentiality cannot be guaranteed.  Personal 
information may be disclosed if required by law. 
 
If you agree to participate in this research, please sign the informed consent form, 
however, if you are under 18 years of age we will require your parent/guardian to also 
sign a similar form giving you permission to participate. Remember you can decline to 
participate or withdraw at any time. 
 
If you have any doubts or questions, please ask for further explanation from the 
researcher/s.  Please feel free to contact me.  I am the head of the research team and 




Head of Cardiology Department at the Inkosi Albert Luthuli Central Hospital  should you 
require any further clarification or explanation please feel free to contact me.  My contact 
details are: Tel. (031) 240 2207 (W) 2617588 (H); Fax (031) 240 2225; email: 
datshananai@ialch.co.za 
 
This study has received ethics approval from the University of KwaZulu-Natal, Nelson R 
Mandela School of Medicine, Research Ethics Committee.  Should you have any queries 
about the ethics of this study, you may contact: The Medical Research Administration – 
tel (031) 260 4495; fax: (031) 260 4410; email: borresen@ukzn.ac.za. 
 
  
INFORMED CONSENT FORM 
 
Consent to Participate in Research 
 
You have been invited to participate in this research study and an information leaflet 
about this study has been given to you and the details of the study and your involvement 
has also been explained to you by our researchers.  
 
You may contact Professor DP Naidoo at Tel No. 031 240 2207 (w) or 031 2617588 (h) at 
any time if you have questions about the research or if you are injured as a result of the 
research. 
 
You may contact the Medical Research Office at the Nelson R Mandela School of Medicine 
at  
031-260 4604 if you have questions about your rights as a research subject. 
 




Your participation in this research is voluntary, and you will not be penalized or lose 
benefits if you refuse to participate or decide to stop at any point in this study. 
 
If you agree to participate, please sign this document and you may keep the information 
sheet which is a written summary of the research. 
 
Freedom of Consent 
 
I agree to voluntarily participate in this research programme. I understand that I can stop 
participating in this programme at any time I may wish without giving any explanation or 
being prejudiced in any way. 
 
I acknowledge that I have read this form in its entirety or it has been read to me or its 
entire contents have been explained to me, and I understand my responsibility in the 
research programme in which I will be participating.  I accept the risks, rules and 
regulations set forth.  Knowing these, and having had the opportunity to ask questions 
which have been answered to my satisfaction, I consent to participate in this research 
programme and consent to my blood sample being stored and used for any additional 
investigation. 
 
----------------------------------------------------  ------------------------------------ 
Signature of Participant    Date 
 
-------------------------------------------------------  









------------------------------------------------    ------------------------------------------ 




INFORMATION DOCUMENT FOR PARENTS 
 
Dear Member of the Phoenix community, 
 
Greetings to You, 
 
I, Professor DP Naidoo, together with other members of my team from the University of 
KwaZulu-Natal, am carrying out a research study on residents in the Phoenix.  You may 
have read of this research in pamphlets circulated to residents and in advertisements in 
the local newspapers. In this study we want to learn about the health, lifestyle (physical 
activity, dietary patterns, smoking and drinking of alcohol habits), psychological well-
being, diseases of lifestyle and sleeping disorders of the residents. 
 
You, perhaps, may know that heart attack, stroke, kidney failure and complications of 
diabetes (high blood sugar levels) – gangrene, problems with the eyes and kidneys are 
becoming a big problem amongst the South African Indian population. The main reason 
for this study is to try to reduce the factors which cause these cardiovascular problems in 
our community.   
 
Your son/daughter who is under 18 years has agreed to participate in this research study. 
 




During this study, a brief detail about yourself and your family will be taken by one of our 
researchers and a questionnaire regarding your son’s/daughter’s lifestyle, diet, physical 
activity, smoking habits, psychological well-being, cardiovascular problems, sleep and 
family history of cardiovascular problems and diabetes will be filled by the researcher. 
This should take about 30-45 minutes to complete and this interview will be held at your 
residence at a time convenient to your son/daughter. In addition, his/her blood pressure 




Following the above an appointment will be then made for your son/daughter to meet, at 
a day and time convenient to him/her at a local doctor’s rooms (at the Sunford Medical 
Centre) the address will be given to you by our researcher. The night before the 
scheduled appointment he/she will be required to fast for about 10 hours.  He/she will be 
transported from the Medical Centre to the Albert Luthuli Central Hospital in Cato Manor. 
At this venue a qualified person (either a nurse or a medical doctor) will measure your 
blood pressure and take an ultrasound picture and ECG recording of your heart. Fasting 
blood and urine samples (to measure blood glucose, insulin and cholesterol and urine 
protein levels) will be done. If your son/daughter agrees, he/she will be given 75 grams of 
glucose to drink over a two-minute period and after 2 hours another sample of blood will 
be taken (to measure blood sugar and insulin levels). In addition, weight and height will 
be measured and measurements of the circumference of the waist, arm, and neck and 
skinfold thickness will be made by the researcher before taking any blood samples.  For 
these procedures the total time time required will be over two and half hours.  .   
 
Should your son/daughter be employed or should he she be attending a school/college a 
leave form for being absent will be given which has to be handed to the employer or 
school teacher before the scheduled visit. 
 
 
Your son/daughter will also be required to participate in a programme designed to reduce 
the risk of developing cardiovascular disease.  Our research assistant will give your 
son/daughter the details of the programme. This programme will go on for one year.  




During this one year your son/daughter will be visited by our researcher at the end of six 
months and again at the end of the one year during which the same questionnaire will 
again be filled and all the measurements will again be made and blood and urine samples 
will also be taken in the same way as the initial time.  We will then compare the results to 
see whether this intervention programme has benefited your son/daughter.  You and 
your son/daughter will be regularly informed of any progress 
  
 
Individuals in the age range 15-64 years, both males and females, will be selected to 
participate in this research project.  In all 2500 people will be randomly selected from the 
Phoenix community.  The person selected must not be pregnant or confined to a wheel 
chair or bed or have any neurological problems e.g., stroke. 
 
There will be no risks to your son/daughter if he/she participates in this research 
programme.  Only slight discomfort will be experienced during withdrawal of blood. Your 
son/daughter will be free to withdraw from the programme at any time should he/she so 
desire. However, if your son/daughter is identified as having disorders such as 
hypertension and diabetes for the first time you will be referred to your family doctor or a 
clinic or a hospital for appropriate treatment: 
. 
In order to benefit optimally from the intervention programme it will be advisable for 
your son/daughter to adhere to the prescribed physical activity, the dietary and 
psychological prescriptions given by one of our researchers for at least one year.  Your 
son/daughter will also be expected to reliably answer questions posed to him/her by our 
interviewer and agree to taking of blood samples and spot urine samples 
 
You and your son/daughter will be informed of all the results, including the effects of the 
intervention programme.  Besides yourself and your son/daughter nobody else will have 
access to any information and results other than your family doctor. 
 




Your son/daughter is assured of confidentially of his/her details and the data of the 
results.  Your son’s/daughter’s name will not appear on the questionnaire, forms and 
containers for blood and urine samples.  He/she will be assigned an identity number by 
the leader of the research team.  This identity number will appear on the questionnaire, 
forms, and blood and urine sample containers.  All information will be securely kept.  
Should any research publications or reports be compiled your son’s/daughter’s identity 
will not be disclosed.  Your son’s/daughter’s anonymity and right to privacy will be 
retained at all times.  However, absolute confidentiality cannot be guaranteed.  Personal 
information may be disclosed if required by law. 
 
If you agree to your son/daughter to participate in this research, please sign the informed 
consent form, however.  Remember your son/daughter can decline to participate or 
withdraw at any time. 
 
If you have any doubts or questions, please ask for further explanation from the 
researcher/s.  Please feel free to contact me. I am the head of the search team and Head 
of Cardiology at the Inkosi Albert Luthuli Central Hospital.  Should you require any further 
clarification or explanation please feel free to contact me. My contact details are: 




This study has received ethics approval from the University of KwaZulu-Natal, Nelson R 
Mandela School of Medicine, and Research Ethics Committee.  Should you have any 
queries about the ethics of this study, you may contact: The Medical Research 









INFORMED CONSENT FORM 
 
Consent to Participate in Research 
 
Your son/daughter has agreed to participate in this research study and an information 
leaflet about this study has been given to you and the details of the study and your 
son’s/daughter’s involvement has also been explained to you by our researchers 
 
You may contact Professor DP Naidoo, the head of the research team.  His contact details 
are: Telephone  (031) 240 2207 (W) or (031) 2617588 (H); Fax (031) 2225; email: 
datshananai@ialch.co.za, at any time if you have questions about the research or if your 
son/daughter is injured as a result of the research. 
 
You may contact the Medical Research Office at the Nelson R Mandela School of Medicine 
at  
031-260 4604 if you have questions about your rights as a research subject. 
 
Your son’s/daughter’s participation in this research is voluntary, and he/she will not be 
penalized or lose benefits if you refuse to allow him/her to participate or if you decide 
he/she should stop at any point in this study. 
 
If you agree to your son/daughter to participate, please sign this document and you may 
keep the information sheet which is a written summary of the research. 
 
 Freedom of Consent 
 
I agree to voluntarily allow my son/daughter to participate in this research programme. I 
understand that I my son/daughter can stop participating in this programme at any time 




he/she may wish without giving any explanation or being prejudiced in any way. 
 
 
I acknowledge that I have read this form in its entirety or it has been read to me or its 
entire contents have been explained to me, and I understand my son’s/daughter’s 
responsibility in the research programme in which he/she will be participating.  I accept 
the risks, rules and regulations set forth.  Knowing these, and having had the opportunity 
to ask questions which have been answered to my satisfaction, I consent to my 
son/daughter to participate in this research programme and consent to my 
son’s/daughter;s blood sample being stored and used for any additional investigation/s. 
 
----------------------------------------------------  ------------------------------------ 










----------------------------------------                         ----------------------------------- 
Signature of Witness    Date 
 
 
 
